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Human poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme 
which catalyzes protein poly(ADP-ribosyl)ation upon binding to DNA. NAD+ is used as 
a co-substrate in the reaction via iterative transfer of its ADP-ribose moiety to acceptor 
proteins including PARP-1 itself, yielding elongated and branched poly(ADP-ribose) 
(PAR) polymers. This type of protein posttranslational modification has been 
demonstrated in the regulation of diverse biological processes including DNA repair, 
gene expression, cell cycle, etc. Therefore, elucidating the catalytic mechanism of PARP-
1 would not only advance our understanding of how its enzymatic activity is regulated 
under physiological and pathophysiological conditions, but also greatly benefit the 
development of novel therapeutics involving pharmacological manipulation of PARP-1.  
In this dissertation, the molecular mechanism of DNA-dependent poly(ADP-
ribosyl)ation by human PARP-1 was addressed from an enzymological perspective in 
terms of the allosteric ligand DNA, the substrate NAD+, and the PARP-1 protein–DNA 
complex as a whole. By site-specific labeling of the DNA-binding domain AB of PARP-
1 and DNA ligands with fluorophores, quantitative binding kinetics of AB with DNA was 
investigated by single-molecule fluorescence spectroscopy. Two binding modes, one 
involving a strongly-associated protein–DNA complex and the other being transient, 
 ix 
were suggested by the experimental data. To probe the catalytic mechanism of the 
initiation, elongation, and branching step of poly(ADP-ribosyl)ation with regard to NAD+ 
substrate scope, analogues of NAD+ with fluoro-substituted ribose ring were synthesized 
chemoenzymatically and employed as substrates. The results are consistent with the 
proposed mechanism that the ADP-ribosyl transfer reaction proceeds through an 
oxocarbenium-like transition state. Mass spectrometry and biochemical approaches were 
utilized to decipher the poly(ADP-ribosyl)ation sites on PARP-1 and the chemical nature 
of PAR–protein linkages. The data confirm the existence of automodification sites 
beyond domain D, and lysine could be the targeted residue for poly(ADP-ribosyl)ation, 
either enzymatically or nonenzymatically. The macromolecular mechanism of DNA-
dependent PARP-1 automodification was established by an in vitro radioactivity-based 
poly(ADP-ribosyl)ation assay using structurally distinguishable PARP-1 mutants. The 
data support the model of an intermolecular process. Top-down MS analysis and 
crosslinking assay bolster the monomeric structure of domain C in solution and its 
participation in interdomain contacts during PARP-1 catalysis. Taken together, these 
mechanistic studies provide further insight into the catalytic strategies exploited by 
human PARP-1 complementary to recent reports of structural characterization, and may 
help discover better therapeutic agents modulating poly(ADP-ribosyl)ation. 
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Chapter 1. Background and Significance 
1.1 NAD+ AND ADP-RIBOSYLATION 
Nicotinamide adenine dinucleotide (NAD+, and its reduced form NADH, Figure 
1-1) is an important organic molecule found in all living organisms. It consists of two 
mononucleotides, adenosine 5′-monophosphate (AMP) and nicotinamide mononucleotide 
(NMN) joined together by a phosphodiester bond. It has been well-established that NAD+ 
serves as a coenzyme for cellular redox reactions catalyzed by oxidoreductases, where 
two-electron chemistry occurs on the pyridine ring of the nicotinamide base (1). 
Additionally, NAD+ can also be utilized as a co-substrate by transferases. These transfer 
reactions include adenylation and ADP-ribosylation, where the phosphodiester bond and 
the N-glycosidic bond involving nicotinamide are cleaved, respectively (Figure 1-1). 
NAD+-dependent DNA ligases in many bacteria species catalyze NAD+-dependent 
adenylation reactions. These enzymes use NAD+ to form an adenylate-ligase 
intermediate, which then transfers the AMP moiety to the 5′-phosphate of nicked DNA 
ends. Adenylation of the 5′-end of DNA facilitates the subsequent DNA ligation, 
resulting in the release of free AMP (2). The majority of NAD+-consuming enzymes 
catalyze ADP-ribosyltransfer reaction, or ADP-ribosylation reaction (3). Based on the 
target molecules they modify, ADP-ribosyltransferases can be categorized into three 
classes: protein ADP-ribosyltransferases, nucleic acid ADP-ribosyltransferases, and small 
molecule ADP-ribosyltransferases (4). The following sections will give a brief 
introduction of each class of enzymes and the chemistry involved therein. 
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Figure 1-1. NAD+-dependent enzymatic reactions. NAD+ serves as a substrate in 
adenylation (pathway a) and ADP-ribosylation (pathway b) reactions. This 
is in contrast to its role as a coenzyme in redox reactions (pathway c). 
 
1.1.1 Protein ADP-ribosyltransferases 
Protein ADP-ribosyltransferases represent the largest group of all NAD+-
consuming enzymes. Protein ADP-ribosylation is an important type of protein 
posttranslational modifications which involves the transfer of ADP-ribose group(s) onto 
specific amino acid residues. Similar to phosphorylation, ADP-ribosylation of proteins 
can alter their enzymatic activities or molecular recognition properties, and thus modulate 
downstream biological effects. Enzymes that catalyze these reactions are poly(ADP-
ribose) polymerases (5-9), mono-ADP-ribosyltransferases (10), and NAD+-dependent 
deacetylases (11). 
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Poly(ADP-ribose) polymerases 
Poly(ADP-ribose) polymerases (PARPs) carry out poly(ADP-ribosyl)ation mostly 
found in eukaryotes. The outcome of the reaction is the covalent attachment of multiple 
ADP-ribose groups from NAD+ onto substrate proteins (Figure 1-2A). The first ADP-
ribose group is typically added onto the carboxylate side chain of Glu or Asp residues on 
the substrate proteins, although recently ADP-ribosylation at lysine residue has also been 
found (12, 13).  Following the initiation reaction, subsequent addition of ADP-ribose 
units can occur either on the 2′-hydroxyl group of the adenosine ribose, leading to linear 
elongation of poly(ADP-ribose) (PAR) polymer, or on the 2″-hydroxyl group of the 
nicotinamide ribose, creating a branching point (Figure 1-2A).  Currently 17 PARPs have 
been identified in the human genome, with PARP-1 being the most extensively-studied 
member (14). PARPs exert myriad biological functions by covalently modifying their 
target proteins, or employing noncovalent interaction between PAR polymer and the 
recognition proteins (15). The detailed biochemistry and physiological functions of the 
PARP superfamily will be presented in later sections. 
Mono-ADP-ribosyltransferases 
Mono-ADP-ribosyltransferases (ARTs) catalyze the transfer of single ADP-ribose 
group onto substrate protein, similar to the first step of poly(ADP-ribosyl)ation reaction. 
The acceptor amino acid residues include Arg, Cys, Asn (less likely), and 
posttranslationally modified diphthamide (Figure 1-2B) (16). Mono(ADP-ribosyl)ation 
was originally discovered through studying bacterial toxins such as diphtheria toxin, 
cholera toxin, pertussin toxin, and pseudomonas exotoxin A (16, 17). In Rhodospirillum 
rubrum and other free-living photosynthetic bacteria, mono(ADP-ribosyl)ation by DraT 
is used to regulate the activity of enzyme involved in nitrogen fixation (18). 
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A 
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C 
 
Figure 1-2. Enzymatic activities of protein ADP-ribosyltransferases. (A) PARPs 
catalyze the addition of multiple ADP-ribose groups onto Glu, Asp, or Lys 
residues, generating long and branched ADP-ribose polymers. (B) ARTs 
catalyze the addition of single ADP-ribose group onto Arg, Asn or Cys 
residues. (C) NAD+-dependent deacetylases (sirtuins) catalyze lysine 
deacylation. The net reaction is the generation of free lysine and O-acylated 
ADP-ribose.  
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Eukaryotic ARTs have not been discovered until very recently (8, 19).  
Mammalian ART1-5 are the only ARTs that are structurally related and have been 
characterized to molecular level (19). They are ectoenzymes that catalyze extracellular 
mono(ADP-ribosyl)ation of integrins, defensins, and purinergic receptors, modulating 
cellular immune response (10). Intracellular mono(ADP-ribosyl)ation has been reported, 
but no definitive molecular characterization of enzymes responsible for this modification 
exists. Two groups of proteins may be involved in this process, the NAD+-dependent 
deacylases (20) and members within the PARP superfamily possessing “PARP-like” 
feature (21). 
NAD+-dependent deacetylases 
Protein acetylation, including histone acetylation, is an emerging posttranslational 
modification that correlates with not only gene expression but also metabolic regulation 
(22, 23). Histone deacetylases (HDAC) are Zn2+-dependent protein deacetylase that use 
Zn2+ ion in the active site to activate a water molecule to perform amide bond hydrolysis 
(24).  Another class of deacetylases is NAD+-dependent, which couples protein 
deacetylation with the consumption of NAD+ (Figure 1-2C). Sir2 (silencing information 
regulator 2) is the first discovered protein in this class, thus Sir2-like proteins have been 
collectively called “sirtuins.” Sirtuins are evolutionarily conserved in all kingdoms, with 
seven homologues (SIRT1-7) identified in human (20). Sirtuins have been implicated in 
regulating various biological processes including metabolism and aging (25). In addition 
to its deacetylation activity, several sirtuins have been found to possess ADP-
ribosyltransferase activity. However, such side activity may not be physiologically 
relevant (26). More recently, some sirtuins were found to be able to hydrolyze several 
newly identified lysine posttranslational modifications including succinylation, 
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malonylation, and palmitoylation very efficiently, suggesting this class of enzymes could 
catalyze protein “deacylation” reactions in general (27, 28). 
 
1.1.2 Nucleic acid ADP-ribosyltransferases 
There are only a few examples of ADP-ribosyltransferases that use nucleic acids 
as substrates. The first one is tRNA-dependent 2′-phosphotransferase Tpt1 found in yeast, 
whose function is to remove the 2′-phosphate group from the spliced tRNA in the 
presence of NAD+ (Figure 1-3) (29, 30). The mechanism involves a two-step process, 
where the ADP-ribose group is first transferred to the 2′-phosphate of spliced tRNA, 
resulting in an ADP-ribosyl-tRNA intermediate (31). The second step is the attack of the 
phosphate linkage by the adjacent 2′-hydroxyl group, generating dephosphorylated tRNA 
and ADP-ribose-1′,2′-cyclic phosphate (32). 
Pierisin-1, identified from the cabbage butterfly Pieris rapae, is an DNA ADP-
ribosyltransferase. This enzyme has been shown to catalyze mono(ADP-ribosyl)ation of 
2′-amino group of guanine residues in DNA and induces apoptosis in mammalian cells 
(33). The clam DNA ADP-ribosylating proteins (CARPs) and a secretory protein 
SCO5461 from Streptomyces coelicolor with similar activities have also been 
characterized (34, 35). 
 
 
Figure 1-3. Proposed mechanism for NAD+-dependent tRNA 2′-phosphotransferase. 
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1.1.3 Small molecule ADP-ribosyltransferases 
Representative ADP-ribosyltransferases that modify small molecules include 
CobT from the biosynthetic pathway of cobalamin in bacteria (36, 37), rifampin ADP-
ribosyltransferase Arr (38), and the special type ADP-ribosyl cyclases (39). CobT can use 
either NAD+ or nicotinate mononucleotide (NaMN) as a substrate to modify 5,6-
dimethylbenzimidazole (DMB), the base of the lower ligand of cobalamin (40). The Arr 
is responsible for the inactivation of antibiotic rifampin in mycobacteria species (38). 
ADP-ribosyl cyclases use NAD+ to generate cyclic ADP-ribose (cADPR, Figure 
1-4A). The first ADP-ribosyl cyclase was identified from sea urchin egg homogenate 
(41). Mammalian cells contain two homologues identified so far, CD38 and CD157, both 
of which are ectoenzymes (39). Catalysis by ADP-ribosyl cyclases is initiated by forming 
an enzyme-stabilized oxocarbenium intermediate or a transient ADP-ribosyl-enzyme 
intermediate. The attack of such intermediate intramolecularly by the adenine base gives 
cADPR as a product (Figure 1-4A). Interestingly, ADP-ribosyl cyclases also catalyze the 
hydrolysis of cADPR (Figure 1-4A), and the base exchange reaction of nicotinamide with 
nicotinic acid in NADP+ to produce nicotinate adenine dinucleotide phosphate (NAADP+, 
Figure 1-4B). Both cADPR and NAADP+ can serve as signaling molecules for the 
regulation of intracellular calcium concentration, distinct from inositol 1,4,5-triphosphate 
(IP3) pathway (42, 43). 
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Figure 1-4. Enzymatic reactions catalyzed by mammalian CD38. (A) The formation of 
cADPR from NAD+ and its hydrolysis. (B) The formation NAADP+ from 
NADP+.   
In summary, ADP-ribosyltransferases are a diverse group of enzymes that use 
NAD+ to modify a variety of molecules to induce a wide range of biological activities. 
Mechanistically, they also perform fascinating chemistry at the anomeric carbon of the 
nicotinamide ribose ring. More mechanistic details will be discussed in the following 
sections for poly(ADP-ribosyl)ation and the major enzyme that catalyzes the reaction, 
PARP-1. 
 
1.2 BIOCHEMISTRY OF PROTEIN POLY(ADP-RIBOSYL)ATION 
1.2.1 Discovery of poly(ADP-ribosyl)ation 
The first report of poly(ADP-ribose) formation was published in 1963 by 
Chambon et al. (44). It was observed that the radioactivity of [adenine-14C]- or [α-32P]-
labeled ATP was incorporated into the acid-insoluble fraction of hen liver nuclei upon the 
addition of NMN. The stimulated enzymatic activity was DNA-dependent, and the 
resulted product was resistant to DNase, RNase, or protease treatment, suggesting the 
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structure to be polyadenylate (poly(A)). This result was quickly confirmed by Sugimura 
et al., in which they used the similar nuclear preparation from rat liver and hepatoma 
cells (45). 
Following the initial report, the same authors showed that radiolabeled NMN and 
ATP were incorporated into the polymer in equimolar amount (46). Therefore, previously 
observed stimulatory effect of NMN could be attributed to its capability to serve as the 
biosynthetic precursor of the substrate for the polymer formation. This suggests that 
NAD+, whose biosynthetic precursors are NMN and ATP, is the immediate substrate for 
polymerization (46). 
 
1.2.2 Structural features of poly(ADP-ribose) polymer 
The structure of the polymer was first examined by degradation of the polymer 
using alkaline hydrolysis, acid hydrolysis, snake venom phosphodiesterases and alkaline 
phosphatase. The polymer was resistant to alkaline hydrolysis, ruling out the possibility 
of being poly(A). Complete digestion of the polymer yielded a mixture of adenine, ribose 
and phosphate with a ratio of 1:2:2, respectively, indicating ADP-ribose (or its isomer) as 
the monomer unit. This observation was later confirmed by Hayaishi et al. (47, 48) as 
well as Sugimura et al. (49, 50). The studies carried out by Hayaishi et al. also suggested 
that the polymer is composed of ADP-ribose units connected through ribose-ribose 
linkages (48). 
Extensive characterizations of PAR polymer were done in the 1970s to gain new 
information about its chemical structure (Figure 1-5A). 13C-NMR (nuclear magnetic 
resonance) studies carried out by Miwa et al. established that the ADP-ribose unit is 
connected through an α-(1″→2′)-ribose-ribose glycosidic bond (51, 52). Upon enzymatic 
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digestion with snake venom phosphodiesterase, the resulting compounds released from 
the polymer is 2′-(5″-phosphoribosyl)-5′-AMP (PRAMP, or iso-ADP-ribose), which is 
termed the elongation monomeric unit (52), together with 5′-AMP, to a lesser amount, 
which is derived from polymer termini (53). Therefore, it was proposed that PAR is a 
linear polymer, and the size of the polymer can be estimated by the ratio between 
PRAMP and AMP (54). 
In 1978, Sugimura et al. reported that polymer with at least 65 residues by 
counting bands showing on the polyacrylamide electrophoresis gel, has an average chain 
length of about 30 residues as determined by the radioactivity ratio of the digested 
products (55). This implies the possibility of a branched polymeric structure with 
multiple 5′-AMP termini. Further studies by the same group provided definitive structural 
evidence of the branching unit, O-α-D-ribofuranosyl-(1‴→2″)-O-α-D-ribofuranosyl-
(1″→2′)-adenosine-5′,5″,5‴-tris(phosphate) (56, 57), abbreviated as (PR)2AMP. Visual 
evidence of a branched PAR polymer was also demonstrated subsequently by electron 
microscopy (Figure 1-5B) (58, 59).  
The investigation of the three-dimensional conformation of PAR was hindered by 
its structural complexity. Specific antibodies have been raised successfully against PAR 
(60). Since they did not cross-react with DNA, RNA, or poly(A), it is possible that PAR 
adopts a unique conformation owing to its α-ribosyl linkages and branching units. Kun et 
al. have postulated the existence of helical structure of PAR based on CD spectroscopy 
(61, 62). However, recent NMR study indicated that free PAR appears to be devoid of 
inherent regular structure (63). 
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Figure 1-5. (A) Structure of PAR polymer and its enzymatic digestion products. Arrows 
indicate the cleavage site by specific enzyme. (B) An electron microscopic 
image of branched PAR structure adapted from (58). 
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The polymer size and average branching frequency can be estimated by the 
following formula, 
Average polymer size per molecule = AMP + PRAMP +[(PR)2AMP]AMP -­‐[(PR)2AMP]  
Average number of branching points per molecule = [(PR)2AMP]AMP -­‐[(PR)2AMP] 
where AMP, PRAMP, and (PR)2AMP are produced by phosphodiesterase digestion. The 
size distributions of the polymers isolated from cell extracts are highly heterogeneous 
based on polyacrylamide gel electrophoresis (55). It was determined that the chain length 
of PAR polymer, generated in vitro or in vivo, ranges from a few oligomer up to 200 
units, with branching point occurring every 20 to 50 units (64). 
Shortly after the discovery of PAR, Hayaishi et al. revealed that PAR is 
associated with histones in the form ranging from monomer to oligomers, suggesting the 
possibility of covalent linkage to histones (65). This observation was confirmed and 
extended by a number of researchers both in vitro and in vivo (66-68). Based on the 
chemical instability to neutral hydroxylamine treatment and alkaline liability, it was 
proposed that an ester bond involving the carboxylate group of either Glu or Asp and the 
ADP-ribose moiety could be the covalent linkage (69). In the early 80s, several Glu 
residues and the terminal carboxylate group have been determined to be the sites of 
poly(ADP-ribosyl)ation on histones (70, 71). However, the automodification sites of 
PARP-1, the most abundant nuclear enzyme responsible for this reaction, remained 
unresolved until 2009 when our previous group member Dr. Zhihua Tao verified three 
ADP-ribosylation sites using mass spectrometry (MS) (72). More recent publication 
suggested that lysine could also serve as the acceptor residue for poly(ADP-ribosyl)ation 
in both PARP-1 and core histones (12, 13, 73). 
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1.2.3 Enzymes involved in poly(ADP-ribose) metabolism 
Poly(ADP-ribosyl)ation is an important protein posttranslational modification that 
involves in the covalent attachment of ADP-ribose polymer onto specific amino acid 
residues of target proteins. The modification drastically changes the physicochemical 
properties of the substrate proteins to modulate their biological functions. This process 
appears to be highly dynamic and reversible in vivo, as long polymers generated upon 
DNA damage have a half-life of less than 1 min, in contrast to 7.7 h of constitutive short 
ADP-ribose polymers (74). In addition, the co-substrate of this reaction, NAD+, is an 
essential coenzyme involved in energy metabolism and redox balance (75), underscoring 
the important connection between posttranslational modification and cellular metabolism. 
Therefore, the metabolism of PAR polymer is tightly controlled in eukaryotic cells (5, 8). 
Three types of enzymes are involved in PAR metabolism (Figure 1-6) (8): PARPs 
which catalyze the synthesis of PAR polymer on the acceptor proteins, poly(ADP-ribose) 
glycohydrolase (PARG) or ADP-ribosylhydrolase 3 (ARH3) (76), which catalyzes the 
degradation of PAR into free polymer or ADP-ribose monomer, leaving the proteins 
mono(ADP-ribosyl)ated, and ADP-ribosyl protein glycohydrolase or ADP-ribosyl 
protein lyase, which removes the final ADP-ribose unit from the acceptor proteins. 
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Figure 1-6. Metabolism of PAR polymer. (8). The synthesis of PAR polymer requires 
three steps: step 1, initiation, or mono(ADP-ribosyl)ation of the acceptor 
protein residues (Glu carboxylate is shown as an example); step 2, 
elongation of the polymer; and step 3, branching of the polymer. Step 1-3 
are catalyzed by PARPs. The degradation process consists of step 4, the 
endoglycolytic and step 5, exoglycolytic cleavage catalyzed by PARG to 
give mono(ADP-ribosyl)ated proteins. The final stage of degradation 
involves step 6, cleavage of the terminal ADP-ribose unit from protein 
residues by TARG, or other macrodomain-containing hydrolases, or step 7, 
ADP-ribose lyase to complete the reaction cycle. 
The PARP superfamily 
The gene encoding human PARP-1 was first cloned in the late 80s (77). For many 
years, PARP-1 was believed to be the only PARP responsible for poly(ADP-
ribosyl)ation. However, it was later found that parp-null mice cells could also synthesize 
PAR, suggesting the presence of other genes capable of producing PAR (78, 79). To date, 
a total of 17 genes have been identified as members of the “PARP superfamily” based on 
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their sequence homology to the “PARP signature” motif within the catalytic domains 
(Figure 1-7) (7, 14), but not all members within the family can synthesis PAR. 
Biochemical characterizations have shown that only PARP-1, PARP-2, tankyrase-1 and 
tankyrase-2 possess true polymerase activities. PARP-1 and PARP-2 can synthesize long 
and branched PAR polymers (64, 79), wherease tankyrase-1 could only synthesize linear 
polymers (80). Tankyrase-2 is also capable of forming poly(ADP-ribosyl)ated structures 
noticed as a smear on anti-PAR western blot, but its ability to introduce branching units 
has not been verified (81). A recent study aimed to establish the exact enzymatic activity 
of each member within the PARP superfamily showed that the majority of PARPs only 
generate mono-ADP-ribose, suggesting that the H-Y-E catalytic triad located within the 
active site is not the sole indicator of PARP activity (82). Indeed, there has been a call 
from the PARP research community to adopt a new nomenclature system toward 
mammalian ADP-ribosyltransferases according to their structural and biochemical 
features (3). 
PARP-1 is the most abundant nuclear protein able to catalyze initiation, 
elongation, and branching reactions to synthesize PAR onto different acceptor proteins, 
including itself (83), with more than 90% of the overall cellular PAR found (84). PARP-1 
is activated by single strand and double strand DNA breaks, giving rise up to a 500-fold 
increase in PAR level (74, 85). In addition to PARP-1, histones are also considered to be 
the major acceptors for PAR (86). A significant number of nuclear proteins have been 
identified as substrate proteins for poly(ADP-ribosyl)ation by PARP-1 including 
enzymes involved in DNA repair and transcription (87). 
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Figure 1-7. Domain organization of the PARP superfamily members (88). 
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Two other members, PARP-2 and PARP-3, belong to the same subgroup as 
PARP-1 because of the similarity of their domain architectures. PARP-2 activity can be 
activated by binding to RNA (89), whereas PARP-3 which lacks DNA-binding domain 
acts as a mono-ADP-ribosyltransferase and can in turn activate PARP-1 in the absence of 
DNA (90). Both PARP-2 and PARP-3 have been implicated to play a role in the DNA 
repair pathway (91).  
Tankyrases are PARPs found to be associated with human telomeres that regulate 
telomere length, mitotic spindle formation, transcription, and protein degradation (15, 92-
94). Relatively little is known about other members of the PARP superfamily. But several 
articles published recently have provided valuable insights into their biochemical 
properties as well as physiological functions in transcription, antiviral response, and 
stress granule assembly (95-99). 
Poly(ADP-ribose) glycohydrolase 
PARG is the principal enzyme responsible for the catabolism of PAR (100, 101). 
While multiple genes encode different PARPs, there is only one gene known to encode 
PARG (102). Mammalian cells contain several PARG isoforms located within various 
subcellular compartments, each of which is derived from alternative splicing of the same 
parg mRNA (103). Two isoforms are predominant: a 110-kDa full-length protein 
localized within nucleus, and a 60-kDa catalytically active isoform localized within 
cytoplasm/mitochondria (103, 104). Isoforms are different in the arrangement of the N-
terminal regulatory domain and the presence or absence of cellular localization signal 
sequences, while the C-terminal catalytic domain is always conserved. 
PARG has both exo- and endoglycosidase activities. Its reaction leads to 
monomeric ADP-ribose and free PAR polymers (Figure 1-5, the cleavage sites; Figure 1-
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6, step 4 and 5) (100, 105). ADP-ribose could serve as a source for potential histone 
glycation or glycoxidation (106), whereas free PAR could interact noncovalently with 
PAR-recognition proteins and serve as a signaling molecule to induce downstream 
biological effects such as apoptosis (107, 108). Therefore, the dynamic interplay between 
PARPs and PARG could be vital for regulating many cellular processes (101, 109).  
ADP-ribosyl protein lyase / ADP-ribose protein glycohydrolase 
After PARG hydrolyzes the PAR polymer, one ADP-ribose residue remains 
attached to the proteins. To remove the very last ADP-ribose unit, it was hypothesized 
that an ADP-ribosyl protein lyase facilitates this reaction (Figure 1-7, step 6, 7). In the 
late 70s, Hayaishi et al. reported the observation of enzymatic activity capable of 
cleaving ADP-ribosyl histone linkage from partially purified rat liver cytosol (110), and 
an 83-kDa enzyme was subsequently purified to homogeneity by Oka et al. (111). 
However, no further characterization or genetic information of this enzyme was 
published ever since its discovery. It was until 2013 that a group of scientists identified a 
terminal ADP-ribose protein glycohydrolase (TARG) from patients with severe 
neurodegeneration attributable to the genetic abnormality of an unidentified enzyme 
involved in the cleavage of the bond between glutamate and ADP-ribose (112). It was 
noted that the enzyme TARG has a different molecular weight from 83-kDa, thus the 
existence of ADP-ribosyl lyase awaits to be confirmed. 
 
1.2.4 Noncovalent protein interactions with poly(ADP-ribose) 
Poly(ADP-ribosyl)ation is a posttranslational modification of target proteins with 
PAR polymers (113). While the covalent attachment of negatively-charged polymers may 
directly alter the physicochemical properties of the acceptor proteins, the size and 
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structural flexibility of the PAR polymers could also be exploited in noncovalent 
interactions with other proteins. Namely, the PAR polymer may serve as scaffolds for the 
assembly of multiprotein complexes or play roles in ligand binding-induced allosteric 
responses. Several evolutionarily conserved protein domains have been identified to be 
the recognition motifs for binding to PAR (99, 113). 
PAR-binding motif 
The phenomenon of noncovalent protein–PAR interaction was first observed for 
histones (67, 114), and later demonstrated in vitro using purified PAR polymers (115). 
Similar behavior was also noted for non-histone nuclear proteins such as p53, DNA-PK, 
and DNA ligase III, leading to the identification of a common PAR-binding motif (PBM) 
composed of an assortment of hydrophobic and basic amino acid residues downstream of 
a Lys- and Arg-rich region (Figure 1-8A) (116). Further alignments of this motif to better 
locate PBM in proteome had refined the types of hydrophobic residues around the dual 
K/R cores (Figure 1-8B) (117). The PBM is considered to be more of a physicochemical 
property pattern rather than exact amino acid sequence. No structural details of how PAR 
being recognized by PBM is available. 
 
 
Figure 1-8. The noncovalent PAR-binding motif. 
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PBMs are present on the surface of a large number of proteins involved in 
chromatin-related processes such as DNA damage repair, DNA replication and 
transcription (99, 116). Thus PAR (protein-linked or free form) may function as a signal 
platform to recruit binding partners to chromatin where they execute biological tasks. 
Alternatively, PAR-binding can disrupt protein-ligand or protein–protein interactions, or 
even destabilize the folding of the domain to which it binds, so that protein functions may 
be modulated. As an example, PAR binding to apoptosis-inducing factor (AIF) is 
required for its release from the mitochondria to induce cell death in parthanatos (118). 
Given the fact that both nucleic acids and PAR have negatively-charged phosphate 
backbone and nucleobases, many more nucleic acids-interacting proteins could also bind 
PAR, adding another layer of regulation by poly(ADP-ribosyl)ation (99). 
Macro domain 
The macro domain was first reported for a core histone variant with unknown 
function (119). More than a decade later Karras et al. demonstrated that a macro domain 
homologue found in archaea can hydrolyze ADP-ribose-1″-phosphate to ADP-ribose and 
inorganic phosphate, and provided structural support for its ability to bind ADP-ribose 
(120). Subsequent studies showed that some macro domains could not only interact with 
ADP-ribose, but also with PAR, making it a novel PAR-interaction protein module (121-
123). In spite of minimal sequence homology, the structure of PARG solved lately 
exhibited a similar macro fold housing the PARG signature GGG-X6-8-QEE binding 
motif for ADP-ribose which is critical for its exo- and endoglycolytic activity (124, 125). 
In addition to cleaving the glycosidic bond of PAR, a group of macro domain-containing 
proteins were also demonstrated to be capable of hydrolyzing ADP-ribose derivatives 
including O-acetyl-ADP-ribose and mono(ADP-ribosyl)ated protein carboxylate side 
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chains (126-128). Collectively, macro domains are ADP-ribose-binding module with or 
without hydrolytic enzymatic activities. 
PAR-binding zinc finger 
Zinc fingers with PAR-binding affinity were discovered in a subgroup of proteins 
related to PAR metabolism in eukaryotes (129). Three human proteins carrying PAR-
binding zinc finger (PBZ) motif identified so far are the aprataxin and PNK-like factor 
(APLF), the checkpoint protein with FHA and RING (really interesting new gene) 
domains (CHFR), and the DNA cross-link repair 1A protein (DCLRE1A) (129). PBZ 
motif has been shown to recognize α-(1″→2′)-ribosyladenosine, the core structure of 
PAR elongation unit (130). Upon UV irradiation, APLF is rapidly recruited to DNA 
damage site in a PAR-dependent manner via its PBZ domain to facilitate non-
homologous end-joining (NHEJ) repair (129). CHFR is involved in mitotic checkpoint 
(131), but the function of DCLRE1A is unknown.   
WWE domain 
The WWE domain, named after its most conserved Trp and Glu residues, is a 
common module found in E3 ligases and a subset of PARP members, implying the 
potential cross-talk between ubiquitylation and poly(ADP-ribosyl)ation systems (132). 
Crystal structure and biochemical studies confirmed that some WWE domains, not all, 
could bind PR-AMP, the PAR elongation unit (133). The identification of 
Iduna/RNF146, a RING family E3 ligase containing the WWE domain, provided direct 
evidence that PAR-binding through the WWE domain is required for Iduna’s E3 ligase 
activity which catalyzes the ubiquitylation of PARP-1 and other proteins associated with 
DNA repair (134, 135). Poly(ADP-ribosyl)ation of axin catalyzed by tankyrase can also 
trigger its activity for targeting proteasome degradation and regulating the Wnt signaling 
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pathway (136). PAR-binding induced conformational change of the RING domain 
reveals a new mechanism of how noncovalent protein–PAR interaction controls protein 
functions (137).  
Miscellany 
More PAR binding modules have been discovered in the last two years, including 
the FHA domain (138), the BRCT domain (139), the oligonucleotide/oligosaccharide-
binding (OB) fold (140), and the PAR-binding regulatory motif (141). The FHA and 
BRCT domain have been established to be phospho-Ser/Thr-binding domains involved in 
the regulation of cell cycle and DNA damage response (142); OB fold is a single strand 
DNA or RNA binding domain found in prokaryotes and eukaryotes (143). The capability 
of these domains to recognize PAR polymer is not surprising owing to the high similarity 
of the structural elements between PAR and nucleic acids. It is also noteworthy that not 
all proteins containing the abovementioned domains can bind PAR. Hence, biochemical 
characterization of each individual protein is still needed to verify the predicted 
properties.  
 
1.2.5 Cellular functions and therapeutic implications 
Since the first discovery of PAR in rat liver nuclei and its association with 
chromatin, poly(ADP-ribosyl)ation has been postulated to play a regulatory role in the 
biological processes in relation to nuclei (54). Indeed, a significant body of literature 
published over the years indicated that poly(ADP-ribosyl)ation is crucial to stress 
response, maintenance of genome stability, and cell survival, dictated by genetic 
manipulations and pharmacological perturbations on enzymes involving PAR metabolism 
(6, 144). 
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DNA repair and other DNA-dependent biological processes 
DNA repair is a collection of nuclear processes found in all cellular organisms 
that have evolved to cope with ubiquitously occurring DNA damage and to maintain 
genome integrity (145). The mechanism of PAR formation during DNA repair was first 
reported in a seminal paper by Lindahl, et al. in 1992 (146). It is now well-established 
that under low to moderate levels of DNA damage caused by alkylating agents, 
oxidation, or ionizing radiation, PARP-1 binds to DNA lesions and its activity is rapidly 
activated to produce long and branched PAR polymers onto itself and various substrate 
proteins including histones. PAR polymers generated thereafter can facilitate DNA repair 
processes as a result of covalent modifications of proteins involved or through 
noncovalent interactions with other proteins. The automodified PARP-1 has decreased 
affinity for DNA and therefore dissociates from DNA, allowing DNA repair enzymes 
such as DNA polymerase β, XRCC1 (X-ray repair cross-complementing protein 1), and 
DNA ligase III to have access to lesions. The PAR polymers can also attract histones 
from the nucleosomes and expose DNA to the repair enzymes, suggesting chromatin 
remodeling being a PAR-regulated process (147). Recent findings further demonstrated 
that PARP-1 is an architectural protein for chromatin and automodified PARP-1 
promotes nucleosome assembly and thereby facilitates chromatin remodeling (148, 149). 
The effect of poly(ADP-ribosyl)ation is terminated by the removal of PAR polymers by 
PARG or other PAR-degrading enzymes.  
DNA damage response (DDR) is a complex signaling pathway from sensing the 
aberrations, transducing the signals to downstream effectors and coordinating this whole 
process spatiotemporally (150). Poly(ADP-ribosyl)ation is one of the earliest 
posttranslation modifications in response to DNA single-strand or double-strand breaks 
(SSBs or DSBs) (151). In SSB or single-strand DNA damage, only one of the two strands 
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of a double helix has a defect, and this type of damage can be reversed by base excision 
repair (BER) pathway, in which PARP-1 is directly involved as mentioned earlier. DSBs 
are more deleterious to cells as these breaks can cause genome rearrangement or collapse 
of DNA replication fork, leading to developmental disorders and cancer. There are three 
mechanisms to repair DSBs: non-homologous end-joining (NHEJ), microhomology-
mediated end joining (MMEJ) or alternative NHEJ, and homologous recombination (HR) 
(151). Accumulating evidence implicates that poly(ADP-ribosyl)ation participates in the 
determination of appropriate repair mechanisms to counteract DNA lesions (152). 
Poly(ADP-ribosyl)ation either provides a docking site for the targeted proteins, or 
modulates their conformation, stability, or enzymatic activity. Studying the molecular 
mechanisms of poly(ADP-ribosyl)ation in DDR has led to the development of novel 
therapeutic agents against certain types of cancer with inherent defects in DNA repair 
(94). Such cancer cells can only rely on PARP-1-dependent DNA repair pathway for 
survival, thus inhibition of PARP-1 creates a phenomenon referred to as “synthetic 
lethality.” 
In addition to DNA repair, poly(ADP-ribosyl)ation has also been suggested in 
other DNA-dependent processes including chromatin remodeling, transcription, 
replication, recombination, mitosis (152-155). PARP-1 can affect chromatin structure, be 
part of the transcription complexes, or control the actions of insulator. PARP-1 also 
controls the progression of replication fork in the presence of DNA damage. PARP-1 and 
PARP-2 catalytic activity may indirectly contribute to V(D)J recombination in immune 
cells. PARP-1 and other PARPs are associated with centrosomes and regulate spindle 
formation during mitosis. These results further underscore the importance and 
universality of poly(ADP-ribosyl)ation in chromatin-related processes and epigenetics. 
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Cell death 
Contrary to the preservative role of poly(ADP-ribosyl)ation under low levels of 
DNA damage, PARP-1 activation in the presence of moderate to severe DNA damage 
promotes cell death (156). Early studies of PARP-1’s involvement in cell death pathways 
focused on caspase-dependent apoptosis. It has been shown that PARP-1 cleavage by 
caspase-3 or 7 is the hallmark of cells undergoing apoptosis (157). Loss of enzymatic 
activity in the cleaved PARP-1 fragments is believed to be important for preserving 
energy for apoptosis. 
PARP-1 also plays a pivotal role in caspase-independent apoptotic pathway 
mediated by apoptosis-inducing factor (AIF) (158). PAR polymers generated by PARP-1 
in response to moderate DNA damage serve as a death signal and triggers the release of 
AIF from the mitochondria outer membrane, resulting in its translocation into nucleus to 
induce DNA fragmentation (107, 108). 
When cells encounter severe DNA damage or other types of acute injury, PARP-1 
hyperactivation may cause cell necrosis. The phenomenon is attributed to the depletion of 
cellular NAD+ or ATP pool, leading to energy imbalance and mitochondria dysfunction 
(159, 160), and can be attenuated by treating cells with PARP inhibitors (161). This 
model connects poly(ADP-ribosyl)ation with cellular metabolism in terms of NAD+ 
metabolome, which can be altered during ischemic reperfusion injury and cancer 
development (75). 
Stress response 
From a stress-coping perspective, the role of poly(ADP-ribosyl)ation (or 
specifically, PARP-1) in determining cell fate depends on the type, strength and duration 
of the stress stimuli (Figure 1-9). PARP-1 activation under mild stress conditions would 
lead to transcription and DNA repair responses that help reverse the damage, promote 
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transient inflammatory response, re-establish homeostasis, and maintain cell survival. 
Moderate to severe extent of stress gives cell death programs a cue to execute either 
apoptosis or necrosis. The regulatory effect of poly(ADP-ribosyl)ation in response to 
stress stimuli can happen at the DNA level, affecting transcription and other chromatin-
related processes, or at the posttranslational level, or the protein–PAR interactions. 
Growing evidence published in the past few years also shed light on the emerging role of 
poly(ADP-ribosyl)ation in RNA biology, including noncoding RNA in gene regulation, 
RNA processing, and ribosome biogenesis (162-164). Taken together, poly(ADP-
ribosyl)ation exerts its cellular functions at essentially all steps of central dogma, and 
elucidation of the underlying mechanisms at physiological or pathophysiological 
conditions could have tremendous impact on its therapeutic applications. 
 
 
Figure 1-9. PARP-1 functions as a gauge of cellular stress response (156). 
PARP inhibitors 
Given the multifaceted roles of poly(ADP-ribosyl)ation in a wide range of 
physiological processes, it is of great interest to develop small molecules capable of 
modulating PARP activity as therapeutic agents (165). 3-Aminobenzamide (3-AB, Figure 
1-10), a nicotinamide analogue, is the first reported PARP inhibitor which enhances the 
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cytotoxicity of DNA alkylating agents in murine leukemia cells. Its mode of action 
inspires the development of PARP inhibitors as sensitizing agents for chemotherapy (166, 
167). Since then, a plethora of medicinal chemistry programs began to develop 
nicotinamide mimetic scaffolds as NAD+ competitive inhibitors for PARP-1 (Figure 1-
10) (168). Historically, the research effort has been devoted mostly to PARP-1 inhibition, 
but more and more data now suggest that other PARPs also have distinct biological 
functions. A Swedish group recently showed that most PARP inhibitors being used in 
research or evaluated clinically lack specificity and have promiscuous inhibitory activity 
(169). As a result, chemical optimization for isoform-specific PARP inhibitors is needed 
to assess whether cross-inhibitory activity is therapeutically relevant, and to dissect the 
biological functions of those poorly studied PARPs. 
 At present, seven PARP inhibitors are under active clinical trials as a single agent 
or in combination with other chemotherapeutic agents, with all indications against tumors 
(Table 1-1). Rucaparib was the first PARP inhibitor to enter human clinical trial in 2003 
along with alkylating agent temozolomide to treat patients with advanced solid tumors 
(170). Iniparib, unlike others, was identified as a noncompetitive PARP-1 inhibitor which 
disrupts PARP-1 zinc finger/DNA interaction, preventing PARP-1 activation (171). The 
compound was brought into clinics and gained success in phase 1 and phase 2 trials 
without firm characterization of its mechanism of action. It was until the report of failure 
in a large-scale phase 3 trial of iniparib that prompted researchers to re-examine the 
preclinical data and found that this compound was not a bona fide PARP inhibitor after 
all (172). This result again reminds scientists that sufficient preclinical data, proof-of-
mechanism studies, criteria for patient selection, and careful interpretation of clinical 
outcomes are all key to the success of drug development (173). Despite the downside of 
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iniparib, olaparib (LynparzaTM), developed by AstraZeneca, was granted approval by the 
FDA in December 2014 for the treatment of ovarian cancer with BRCA mutation (174). 
 
 
Figure 1-10. PARP-1 pharmacophore (168) and chemical structures of PARP inhibitors. 
Beyond oncologic indications, the therapeutic effect of PARP inhibition has also 
been explored in the field of anti-inflammation and cytoprotection (175). As 
hyperactivation of PARP-1 causes cellular energy failure and induces necrosis, inhibition 
of PARP was expected to alleviate the cytotoxicity elicited by oxidative stress (176). 
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INO-1001 was the only PARP inhibitor that entered clinical studies for cardiac ischemia, 
particularly ST-elevated myocardial infarction, but unfortunately no significant response 
was observed (168). The “no-go” decision of this drug highlights the challenges in this 
clinical path and warrants further fundamental studies of the functions of poly(ADP-
ribosyl)ation in stress response. 
Poly(ADP-ribosyl)ation has been implicated in various cellular pathways and 
compelling evidence substantiates the therapeutic benefits of PARP inhibition. While 
elucidation of the mechanism of action of existing PARP inhibitors could provide 
important insights into PARP biology (177), the molecular mechanism of enzymatic 
catalysis, especially for PARP-1, is still unsettled. Learning the mechanistic details could 
have significant impact on the development of specific PARP-1 inhibitor with novel 
mechanism of action. The following sections will describe the current understandings of 
PARP-1 with an emphasis on mechanistic enzymology. 
 
 
PARP inhibitor Company Status Indication 
AG-014699/Rucaparib Pfizer/Clovis Phase 2, 3 Solid tumors, melanoma 
BSI-201/Iniparib BiPAR/Sanofi-aventis Phase 3 (terminated) Triple negative breast cancer 
INO-1001 Inotek/Genentech Phase 1 (terminated) Melanoma 
GPI-21016/E-7601 MGI Pharma/Eisai Phase 2 Melanoma 
ABT-888/Veliparib Abbott/AbbVie Phase 3 Solid, hematological tumors 
AZD-2281/Olaparib AstraZeneca Approved BRCAmutant ovarian cancer 
CEP-9722 Cephalon/Teva Phase 1, 2 (terminated) Solid tumors 
MK-4827/Niraparib Merck/Tesaro Phase 3 Solid, hematological tumors 
BMN-673/Talazoparib BioMarin Phase 2, 3 Solid, hematological tumors 
Table 1-1. PARP inhibitors under clinical trials (168, 176). 
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1.3 OVERVIEW OF HUMAN PARP-1 
1.3.1 Modular organization of human PARP-1 
PARP-1 is the founding member of the PARP superfamily and the best 
characterized enzyme for poly(ADP-ribosyl)ation in eukaryotes. It is the most abundant 
nuclear protein after histones. The 113-kDa polypeptide chain can be separated into three 
distinct functional units by limited proteolysis: the DNA-binding domain, the 
automodification domain, and the substrate binding/catalytic domain (178). Multiple 
sequence alignment across species can further divide PARP-1 into six subdomains 
(Figure 1-11) (179). 
A 
 
B 
 
Figure 1-11. Modular structure of human PARP-1. (A) Classical naming system divides 
PARP-1 into six domains in alphabetic order according to their functions. 
(B) Naming with specific structural motifs (180). 
Domain A contains two unusually long CX2CX28/30HX2C zinc finger motifs, 
termed zinc finger I (FI) and zinc finger II (FII), which can recognize a large set of 
different DNA lesions with high affinity rather than specific nucleotide sequence (181-
183). This protein–DNA interaction triggers the catalytic activation of PARP-1. FI has 
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also been shown to be important for PARP-1 activation, as PARP-1 FII deletion mutant 
only showed reduced DNA binding affinity but remained catalytic active (181). These 
“PARP-like” zinc fingers have only been found to be present in a small number of 
proteins including DNA ligase IIIα and DNA 3′-phosphodiesterase from Arabidopsis 
thaliana (AtZDP) (184).  
Domain B is a short oligopeptide region with a bipartite nuclear localization 
signal (NLS) in the form of KRK-X11-KKKSKK. This sequence is essential for targeting 
PARP-1 to the nucleus (185). Within the NLS eleven amino acid linker X11 harbors the 
caspase-3 cleavage site D211EVD214. The cleaved enzyme fragment possesses only basal 
activity and can no longer be activated in the presence of damaged DNA (157). PARP-1 
cleavage by caspase-3 has been considered to be one of the hallmarks of apoptosis (157). 
Domain C has been known to be important for PARP-1 activity (186). In 2008, 
both X-ray crystallographic (187) and NMR study (188) unraveled that domain C 
contains a novel CX2CX12CX9C zinc-binding motif, termed zinc finger III (FIII). Unlike 
FI and FII, FIII alone does not bind to DNA, however, it is required for DNA-dependent 
PARP-1 activation (187, 188). It was proposed that interdomain contact mediated by 
domain C could be crucial to PARP-1 activity. Domain C forms a homodimeric structure 
in the crystal, but exists as a monomer in solution NMR study. Following structure-
guided mutagenesis showed that residues located in the dimeric interface are not required 
for DNA-dependent PARP-1 activation (189). Whether full-length PARP-1 function as a 
monomer or dimer upon activation by DNA remains elusive, and will be part of the focus 
of this dissertation. The discrepancy between two structural studies could be due to the 
effect of crystal packing. In Chapter 4 of this dissertation, a MS-based approach used to 
probe the solution structure of domain C will be presented. 
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Domain D was first called the automodification domain attributed to its high 
occurrence of Glu and Asp residues as potential automodification sites (190-193). 
Recently, multiple automodification sites within this region have been confirmed by MS 
(72, 73, 112, 194, 195), and surprisingly a significant number of sites are present beyond 
domain D. The domain also contains a breast cancer 1 protein (BRCA1) C-terminus 
(BRCT) fold which also presents in many DNA damage repair and cell cycle checkpoint 
proteins, and is critical for mediating protein–protein interactions (196). It has been 
thought that the BRCT motif is the dimerization interface of PARP-1 upon activation. 
But a recent solution NMR and small-angle X-ray scattering (SAXS) study indicated that 
the BRCT fold exists as a monomer and no interactions could be detected either with 
other BRCT-containing proteins or PARP-1 itself (197), casting doubt of its role in the 
molecular mechanism of PARP-1 catalysis. 
Domain E contains a WGR motif, which was named after the conserved Trp, Gly 
and Arg amino acid residues. This domain is essential for PARP-1 activity (12, 198). 
Recent findings demonstrated that domain E is capable of binding to short RNAs, PAR 
polymer, and double strand DNA (198, 199). Structural studies also provided evidence 
for its DNA-induced interdomain contacts with FI, FIII, and the helical subdomain (HD) 
within domain F (200). 
Domain F is referred to as the minimal catalytic domain and is responsible for the 
basal level of DNA-independent activity of PARP-1 (201). Many important amino acid 
residues involving NAD+ binding and catalysis are located within this domain. The single 
active site can catalyze the initiation, elongation, and branching reactions for the 
synthesis of PAR polymer, as well as the hydrolysis of NAD+ to produce free ADP-ribose 
(83). In human PARP-1, the region spanning from residue 859 to 908 enclosing NAD+ 
binding is phylogenetically well conserved in the PARP superfamily and thus designated 
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as the “PARP-signature” fold (179). The N-terminal section of domain F is the α-helical 
PARP regulatory domain (PRD, or HD), and its detailed function during DNA-dependent 
PARP-1 activation is to destabilize the catalytic domain as demonstrated in a recent 
structural study (200). Crystal structure of the PARP-1 catalytic domain displayed a 
striking homology to bacterial toxins that act as mono-ADP-ribosyltransferase (202, 203). 
The reaction mechanism will be discussed in Section 1.5. 
 
1.3.2 Posttranslational modifications 
Like other proteins that play key roles in regulating physiological processes, 
PARP-1 is subject to numerous posttranslational modifications, including poly(ADP-
ribosyl)ation, acetylation, phosphorylation, ubiquitylation, and SUMOylation (204). 
PARP-1 is poly(ADP-ribosyl)ated by itself, PARP-2, and perhaps other PARPs. 
Extensive automodification inhibits its DNA binding and catalytic activities (5). 
Acetylation of PARP-1 by p300/CREB-binding protein regulates NF-κB-dependent gene 
transcription in immune cells (205). Phosphorylation of PARP-1 by ERK1/2 reinforces or 
promotes sustained catalytic activity under stress conditions (206, 207). SUMOylation of 
PARP-1 affects its function as a transcription co-activator of hypoxia-responsive genes 
(208), and this modification is stimulated by PARP-1 binding to intact, undamaged DNA 
(209). Polyubiquitylation of PARP-1 promotes its degradation and therefore regulating its 
overall activity (210). 
 
1.3.4 Substrate proteins for PARPs 
PARP-1 acts as the major acceptor in the cell for over 90% of PAR synthesized 
under stress stimuli (84). However, several nuclear substrate proteins have also been 
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identified in vitro and in vivo, which are predominantly involved in the metabolism of 
nucleic acids and in the maintenance of chromatin structure (5). With the advance of 
analytical technology, proteomic profiling of substrate proteins for ADP-
ribosyltransferases or PARPs have made significant progress in the past five years (211). 
Di Girolamo et al. reported a method using an ADP-ribose-binding macro domain to 
enrich the ADP-ribosylated proteins in mammalian cell lysates and identified ART 
substrates by MS (212). In our laboratory, we have taken effort to screen PARP-1 
substrates using both yeast and human proteome microarray and found a number of 
ribosomal proteins being modified by PARP-1, implying the potential regulatory function 
of poly(ADP-ribosyl)ation in ribosome biogenesis (164). Similar strategy has been 
applied for the identification of PARP-2 substrates (213). Poirier et al. adopted an 
antibody affinity purification coupled with MS analysis to profile the interactome of 
PARP-1, PARP-2, and PARG in human cancer cell lines (214). However, this procedure 
cannot distinguish between protein covalent poly(ADP-ribosyl)ation, noncovalent 
protein–PAR interaction, and direct protein–protein interaction. The same group later 
profiled the poly(ADP-ribosyl)ation proteome using anti-PAR 10H antibody. The 
experiment was carried out with the enrichment of poly(ADP-ribosyl)ated proteins by 
inactive (macro domain-like) PARG mutant and MS was used as the analytic tool to 
provide time-resolved information of cellular proteins associated with PAR under 
genotoxic insult (215). A SILAC- (stable isotope labeling by amino acids in cell culture) 
based quantitative proteomic analysis was also developed to discover poly(ADP-
ribosyl)ated proteins under different stress conditions (216). 
The concept of chemical biology has influenced the PARP field and stimulated 
newly designed experiments (211, 217). Lin et al. chemically synthesized clickable 
NAD+ analogues and biotin affinity tag to profile PARP-1 and tankyrase-1 substrates and 
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found not only nuclear but also mitochondrial proteins being poly(ADP-ribosyl)ated 
(218). Recently a method featuring boronate resin-enrichment combined with 
hydroxylamine elution was developed to specifically convert Glu- and Asp-poly(ADP-
ribosyl)ated residues into hydroxamic tags, which greatly facilitates their detection by 
MS (195). The results revealed a number of poly(ADP-ribosyl)ated proteins with specific 
modification sites, including PARP-1. Inspired by the “bump-and-hole” strategy in 
identifying kinase substrates, Cohen et al. applied the same idea onto PARP-1 and 
PARP-2 to engineer orthogonal enzyme-substrate pairs for substrate profiling (219). 
Their data suggested semi-complementary yet distinct targets for PARP-1 and PARP-2 
under stress paradigms. 
Despite the unfolding of ADP-ribosylation proteome, the identified substrate 
pools remain partially overlapped among different experimental conditions and 
procedures. Methods capable of differentiating specific amino acid linkage are still 
lacking. Nevertheless, protein poly(ADP-ribosyl)ation promises to be an active research 
area in the near future. 
 
1.4 DNA BINDING PROPERTIES OF HUMAN PARP-1 
1.4.1 Differential roles of DNA binding motifs in PARP-1 
It is well known that intracellular PARP-1 activity is strongly stimulated in the 
presence of DNA lesions, and the activity is dependent on the number or types of DNA 
strand breaks, not the nucleotide sequence (220-222). The robust activation of PARP-1 
enzymatic activity is mainly mediated by DNA binding to the two unique zinc fingers, FI 
and FII, located within PARP-1 N-terminal domain (223). They belong to a small family 
of “PARP-like” zinc fingers which were initially found to recognize DNA nicks as 
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evidenced by an electron microscope study (224). Thus, PARP-1 has been referred to as 
the “nick-sensor” (179).  
The two zinc fingers appear to have differential roles in DNA recognition. While 
existing consecutively in PARP-1, phylogenetic analysis indicates that they are divergent 
(184). In early 90s, de Murcia and colleagues first showed by site-direct mutagenesis that 
disruption of the metal binding ability of FII dramatically reduced its binding to DNA 
single-strand break, whereas mutations of the corresponding FI zinc coordinating amino 
acid residues only slightly affects its DNA binding ability (182). Using DNA footprinting 
they also demonstrated that polypeptide containing FI and FII binds at the single-strand 
break via FII, and perhaps as a dimer (182). After less than a year, Ikejima et al. 
published their findings that both FI and FII are required for PARP-1 activation by 
single-strand breaks, but activation by double-strand breaks requires only FI (181). 
The abovementioned studies provided a rough picture of the differential roles of 
the PARP-1 zinc fingers in terms of binding affinity for different DNA structures and 
subsequent catalytic activation. FI appears to be less important in binding to single-strand 
breaks and may prefer double-strand breaks. However, it is essential for all kinds of 
DNA-induced PARP-1 activation perhaps through interdomain interactions. FII is 
primarily responsible for protein–DNA interaction and is dispensable for PARP-1 
activation by double-strand breaks. A novel zinc-ribbon fold distinct from FI and FII has 
recently been identified in domain C, named FIII (187, 188). FIII does not have DNA 
binding affinity, but it is required for DNA-dependent PARP-1 activation (187, 188). 
In addition to three zinc-binding motifs, other regions of the PARP-1 molecule 
have been shown to be able to bind DNA. The existence of a double-strand DNA binding 
(DsDB) domain was confirmed by Satoh et al. (199). The DsDB domain is a highly basic 
60-amino acid stretch located between the BRCT and WGR domain (around the 
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boundary of domain D and E, residues 480–540), which possesses weak double-strand 
DNA binding affinity relative to FI and FII, as well as medium PAR binding affinity. 
PAR binding to the DsDB domain can displace double-strand DNA and results in the 
dissociation of PARP-1 from DNA. DsDB domain may also control PAR synthesis, as 
illustrated in an experiment that a truncated PARP-1 construct containing the WGR and 
catalytic domain can produce long PAR polymers in the presence of dumbbell DNA, 
whereas construct containing additional DsDB domain only produced short PAR 
polymers. It is proposed that DsDB domain may assist in the overall DNA binding of 
PARP-1 by stabilizing intact double-strand DNA adjacent to the lesion sites. The exact 
function of DsDB domain in the context of full-length PARP-1 during the catalytic cycle 
remains to be verified. 
From a recent SAXS study of full-length PARP-1 complexed with 8-mer DNA 
carried out by our laboratory, we discovered that the C-terminal end of the WGR domain 
(residues 626–645) can enhance PARP-1’s binding to DNA, and is important in the 
following catalytic activation (198). The detailed structural studies of how PARP-1 
recognizes different DNAs will be discussed in the later section. 
 
1.4.2 Interactions with various DNA structures 
PARP-1 is capable of interacting with a variety of DNA structures including 
damaged, intact, or even non-B DNA structures (225). PARP-1 shows low nanomolar 
affinity for DNA with nicks, overhangs, as well as blunt ends (226), but the 
corresponding catalytic power (estimated by Vmax, units per mg protein) is not necessarily 
proportional to its DNA binding affinity. A systematic examination of the binding modes 
of PARP-1 DNA-binding domain (residues 1–234) towards different DNA substrates and 
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their correlation with PARP-1 enzymatic activation was performed by Bombarda et al. 
(227). The analysis indicated that PARP-1 can distinguish 3′-overhang (5′-recessive end) 
from 5′-overhang (3′-recessive end) DNA, with higher catalytic activity induced by 
binding to 3′-overhang. DNA with blunt ends gave stimulatory activity similar to DNase 
I-treated activated DNA mixtures. Intrinsic tryptophan fluorescence intensity and 
anisotropy measurements afforded 2:1 and 1:1 protein–DNA binding stoichiometry for 
3′-overhang and 5′-overhang, respectively. The higher catalytic activity could be 
explained by the potential dimerization of PARP-1 at the 3′-overhang lesion site. 
Moreover, DNA intra- or interstrand cross-links created by alkylating agents such as 
cisplatin can promote PARP-1 binding and trigger downstream cytotoxic response (228). 
These data clearly suggested that PARP-1 can adopt different recognition modes 
according to the DNA damage types and exert structure-specific activity. 
Apart from damaged DNA, PARP-1 can occupy intact DNA such as promoter 
regions, regulating gene transcription and chromatin structure through poly(ADP-
ribosyl)ation (148). Numerous non-B DNA structures including hairpins, cruciforms, and 
the stably unpaired regions (loops) are all effective activators of PARP-1 
automodification and heteromodification of histone 1 (183). More recently, PARP-1 was 
shown to be capable of binding to the G-quadruplex structure in the human c-myc gene’s 
promoter and participates in its conversion into transcriptionally more active B-DNA 
form (229). From a chromatin perspective, PARP-1 also possesses nucleosome binding 
properties and functions as a chromatin architectural protein (230-232). The binding is 
dependent on nucleosome particles and does not involve free DNA ends or linkers. 
Automodified PARP-1 has the ability to sequester histones and assemble nucleosomes in 
vitro (149). This model suggests that PARP-1 automodification not only loosens 
chromatin for the recruitment of DNA repair machinery or transcription complex, but 
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also facilitates the re-establishment of chromatin structure through histone chaperone 
activity (149). 
 
1.4.3 Structural evidence for PARP-1–DNA interactions 
The exact mechanism of how PARP-1 recognizes DNAs and the binding 
stoichiometry are largely debated in light of the modular nature of PARP-1 molecule and 
its binding flexibility toward various DNA structures. Nevertheless, several crystal and 
NMR structures published in the past five years have significantly improved our 
understandings of this complex protein–DNA interaction. 
Pascal et al. first determined the structures of individual zinc fingers FI and FII in 
complex with an 8-bp or 10-bp blunt end DNA as a mimic of double-strand break (233). 
FI and FII both bind to DNA in a similar fashion, with the phosphate backbone grips 
interacting with the minor groove of DNA near the 3′-end, and the base stacking loop 
extending 90˚ from the phosphate backbone grip, capping the 5′-end terminal base 
(Figure 1-12A, B). Both proteins associated with duplex DNA in monomeric form. The 
residues responsible for protein–DNA interactions were probed biochemically by site-
directed mutagenesis. But based on the observed structural similarity it remains difficult 
to explain the differential roles of FI and FII, such as FI rather than FII is essential for 
blunt end DNA-induced PARP-1 activation, and FII has stronger affinity than FI for blunt 
end DNA (233). 
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Figure 1-12. Crystal structures of human PARP-1 zinc fingers in complex with DNAs 
(234). (A) Zinc finger I complexed with a 10-bp duplex DNA (PDB: 3OD8) 
(233). (B) Zinc finger II complexed with a 8-bp duplex DNA (PDB: 3ODC) 
(233). (C) PARP-1 DNA-binding domain (residues 5–202) containing FI 
and FII complexed with a 11-bp single-base 5′ overhang duplex DNA (PDB: 
4AV1) (235). mg, minor groove; MG, major groove. 
A clearer picture of how these two zinc fingers cooperate to recognize DNA 
strand breaks can be seen from a following report where the authors used a protein 
construct bearing both FI and FII to crystallize with a duplex DNA containing single-base 
5′-overhang mimicking DNA single-strand break (235). In their structure, FII binds to 
DNA in the same way as isolated domain, but FI binds to the opposite side of DNA, with 
its phosphate backbone grip interacting with the major groove and base stacking loop on 
A B 
C 
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top of the corresponding loop in FII (Figure 1-12C). Unlike the 3′ recessed strand, the 5′-
terminus is free from protein obstruction and the phosphate backbone can extend beyond 
the lesion site, implying the suitability of the current structure model for PARP-1 binding 
to single-strand DNA breaks. More importantly, the observed FI and FII proteins at the 
lesion site must come from different polypeptide chains, as the linker between FI and FII 
is too short to connect each other (Figure 1-12C). In vivo DNA damage site recruitment 
studies and in vitro gel shift, GST pull-down experiments confirmed the requirement of 
FI and FII protein–protein interactions for the assembly of a functional PARP-1 DNA-
binding domain in response to DNA damage. DNA-induced dimerization of PARP-1 is 
therefore proposed to operate at the discontinued DNA damage site, facilitating 
intermolecular poly(ADP-ribosyl)ation reaction. 
Despite the observed dimerization of the PARP-1 DNA-binding domain in 
crystallo, biophysical analyses in solution suggested a different recognition mode for 
PARP-1–DNA interaction. Analytical ultracentrifugation and SAXS data modeling 
showed that PARP-1 fragments containing both zinc fingers or with extra FIII and BRCT 
domain bind to model DNAs in a 1:1 stoichiometry (236, 237). Perturbations of NMR 
chemical shift signals indicated that FII binds to single-strand DNA in an identical way 
regardless of whether the protein fragment includes FI or not (237). The discrepancy 
among these studies could be attributed to different protein and DNA constructs used in 
the specific experiments. However, the general notion is that FI is absolutely required for 
DNA-induced PARP-1 activity and FII is primarily responsible for DNA recognition 
(perhaps mainly single-strand DNA breaks). FI, despite its weaker DNA binding affinity, 
can further strengthen the overall DNA binding or serve as a surrogate for DNA 
recognition in the absence of FII, leading to weaker enzymatic activation. 
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1.5 CATALYTIC MECHANISMS OF HUMAN PARP-1 
1.5.1 Activation mechanisms 
DNA-dependent activation 
DNA-dependent PARP-1 activation has been well-documented and represents the 
mechanistic paradigm for this intriguing enzyme. It has been proposed that DNA ligand-
induced protein conformational changes allosterically activate PARP-1 enzymatic 
activity, but evidence regarding the protein–DNA binding stoichiometry and the reaction 
molecularity (intra- vs intermolecular) is still equivocal (Figure 1-13 and 1-14). Early 
biochemical studies suggested the possible dimer formation and/or macromolecular 
association upon DNA binding (182, 238). A kinetic study of PARP-1 automodification 
reaction using radiolabeled NAD+ as substrate showed that the initial rate measured by 
the incorporation of radioactivity into PARP-1 increases with the square of the enzyme 
concentration, suggesting a second-order kinetic behavior, or an intermolecular process is 
operating (239). Maximal production of PAR was also observed in vitro at PARP-1 to 
DNA molar ratio of 2:1 (240). Moreover, 3′-overhang DNA-induced dimerization of 
PARP-1 DNA binding domain (residues 1–234) was observed using fluorescence 
spectroscopy and correlated with elevated enzyme activity (227, 241). Therefore, the 
mechanism in which DNA ligand-induced dimerization and subsequent intermolecular 
trans-modification of PARP-1 molecule prevails in the PARP field. Consistent with this 
model, two PARP-1 molecules could dimerize at the DNA lesion site through FI from 
one molecule and FII from the other as detected in the crystal structure, thereby 
permitting trans-modification (Figure 1-13) (235). 
 43 
 
Figure 1-13. Proposed model for DNA-dependent PARP-1 dimerization and 
intermolecular trans-modification reaction (235). 
A      B 
 
Figure 1-14. DNA-dependent PARP-1 activation: a monomeric perspective (180). (A) 
Crystal structure of PARP-1 domains in complex with blunt end DNA 
(PDB: 4DQY). FII (Zn2) and BRCT are computer-modeled in and not 
present in the real crystal. (B) A beads-on-a-string model where PARP-1 
domains are engaged with blunt end DNA in the monomeric form. DNA 
binding destabilizes the catalytic domain (ART), leading to increased 
protein flexibility poised for higher catalytic turnover. 
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Although the structure of PARP-1 DNA-binding domain together with DNA 
provided a snapshot of how PARP-1 zinc fingers recognize DNA lesions, it is still 
unclear how DNA binding correlates to the catalytic activation of poly(ADP-
ribosyl)ation. In a groundbreaking paper published in Science, Pascal and colleagues 
solved the crystal structure of PARP-1 multiple domains in complex with a 26-bp blunt 
end DNA mimicking double-strand break (200). These domains, comprised of FI, FIII, 
and the WGR-CAT domain (residues 518–1014, domain E and F), represent the minimal 
catalytic components for DNA-dependent PARP-1 activity. As shown in Figure 1-14A, 
FI, FII, and the WGR domain collapse onto DNA blunt end, creating a compact network 
of interdomain contacts. FI binds to the DNA minor groove side and the base stacking 
loop capping the 5′ terminal base in the way similar to its isolated form; FIII binds to the 
DNA phosphate backbone adjacent to FI, contrary to the negative result obtained from 
biochemical experiments with isolated FIII (188); the WGR domain occupies the other 
side of DNA, interacting with the 5′-end phosphate backbone. FI, FIII, and one face of 
the WGR domain form extensive interdomain contacts central to the DNA end. The 
opposite face of the WGR domain is in contact with the regulatory HD domain (N-
terminus of domain F). Upon DNA-binding the HD domain is perturbed through its 
hydrophobic core, which in turn destabilizes the catalytic domain and results in elevated 
enzymatic activity (Figure 1-14B). Based on the amino acid linkage, the BRCT domain 
with multiple automodification sites is in proximity toward the catalytic domain so that 
the preference of PARP-1 for self-modification can be readily explained (Figure 1-14B). 
The model also confirmed the importance of several amino acid residues involved in 
interdomain contacts and paved the way for designing inhibitors targeting domain–
domain interactions (242). 
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The monomeric structure of near full-length PARP-1 domains complexed with a 
blunt end DNA is in stark contrast to the previous reported dimerization of FI and FII in 
the presence of an overhang DNA (235). It is noteworthy that the exclusion of FII in the 
crystallization experiment, perhaps due to technical difficulty, might result in an 
incomplete view of DNA-dependent PARP-1 activation process. Monomeric PARP-1–
DNA complex may possibly represent binding to double-strand break whereas dimeric 
PARP-1 DNA-binding domain is more relevant to single-strand break recognition. 
Nonetheless, SAXS studies using N-terminal partial (residues 1–486) or full-length 
PARP-1 with DNA ligands all suggested a compact conformational change upon DNA 
binding (198, 236). A stretch of amino acid residues 626 to 645 within the WGR domain 
(domain E) was found to support the DNA-binding ability of the DEF domain (residues 
374-1014) of PARP-1 and crucial to the overall enzymatic activity based on the SAXS 
modeling of full-length PARP-1 with 8-bp DNA (198), but it is not seen in direct contact 
with DNA in the crystal structure (200). It is likely that residues assisting interdomain 
contacts could indirectly reinforce the overall DNA binding ability, leading to PARP-1’s 
catalytic activation. It may be difficult to entirely deconvolute the effect of interdomain 
interactions in the context of DNA-binding affinity and catalytic activity. These 
contrasting models of DNA-dependent PARP-1 activation in terms of binding 
stoichiometry and reaction molecularity provided the founding hypotheses that would be 
examined in the later chapters. 
DNA-independent activation 
Free DNA is not the only stimulatory factor for PARP-1 activity; nucleosomes, 
RNAs, and protein posttranslational modifications can also activate PARP-1 poly(ADP-
ribosyl)ation. PARP-1 is capable of binding to nucleosome particles through histones H3 
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and H4, and the N-terminal tail of H4 triggers PARP-1 activity independently of DNA 
(231). Single-strand RNAs such as poly(rA), poly(U), and poly(rC) can bind to the WGR 
domain of PARP-1 and activate the enzymatic activity of the WGR-CAT domain more 
than single-strand DNAs do (199). PARP-3, a mono-ADP-ribosyltransferase, can interact 
with PARP-1 in vitro through its N-terminal WGR domain and activate PARP-1’s 
poly(ADP-ribosyl)ation activity in the absence of DNA (90); SIRT6 can mono-ADP-
ribosylate PARP-1 on Lys521 and further stimulates its activity to a higher extent in the 
presence of DNA (243). Mono-ADP-ribosylation of PARP-1 by PARP-3, SIRT6, and 
perhaps other cellular PARPs possessing mono-ADP-ribosyltransferase activity may thus 
function as a “kickstart” for PARP-1-mediated poly(ADP-ribosyl)ation. 
Posttranslational modifications other than poly(ADP-ribosyl)ation can also 
modulate PARP-1 activity (see Section 1.3.2). Phosphorylation of PARP-1 by ERK1/2 is 
required for maximal PARP-1 activation after DNA damage (206, 207). Moreover, 
phosphorylated ERK2 can direct interact with PARP-1 and promotes its activation more 
than damaged DNA does at NAD+ concentration lower than physiological condition (206, 
207). These results suggest that a mechanism of protein-mediated PARP-1 activation 
could resemble the effect of DNA lesions as allosteric regulators for PARP-1 activity. 
 
1.5.2 Reaction mechanisms 
PARP-1-catalyzed poly(ADP-ribosyl)ation produces long, branched PAR 
polymers attached to substrate proteins. The reaction can be divided into three steps: 
initiation, elongation, and branching (Figure 1-15A). Initiation involves the formation of 
a covalent bond between the attacking carboxyl group of glutamate or aspartate (or the ε-
amino group of lysine) from the substrate protein and the anomeric carbon of the NMN 
 47 
moiety in NAD+, cleaving the ribose–nicotinamide glycosidic bond. Next, elongation 
happens when the 2′-hydroxyl group of the adenosine moiety from the just added ADP-
ribose becomes the nucleophile to attack another NAD+ molecule at the same anomeric 
position, extending the modification with one more ADP-ribose unit. In contrast to 
elongation, branching reaction takes place when the 2″-hydroxyl group of the original 
NMN ribose moiety serves as the nucleophile to branch out from the linear PAR chain. 
These newly formed glycosidic linkages are believed to be in α-stereochemistry. In 
addition, PARP-1 can also catalyze the hydrolysis of NAD+, though to a less extent as 
compared to the polymerase activity (83). The distinction between initiation, elongation, 
branching, and hydrolysis reactions can be perceived as the transfer of ADP-ribose group 
onto different acceptors, i.e., protein amino acid residues, 2′-hydroxyl of the adenosine 
ribose, 2″-hydroxyl of the NMN ribose, and water molecule, respectively. 
Early studies regarding the catalytic mechanism of PARP-1-catalyzed poly(ADP-
ribosyl)ation were based on the sequence similarities between PARP-1 catalytic domain 
and those of ADP-ribosylating bacterial toxins including diphtheria toxin and 
Pseudomonas aeruginosa exotoxin A (244). In the toxins, a conserved glutamate was 
found to be essential for the attachment of a single ADP-ribose moiety onto specific host 
protein. Mutation of this residue impaired the ADP-ribosyltransferase activity and 
toxicity, while having little effect on NAD+ binding (245). This result suggested a 
catalytic role for the active site glutamate. Similarly, the role of a conserved Glu-988 
found in the catalytic domain of PARP-1 in catalyzing the formation of PAR polymer 
was investigated by site-directed mutagenesis (246). By estimating the amount of 
enzyme-digested components of PAR (see Section 1.2.2), the E988Q and E988A mutants 
were found to have limited reduction in initiation reaction, but almost incapable of 
performing chain elongation. E988D, on the other hand, could still produce PAR 
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polymers with branches, although to a shorter length. These data led to a proposed 
reaction mechanism for PARP-1 involving catalytic Glu-988, which is reminiscent of 
bacteria ADP-ribosylating toxins (Figure 1-15A). Glu-988 could serve in initiation by 
hydrogen bonding to position the incoming acceptor nucleophile or the donor NAD+ 
molecule. Acidic nucleophiles such as glutamate or aspartate carboxylic groups are 
presumably ionized at neutral pH, and may not require the activation by Glu-988, as 
implied by the minor effect in chain initiation of the E988A and E988Q mutants. For 
chain elongation, the 2′-hydroxyl group of the adenosine ribose is activated by the 
general base Glu-988 to perform nucleophilic attack to the donor NAD+ molecule. The 
activation process could involve a proton relay system which also includes the 3′-
hydroxyl group of the ribose, because PARP-1 automodification reaction using 3′-deoxy 
NAD+ analogues as substrates can only form either mono-ADP-ribosylated PARP-1 or 
protein-bound ADP-ribose oligomers (247-249). 
Later, the crystal structure of human PARP-1 catalytic domain complexed with 
carba-NAD+, an NAD+ analogue, revealed the striking homology of the active site 
architecture between PARP-1 and diphtheria toxin (250). Although only the electron 
density of the adenosine moiety within carba-NAD+ can be seen, it is believed that carba-
NAD+ occupies the acceptor site which the terminal ADP-ribose from a PAR chain 
would typically reside. By modeling in the donor NAD+ molecule from the diphtheria 
toxin–NAD+ co-crystal, the snapshot of the elongation reaction can be envisioned and the 
catalytic role of Glu-988 is justified (Figure 1-15B). 
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Figure 1-15. Reaction mechanism of protein poly(ADP-ribosyl)ation catalyzed by PARP-
1. (A) Proposed mechanisms for initiation, elongation, and branching 
reactions. Glu988 is the catalytic base. (B) Structure view of human PARP-1 
catalytic domain in complex with carba-NAD+ (PDB: 1A26) (250). The 
donor NAD+ (yellow) was modeled from the alignment of diphtheria toxin–
NAD+ crystal structure (PDB: 1TOX) (251). 
The mechanism of PAR branching is somewhat implicit. Based on the chemical 
linkage, the NMN moiety from NAD+ is assumed to occupy the same position as the 
adenosine moiety, and Glu-988 can facilitate the nucleophilic attack by the 2″-hydroxyl 
group in a similar fashion as the elongation reaction (Figure 1-15A). However, it is 
difficult to account for the low branching frequency (ca. 2%) in the overall polymerized 
ADP-ribose residues. One possible explanation based on the available crystal structure 
information is that the orientation of the nascent PAR polymer chain when entering the 
active site determines whether elongation or branching reaction would occur (Figure 1-
16). It is the pyrophosphate group rather than the adenosine moiety that is fixed by a 
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more extensive hydrogen bond network, thus giving the flexibility for the terminal ADP-
ribose unit to position differently. Catalysis proceeds through elongation or branching 
reaction depends on whether the terminal adenosine ribose or internal NMN ribose is 
closer to the donor NAD+ binding site, respectively (250) (Figure 1-15). Consistent with 
this hypothesis, Tyr-986, which forms hydrogen bond with the pyrophosphate group, was 
found to be an important residue to modulate the branching frequency of PAR in a 
random mutagenesis study of PARP-1 (252). While the Y986H mutant retained 14% of 
the wild-type enzyme activity, the branching frequency was about 15-fold higher. It is 
proposed that the histidine mutant could have more favorable hydrogen bond with the 
pyrophosphate group, augmenting the symmetry of the acceptor binding site. Enhanced 
symmetrical binding of the terminal ADP-ribose unit in two orientations gives the 
increased branching frequency, despite the fact that shortened polymer was produced. 
The model is also in agreement with distal addition mechanism during polymer 
elongation/branching (247, 253). 
 
 
Figure 1-16. Surface representation of human PARP-1 catalytic domain in complex with 
carba-NAD+ (PDB: 1A26) (250). The light green arrows indicate the 
possible two orientations of incoming acceptor PAR polymer. 
Donor NAD+ binding pocket 
Acceptor 
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1.5.3 Regulation of PARP-1 activity 
While PARP-1 activity is stimulated by binding to damaged DNA, negative 
charges from the PAR polymers are rapidly accumulated on PARP-1 as a result of 
automodification. PARP-1 activity is inhibited consequently. Ebisuzaki et al. first studied 
the mechanism of how PARP-1 is inactivated following automodification. They showed 
that automodified PARP-1 has decreased affinity for DNA by sucrose gradient 
differential centrifugation, and the addition of PARG into the reaction reactivates PARP-
1 by degrading PAR polymers and restoring PARP-1–DNA complex (254). These data 
suggested a “PARP shuttling” model where electrostatic repulsion between the newly 
formed PAR polymers and DNA leads to the dissociation of automodified PARP-1 from 
DNA (5). Subsequently, PARG can hydrolyze the PAR polymers presented on PARP-1, 
allowing a new catalytic cycle to begin. The presence of PARG could have important 
regulatory effect on PARP-1 activity, as demonstrated in vitro where sustained PARP-1 
activity can be achieved (255).  
Several other cellular components can also regulate PARP-1 activity. Histones, 
including H1 and core histones, can affect the size distribution of PAR polymers and the 
modification proportion among different acceptor proteins (256). Small molecules or 
bivalent cations such as Mg2+ and Ca2+, polyamines, and ATP were demonstrated to be 
allosteric regulators for PARP-1 in addition to DNA (257). The effects of 
posttranslational modifications on PARP-1 activity have already been discussed in 
Section 1.3.2. 
 
1.6 THESIS STATEMENT 
PARP-1-catalyzed poly(ADP-ribosyl)ation is a protein posttranslational 
modification reaction implicated in various cellular processes including DNA repair, 
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inflammation, and cell death. The enzymatic activity of PARP-1 is allosterically 
stimulated by binding to DNA, resulting in the synthesis of PAR polymers from NAD+ 
onto specific proteins. Despite its discovery over fifty years ago, the molecular 
mechanism used by PARP-1 remains unsettled. Work presented in this dissertation aims 
to provide further mechanistic details regarding PARP-1 catalysis from three different 
perspectives. Chapter 2 describes the DNA binding properties of PARP-1 in a 
quantitative way using single-molecule fluorescence spectroscopy and enzyme kinetics. 
Chapter 3 and chapter 4 address the mechanistic issues with an emphasis on the role of 
NAD+. In chapter 3, fluorinated NAD+ analogues were designed and synthesized to 
investigate the distinct steps of poly(ADP-ribosyl)ation involving the cleavage of the 
NAD+ ribose–nicotinamide glycosidic bond. The result is consistent with the proposed 
mechanism that an oxocarbenium-like transition state is formed during enzyme catalysis. 
In chapter 4, biochemical and analytical methods were applied to locate the 
automodification sites of PARP-1 and characterize the chemical nature of ADP-ribose–
protein linkages. MS data confirm the existence of automodification sites beyond domain 
D in PARP-1. However, whether poly(ADP-ribosyl)ation of lysine residues is attributed 
to the ADP-ribosyltransferase activity of the enzyme remains an open question. In 
chapter 5, a radioactivity-based assay using two structurally distinguishable protein 
constructs was developed to interrogate the molecularity of DNA-dependent PARP-1 
automodification. The results support a bimolecular, intermolecular process. Moreover, 
structural characterization of domain C by top-down MS analysis excludes the possibility 
of a domain C-mediated dimerization of PARP-1. Instead, interdomain contacts involving 
domain C are important for catalysis. 
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Chapter 2. Quantitative Binding Kinetics of Human PARP-1 with DNA  
2.1 INTRODUCTION 
The poly(ADP-ribosyl)ation activity of PARP-1 is strongly activated by binding 
to DNA strand breaks (179), and its binding repertoire is highly diverse in terms of DNA 
structures rather than sequence dependence (225). There are three zinc fingers present in 
human PARP-1 (Figure 1-11), with FI and FII mainly responsible for the recognition of 
DNA (181). It has been proposed that these two zinc fingers have differential roles in 
DNA recognition. PARP-1 lost its ability to bind to DNA single-strand breaks when FII 
was structurally disrupted by mutations, whereas little effect was observed for the 
corresponding mutations in FI (182). Another report, however, suggested that both FI and 
FII are required for PARP-1’s binding to and subsequent enzymatic activation by single-
strand breaks, but only FI is required for similar effect induced by double-strand breaks 
(181). Therefore, how the two zinc fingers cooperate to recognize different DNA 
structures and stimulate PARP-1 activity is still unclear. 
Recent structural characterizations of PARP-1 DNA-binding domains in complex 
with DNA ligands provided a visual aid to understanding the mechanism of this 
recognition process. Pascal et al. reported that FI or FII alone binds to the minor groove 
of a double-strand blunt end DNA, capping the end base in an identical fashion (Figure 1-
12A, B) (233). On the contrary, Oliver et al. found that when using a single polypeptide 
comprising the two zinc fingers to crystallize with a duplex DNA containing 5′ single-
base overhang, FI and FII clustered at the same side of the DNA, with FI flipping its 
polarity from the minor groove to the major groove (Figure 1-12C). Considering the 
amino acid connectivity of the protein in the crystal also implied that the two zinc fingers 
do not come from the same polypeptide chain. Mutation of amino acid residues involved 
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in contouring the hydrophobic interface between FI and FII abolished the relocalization 
of the mutant protein to DNA damaged site. These results support a model of DNA-
induced dimerization of PARP-1 via cooperation of FI and FII. Interestingly, another 
crystal structure of PARP-1 domains complexed with a blunt-end DNA duplex, omitting 
FII and the BRCT domain, showed that FI, FIII, the WGR domain all collapsed onto the 
same DNA end (200). The overall PARP-1 molecule and the DNA interact in a 1:1 ratio. 
These studies shed light on the mechanistic details of how PARP-1 recognizes DNA, but 
on the other hand created controversy regarding the binding stoichiometry of PARP-1 
versus different DNA structures. 
To study the DNA-binding properties of PARP-1 from a different perspective, 
single-molecule fluorescence colocalization technique was employed to address this 
question in a quantitative way. Using a Cy3-labeled PARP-1 DNA-binding domain AB 
and a Cy5-labeled DNA ligand, protein–DNA interactions can be directly visualized in 
real time under the single-molecule platform. Binding rate constants can be deduced from 
the analysis of dwell-time distributions of combined individual binding event. Unlike 
ensemble biochemical techniques which measure averaged signal from the sample, 
single-molecule technique allows the identification of heterogeneity in binding 
properties. Based on the experimental data, two binding modes were suggested for the 
PARP-1 AB domain–DNA interactions, one involving a strongly-associated protein–
DNA complex and the other being transient. Specific time trajectories revealed some 
binding events involving multiple proteins. In addition, a continuous kinetic assay was 
developed to monitor the enzyme activity of PARP-1, and the effect of DNA ligands was 
also estimated. 
 
 
 55 
2.2 MATERIALS AND METHODS 
2.2.1 Preparation of Cy3-labeled AB domain of PARP-1 
Preparation of Cy3-labeled AB domain of PARP-1 was conducted by Dr. Meilan 
Wu in our laboratory. The protein construct used in the experiments, termed AB-150, 
contains a six amino acid mutations LC*TPSR at residues 150–155 of AB domain of 
PARP-1 (residues 1–232), where C* denotes a formylglycine residue generated in vivo 
by coexpression with His-tagged formylglycine generating enzyme (FGE) (258). The 
formylglycine-containing AB domain, termed Fgly-AB-150, was cloned in the form of 
His-tagged maltose-binding protein (MBP) fusion protein at the N-terminal of AB, 
separated by a tobacco etch virus (TEV) protease cleavage sequence. The resulting 
plasmid His6-FGE/MBP-Fgly-AB-150/pET was used to transform E. coli BL21 
CodonPlus (DE3)-RP or Rosetta strain. The expression and purification of Fgly-AB-150 
was following similar procedures described in Section 3.2.4 and Section 4.2.1. The 
existence of an aldehyde group on the protein was confirmed by reacting with biotin-
hydrazide followed by immunoblotting using horseradish peroxidase (HRP)-conjugated 
streptavidin (Pierce) and colorimetric 1-Step TMB-Blotting substrate solution (Pierce). 
The site-specific labeling of Cy3 to Fgly-AB-150 was accomplished by 
incubating Fgly-AB-150 with 16- to 20-fold molar excess of Cy3-hydrazide (GE 
Healthcare). The unreactive dye was removed by dialysis. The labeling yield was 
determined by UV absorbance at 280 nm and 555 nm using NanoDrop. Typical labeling 
efficiency was about 60%. 
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2.2.2 Preparation of Cy5-labeled DNA ligands 
Single-strand DNA primers were all purchased from IDT. The sequences are 
listed in Table 2-1. To generate double-strand DNA duplex 66G (66-mer duplex with a 
single base gap in the center) and 32B (32-mer duplex with blunt ends) (Figure 2-1), 
corresponding single-strand primers were diluted to a 25 μM final concentration in the 
annealing buffer containing 30 mM HEPES, pH 7, and 100 mM potassium acetate. The 
mixtures were heated at 95°C for 2 min and then slowly cooled down to room 
temperature. The DNAs were aliquoted and stored at −20°C until further use. 
 
 
DNA duplex Primers used Primer sequence 
66G 
66-bpR 5′-AAGGGCAAGGCTGCTGTGGACCCTGCTGTGGGC TGGAGAACAAGGTGATCTGCGCCCTGGTCCTGG-3′ 
33-bp 5′-GCCCACAGCAGGGTCCACAGCAGCCTTGCCCTT-3′ 
 32-bp 5′-CCAGGACCAGGGCGCAGATCACCTTGTTCTCC-3′ 
32B 
32-bp 5′-CCAGGACCAGGGCGCAGATCACCTTGTTCTCC -3′ 
32-bpR 5′-GGAGAACAAGGTGATCTGCGCCCTGGTCCTGG-3′ 
Table 2-1. Primer sequences for the DNA ligands used in the experiments. Base 
underlined and in boldface was labeled with Cy5 at its 3′-end. 
 
 
Figure 2-1. Diagrams for the DNA duplex 66G and 32B used in the experiments. 
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2.2.3 Single-molecule fluorescence colocalization experiments 
Biotinylated Cy5-DNA duplexes were immobilized onto a surface-passivated 
quartz slide via streptavidin conjugation. Briefly, the quartz slide was passivated with a 
mixture of methoxy polyethylene glycol (mPEG) and biotinylated mPED (1-2%), which 
allowed the immobilization of streptavidin on the slide. Biotinylated Cy5-DNA was then 
captured by streptavidin, forming a three-layer sandwich. 
A typical image chamber (0.5 × 1.5 cm) sealed with double-sided tape was made 
between the quartz slide surface and a cover slip. Typically, a 50-μL sample of 50 pM 
DNA duplex in the loading buffer containing 50 mM Tris-HCl, pH 8.0, and 250 mM 
NaCl was loaded onto the slide which had been pre-treated with streptavidin. Unbound 
DNA was washed out by loading buffer. Various concentrations of Cy3-labeled AB-150 
proteins diluted in a buffer containing 50 mM Tris-HCl, pH 8.0, and 25 mM NaCl were 
used for imaging. To extend the fluorescence lifetime during experiments, an oxygen 
scavenging system consisting of 0.6 mM Trolox, 11% glucose, 0.1 mg/mL glucose 
oxidase, 0.05 mg/mL catalase, 1 mM MgCl2, and 10 mM DTT was pre-mixed with AB-
150 protein before loading into the chamber. PEGylated slides, the oxygen scavenging 
system, and the access to a microscope equipped with a total internal reflection 
fluorescence (TIRF) platform were all kindly provided by Dr. Rick Russell in the 
Department of Molecular Biosciences at UT-Austin.  
Protein–DNA binding events were recorded in real time by mounting the imaging 
chamber beneath the prism-type total internal reflection (TIR) microscopy consisting of 
an inverted Olympus IX-71 microscope connected to an I-PentaMAX IIC CCD camera 
with a cooling unit (Princeton Instruments). For fluorescence colocalization experiment, 
Cy3-labeled proteins were directly excited with a 532 nm laser (Crystalaser). The 
excitation was conducted continuously with 10 frames per second and data acquisition for 
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90 s. Alternatively, it was done with a 2-s on/2-s off pulsed excitations manner for a total 
of 300 s of 1 frame per second data acquisition. To confirm the existence of immobilized 
Cy5-labeled DNA molecules, the chamber was excited with a 637 nm laser (Coherent) 
for 10 s at the end of each movie. Movies were taken from random fields of view for each 
protein concentration. All the single-molecule experiments were conducted with the 
assistance of Dr. Brian Cannon, a postdoctoral associate in Dr. Rick Russell’s laboratory. 
 
2.2.4 Single-molecule experiments data analysis 
Fluorescence produced from each field of view was splitted into Cy3 (donor) and 
Cy5 (acceptor) intensity signals by a pair of dichroic mirrors. Colocalized signals from 
Cy3 and Cy5 dyes were matched using an affine transformation that was based on pre-
determined fiducial markers using fluorescent nanobeads (259). Raw intensity time 
trajectories of the colocalized Cy3 and Cy5 signals were generated for each movie using 
a in house single-molecule data analysis program written by Dr. Brian Cannon. For the 
pulse-type excitation experiments, the dwell time of individual binding event was 
manually identified based on the appearance and disappearance of the Cy3 or Cy5 signals 
above average background threshold of each time trace. The combined cumulative dwell-
time histograms from each individual binding event were fitted to a single- or double-
exponential cumulative function ( f (t) = Σ Ai [1 – exp (−ki t) ], where i = 1 or 2) to obtain 
binding rate constants. 
 
2.2.5 Continuous kinetic assay for poly(ADP-ribosyl)ation 
An enzyme-coupled continuous kinetic assay was developed to monitor 
poly(ADP-ribosyl)ation activity (Figure 2-2). A nicotinamide molecule is produced for 
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each round of NAD+ turnover, which can be converted to nicotinic acid and ammonia by 
E. coli nicotinamidase PncA. The resulting ammonia can be further used in a second 
coupled reaction where α-ketoglutarate (α-KG) is reductively aminated to glutamate by 
glutamate dehydrogenase (GDH) from Proteus sp. in the presence of NADPH. The 
reaction can be continuously monitored at 340 nm UV absorbance, reflecting the 
consumption of NADPH which is correlated to the consumption of NAD+ by PARP-1. 
Briefly, a 100-μL reaction containing varying concentrations of NAD+, 1 mg/mL 
DNA, 150 μM NADPH, 3.5 μM PncA, 5 mM α-KG, 1 unit GDH, 100 mM Tris-HCl, pH 
8.0, and 10 mM DTT was premixed for 5 min to equilibrate the background signal. The 
reaction was initiated by adding PARP-1 into the mixture. Initial rate was obtained by 
monitoring the reaction at 340 nm. For steady-state kinetics with regard to DNA, 1 mM 
NAD+ was used with varying concentrations of DNA. In some cases, PARP-1 was 
substituted by equimolar of AB and CDEF domains to reconstitute a functional PARP 
complex in trans. 
 
 
Figure 2-2. Enzyme-coupled continuous assay for monitoring poly(ADP-ribosyl)ation 
of PARP-1. 
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2.3 RESULTS 
2.3.1 Rationale of generating AB with site-specific labeled Cy3 fluorophore 
To study the DNA binding kinetics of PARP-1, the DNA-binding domain AB was 
selected to be the protein construct in use, considering the major functions of the two zinc 
fingers and the feasibility of in vitro protein purification. The labeling positions of 
fluorophores were based on the crystal structure of FI or FII in complex with a duplex 
DNA (Figure 1-12A and B). By putting the fluorophore at the base-stacking loop of FII 
(residue 151), and the 3′-end of double-strand DNA, a colocalization signal and/or 
fluorescence resonance energy transfer (FRET) phenomenon was expected. 
To site-specific label a fluorophore onto the protein, a technique applying 
bioorthogonal reaction was adopted from the literature (258). A stretch of amino acid 
between residues 150 and 155 was replaced by a characteristic sequence LCTPSR. This 
short peptide motif can be recognized by the formylglycine generating enzyme (FGE) 
from Mycobacterium tuberculosis, where the cysteine residue is coverted to a 
formylglycine moiety by this enzyme. The resulting aldehyde tag (Fgly) allows the 
functionalization with different probes carrying a hydrazide group, such as biotin-
hydrazide and Cy3-hydrazide. 
The generation of Cy3-labeled AB-150 protein was achieved by in vivo 
coexpression with the FGE followed by in vitro labeling with Cy3-hydrazide. Control 
reactions using biotin-hydrazide as a probe confirmed the transformation of cysteine to 
Fgly by immunoblotting. The DNA-binding property of AB-150 was comparable to wild-
type AB domain using electrophoretic mobility shift assay. 
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2.3.2 Overview of the single-molecule fluorescence colocalization experiment 
The design of the single-molecule fluroesence colocalization experiment was to 
monitor the binding process of a free Cy3-labeled protein interacting with a immobilized 
Cy5-labeled DNA molecule in a small chamber created on the quartz slide in real time 
(Figure 2-3). The DNA was first immobilized through a biotin-streptavidin affinity 
complex. Cy3-labeled protein, AB-150 in this case, was then loaded into the chamber. 
The binding process was monitored by a prism-type total internal reflection fluorescence 
microscopy (TIRF, Figure 2-4A). TIRF microscopy confines laser to a 100-nm thin layer 
above the glass slide, which greatly improves the signal-to-noise performance of 
fluorescence detection (260). The fluorescence signal was splitted into two channels (Cy3 
and Cy5) and was recorded simultaneously (Figure 2-4B). 
 
 
Figure 2-3. Schematic diagram of Cy3-labeled PARP-1 AB domain interacting with 
Cy5-labeled DNA at the single-molecule platform.  
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Figure 2-4. Experimental setup for the single-molecule fluorescence colocalization 
study. (A) Schematic diagram of a prism-type total internal reflection 
fluorescence microscopy (261). (B) Left, example of a field view in both 
Cy3 and Cy5 channels; right, mapping protein–DNA complexes in the Cy3 
channel based on the locations of DNA molecules in the Cy5 channel. (C) 
Representative time traces for a specific protein/DNA molecule. ton and toff  
are protein on-time, off-time, respectively. (D) Dwell-time analysis of 
individual binding events leads to a cumulative histogram, which can be 
fitted to a cumualtive exponential function to obtain binding constants. 
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For the initial 300 s, a 532 nm laser was used in a pulsed manner (2-s on/2-s off) 
to excite the protein. Binding (association) of the protein onto DNA would result in an 
increase of Cy3 fluorescence signal, whereas dissociation would result in a decrease of 
the signal. At 305 s, the locations of DNA molecules were visualized by direct excitation 
with a 637 nm laser for 10 s. This also caused the photobleaching of Cy5 dyes. The 
number of DNA molecules was used as basis to search for effective protein–DNA 
complexes presented in the Cy3 channel. The colocalized Cy3 and Cy5 signals were 
matched according to a calibration procedure using fluorescent nanobead markers (259). 
The time trajectories for each spot were then generated by an in house written program 
(Figure 2-4C). The duration of each binding events was manually identified from the Cy3 
fluorescence channel, as exemplified by ton and toff. The combined dwell time (either “on” 
or “off”) were used to construct a cumulative histogram, where the binding constants can 
be estimated by fitting the data to either a cumulative single- or double-exponential 
function, assuming a one-step binding model (Figure 2-4D). Fitting the “on-time” would 
give dissociation constant, whereas fitting the “off-time” would afford association 
constant. Fluorescent intensities of each binding events were also examined as an 
indicator for protein multimerization. Control experiments using Cy3-coated nanobeads 
revealed the fluorophore blinking off rate kblink off to be 0.0096 s−1. No Cy3 signal was 
observed when no DNA was immobilized on the slide, supporting that the observed 
signals truly came from the protein–DNA binding. 
 
2.3.3 Binding kinetics of PARP-1 AB domain with DNA 
Presented in Table 2-2 are the data obtained from AB-150 interacting with either 
66G or 32B DNA assuming a one-step binding model (Protein+DNA <-> P-D) (Figure 2-
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1). In the case of 66G, which mimicks DNA single-strand break, fitting the combined 
“dwell-on” time histogram with single-exponential function gave a dissociation constant 
koff a value of 0.027 s−1. For 32B which mimicks DNA double-strand break, the 
cumulative histogram was best fit with double-exponential function, affording two 
dissociation constants, with 0.039 s−1 representing the averaged slow phase population 
(koff, slow) and 0.65 s−1 describing the fast phase population (koff, fast). Two binding modes 
can thus be assigned to each rate constant. Association constants were also obtained by 
fitting the “dwell-off” time, but low event numbers may hamper further interpretation. 
The fast-phase rate constant for 32B is comparable to the one for 66G. By estimating the 
amplitude of each exponential term, it suggests that about 60% of the population of AB-
150/32B complex accounts for a weakly-associated protein–DNA complex with a 
maximum lifetime of 3 s due to the pulsed time limit. The other 40% population 
represents strongly-associated AB-150/32B complex similar to the AB-150/66G 
complex, and is kinetically more stable than the blinking rate of Cy3 dye (kblink off = 0.0096 
s−1). 
 
 
 66G 32B 
Rate (s−1) koff koff, slow A1 koff, fast A2 appkon A 
[Protein] 
0.1 nM 0.018 0.036 44.51 0.41 57.50 0.022 24.38 
1 nM 0.026 0.040 41.12 0.76 33.89 0.040 23.97 
10 nM 0.036 0.040 49.59 0.79 56.40 0.098 29.11 
Average rate (s−1) 0.027 0.039  0.65    
Table 2-2. Binding constants for AB-150 with DNA ligands. 
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2.3.4 Steady-state enzyme kinetics of PARP-1 
A steady-state continuous enzyme kinetic assay was developed to evaluate PARP-
1 automodification activity (Figure 2-2). For each round of ADP-ribosyl transfer reaction, 
equimolar of nicotinamide is produced, which can be converted in a coupled enzyme 
reaction catalyzed by PncA to nicotinic acid and ammonia. The free ammonia can be 
further used in a GDH-catalyzed reductive amination of α-KG to glutamate in the 
presence of NADPH. Therefore, the consumption of NAD+ by PARP-1 can be correlated 
to the consumption of NADPH by continuous monitoring at 340 nm UV absorbance. 
To ensure that PARP-1 is limiting the reaction, varying concentrations of PARP-1 
were used to see if there is a linear relationship between the PARP-1 concentration and 
enzyme activity readout. Figure 2-5A shows that between 10 and 100 nM PARP-1, the 
enzyme activity (μM/s) is proportional to the enzyme concentration. This result indicates 
that the coupled enzyme reactions are not rate limiting, supporting the measured activity 
attributed to PARP-1. By varying NAD+ concentrations, steady-state kinetic constants of 
PARP-1 can be obtained by fitting to Michalis-Menten equation, with a kcat and KM value 
of 1.39 s−1 and 46 μM, respectively (Figure 2-5B). 
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Figure 2-5. Steady-state kinetics of PARP-1 automodification reaction with respect to 
NAD+.  
It has been shown by previous group member Dr. Peng Gao and other laboratories 
that using PARP-1 truncated domains complementary to each other can reconstitute 
PARP-1 activity. In the previous single-molecule experiments, only binding constants 
were evaluated. Here, the activity of AB in the presence of CDEF was investigated using 
similar kinetic assay using 66G as the DNA activator. Fluorophore-labeled AB or 66G 
counterparts were also tested for the effect of carrying a bulky chemical group on enzyme 
activity. The data are shown in Figure 2-6 and the kinetic parameters are summarized in 
Table 2-3. The kcat values are comparable to the wild type PARP-1. KM values are in 
nanomolar range, indicating tight binding of DNA with the protein. However, there 
seems to be some variations of KM values among samples, ranging from 8 to 36 nM. 
There is no obvious trend in terms of the effect of fluorophore labeling, but the similar 
kcat/KM values obtained from all four samples suggest that the interference of fluorophore 
labeling with enzyme activity is minimal.  
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Figure 2-6. Steady-state kinetics of PARP-1 automodification reaction in the form of 
AB/CDEF protein complex with respect to DNA. 
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Protein DNA kcat (s−1) KM (nM) kcat/KM (s−1nM−1) 
AB 66G 1.77 15.2 0.116 
AB-150 66G 1.32 8.35 0.158 
AB 66G-Cy5 2.44 36.6 0.067 
AB-150 66G-Cy5 2.02 18.8 0.107 
Table 2-3. Steady-state kinetic parameters of AB/CDEF and 66G with respect to DNA. 
 
2.4 DISCUSSION 
2.4.1 Study of PARP-1–DNA interactions using single-molecule technique 
Single-molecule fluorescence microscopy has become an emerging technique to 
study biological problems (262). The advantage of single-molecule over traditional bulk 
biochemical approach is that it can follow the dynamic change over time for each 
individual molecule, which is impossible for ensemble methods because it requires all 
molecules to be synchronized over the observational trajectories. Rapid mix or rapid 
quench apparatus used to study transient kinetics of biological systems at ms scale, but 
single-molecule fluorescence spectroscopy can have a wider time scale, ranging from μs 
to even days. The ability of this method to monitor the entire time trajectory can reveal 
hidden intermediates or multiple pathways within the system. In addition, TIRF 
microscopy further reduced the background signal significantly, allowing possible 
assignment of signals to a “single molecule.” These features all support single-molecule 
techniques to become more useful to address biological questions in a quantitative way 
(263). 
It is well known that PARP-1 is activated upon binding to DNA. Despite early 
biochemical studies of its functions or with regard to individual domain or single amino 
acid residue, the overall picture of how the DNA-binding domains cooperate to recognize 
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DNA and relays this allosteric activating signal to the active site remains elusive. 
Furthermore, recent structural characterizations using different protein fragments and 
DNA constructs showed contradicting results in terms of protein–DNA stoichiometry 
(198, 200, 235, 236). These issues prompted us to investigate this complex protein–DNA 
recognition process using a novel single-molecule technique. 
Single-molecule fluorescence spectroscopy has been proven useful in the studies 
of protein–DNA interactions (260, 264). One of the challenges when we were facing at 
the initial stage of this study is to determine where to label the fluorophore on the protein, 
and which protein construct to work with. We decided to label the Cy3 fluorophore at the 
base-stacking loop of FII based on its proximity to DNA and the solvent accessibility 
without disrupting protein folding from the crystal structure report (233). Domain AB 
was chosen to be the protein construct used in the experiments considering its small size 
(ca. 26 kDa) and major function in DNA recognition.  
Once the location has been derermined, another important technical aspect of the 
experiment is the preparation of site-specifically labeled protein. A widely used method 
for protein labeling is to utilize the chemical reactivity of cysteine toward maleimide. The 
desired location must be a cysteine residue, and all the other Cys need to be mutated to 
Ala or other residues. This method, however, may not be applicable to PARP-1 AB 
domain, due to the potential reactivity of Zn2+-coordinating Cys toward labeling reagents, 
resulting in disruption of protein structure. 
Alternatively, engineering proteins to carry a functional group capable of 
performing bioorthogonal reactions has been rapidly developed (265). Among them, a 
genetically encoded aldehyde tag was selected for this study (258). A stretch of six amino 
acid in the base-stacking loop of FII was mutated to LCTPSR which can be recognized 
by a bacterial FGE enzyme. By coexpression with the enzyme, Cys was converted to 
 70 
formylglycine (Fgly) in vivo. Control experiments successfully verified the labeling of 
biotin-hydrazide onto the aldehyde-containing protein by immunoblotting, and the 
labeled protein AB-150 behaves similarly to the wild type in terms of DNA binding 
ability. This bioorthogonal protein labeling method has recently been demonstrated in a 
single-molecule experimental setup as well (266). 
 
2.4.2 Two binding modes were identified for PARP-1–DNA complexes 
With the materials in hand, single-molecule fluorescence colocalization 
experiments were conducted. The 2-s on/2-s off pulse-type excitation method was 
adopted mainly for the purpose of extending the photostability of Cy3 and Cy5 dyes. 
Despite sacrificing minimal resolution between binding events (3 s apart), binding events 
with intensities higher than the averaged background can still be manually selected. 
There are several technical issues that may complicate the data analysis. One example is 
the photostability of Cy5-DNA molecules used as the basis for identifying true protein–
DNA complexes. The current method is to directly excite the Cy5 dyes to locate these 
molecules while they emit fluorescent signals. The rapid photobleaching of Cy5-DNA 
molecules may result in the low numbers of countable protein–DNA complexes. Low 
numbers of molecules present in each view may require more movies to be taken. The 
extended experimental acquisition time may render the oxygen scavenging system 
ineffective, which in turn accelerate the photobleaching of Cy3 dyes. The solution to this 
problem is to constantly replenishing new oxygen scavenging system to maintain the 
photostability of the cyanine dyes. 
Another complication is the concentration limit. To avoid strong background 
signals, the reaction chamber was set to have minimal volume. However, the highest 
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tolerable concentration at which individual fluorescent molecule can be resolvable is at 
the order of 10 nM. Due to diffraction limit, concentration used above 10 nM may result 
in multiple molecules present at a single spot, complicating the interpretation of a single 
binding event involving multermerized proteins, or more than one event happens at the 
same spot. 
The experimental results suggest that there is one binding mode for AB-150 
interacting with 66G, whereas there are two binding modes for 32B. It is unclear that the 
two binding modes are intercovertible, or there are two binding site present on the very 
32B DNA duplex. Nonetheless, the biphasic distribution of the cumulative histograms 
uncovered the potential multiple protein–DNA complexes with distict lifetime, which 
would otherwise be invisible using ensemble experiments. 
The averaged dissociation constants of the strongly-associated species is about 
0.027 s−1 and 0.039 s−1 for 66G and 32B, respectively. A reported PARP-1–DNA binding 
kinetics using surface plasmon resonance techniques showed a dissociation constant (koff) 
value of 0.0034 s−1 for double-strand break DNA duplex, which is an order tigher than the 
data reported here (267). The weaker binding of domain AB could be due to the 
disruption of the base-stacking loop important for capping DNA end (Figure 1-12). After 
the initiation of the current study, an X-ray crystal structure using FI and FII within the 
same polypeptide in complex with a 5′-overhand duplex DNA revealed a striking 
dimerization composition of FI and FII, underscoring the significance and versatility of 
the base-stacking loop not only in DNA end capping, but also in protein–protein 
interactions (235). 
While discrepancy in kinetic numbers can be attributed to different protein 
constructs being used, it is also possible that there exists additional protein–DNA 
complex within the recognition process. Recently, a loop within PARP-1 residues 480–
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540 contains a double-strand break-binding domain (199). Dr. Meilan Wu also reported 
that the amino acid stretch of residues 626–645 is also important for DNA-binding (198). 
It is possible that protein domains beyond AB also contribute to the over DNA affinity of 
PARP-1. 
Regarding the fluorescence intensities of each binding events, it is evident that 
some event may involve protein multimerization (Figure 2-7). The close proximity of 
Cy3 and Cy5 dyes may also induce FRET to occur. Detailed analysis to clearly dissecting 
the fluorescence intensities regarding whether it is resulted from FRET or crossover 
excitation is currently underway. 
 
 
 
Figure 2-7. Representative time trace of AB-150 interacting with 32B showing possible 
multimerization of the protein. The fluorescence intensity from the Cy3 
channel is colored in green, and the Cy5 channel is colored in red.  
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2.4.3 Steady-state kinetics of PARP-1 
Measuring the incorporation of radioactivity signal into PARP-1 proteins using 
32P-NAD+ represents the paradigmatic method to determine the activity of PARP-1. 
However, this method in discontinuous in its nature. An HPLC-based method has also 
been reported to estimate PARP-1 activity (218), it is also discontinuous. To complement 
the current methods for PARP-1 steady-state kinetics, an enzyme-coupled continuous 
assay involving the bacterial nicotinamidase PncA and GDH was developed. The result 
showed that by properly adjusting the concentration of each reaction component can 
make the PARP-1 activity rate-limiting (Figure 2-5A). The reported kcat and KM values are 
comparable to the literature (0.41 s−1 and 59–278 μM for kcat and KM, respectively) (268). 
Note that the assay cannot distinguish between the NADase activity and the poly(ADP-
ribosyl)ation acitivity, since both reactions produce nicotinamide as by-product. 
To apply this method for the estimation of the effect of fluorophore-labeling of 
protein and/or DNA constructs on the enzyme activity, equimolar of AB and CDEF were 
used in the automodification in the presence of 66G. The results showed that fluorophore-
labeling did not have a significant effect on the enzyme activity. The fitting of the data to 
Michalis-Menten model with regard to the concentration of allosteric DNA ligands may 
be puzzling. But the estimated KM within nanomolar range is consistent with other reports 
that PARP-1 has strong affinity for DNA. 
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Chapter 3. Investigation of Human PARP-1 Catalytic Mechanism 
Using Fluorinated NAD+ Analogues 
3.1 INTRODUCTION 
PARP-1 catalyzes protein poly(ADP-ribosyl)ation reaction in which PAR 
polymers are synthesized from NAD+ onto substrate proteins, with itself being the major 
acceptor (269). The reaction is catalyzed by a single active site located within domain F 
(or the catalytic domain, Figure 1-11), and can be dissected into three steps: initiation, 
elongation, and branching. Each step can be viewed as the cleavage of the ribose–
nicotinamide glycosidic bond and the concomitant transfer of ADP-ribose moiety to 
different nucleophilic acceptors. Based on the sequence homology of PARP-1 catalytic 
domain to bacterial ADP-ribosylating toxins and available crystal structures, a reaction 
mechanism involving Glu-988 as the general base has been proposed (Figure 1-15). The 
γ-carboxylate of the glutamate serves as an anchor for positioning donor and/or acceptor 
substrates, or directly activates the acceptor hydroxyl groups for nucleophilic attack 
(246). 
The mechanism of how enzymes catalyze the nicotinamide–ribosyl bond cleavage 
has been the subject of research by several groups. Early study carried out by 
Oppenheimer and colleagues provided substantial insight into the mechanism of chemical 
and enzymatic hydrolysis (by calf spleen NAD+ glycohydrolase) of NAD+ using a series 
of NAD+ analogues containing H, NH2, OH, N3 and F at the 2′-position, either in ribose 
or arabinose configuration (270). Analogues with arabinose configuration cannot be 
hydrolyzed by the enzyme and instead are slow binding inhibitors. The log of the rate 
constants of the reactions forms a linear relationship with the corresponding inductive 
Taft constants. The log of the Vmax of the enzymatic reaction using natural NAD+ (OH at 
the 2′-position) would directly fall on the line defined by other analogues only with the 
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choice of an alkoxide Taft constant, not neutral hydroxyl group. These results suggested 
that the anionic character developed at the 2′-hydroxyl group may inductively stabilize 
the oxocarbenium intermediate (or oxocarbenium-like transition state) during enzyme 
catalysis (271). An active site base, later confirmed to be Glu-988 in PARP-1, could 
facilitate the inductive stabilization through interacting with the 2′-hydroxyl group. 
Schramm et al. measured the kinetic isotope effect (KIE) of diphtheria toxin-catalyzed 
NAD+ hydrolysis and the data is consistent with an ANDN mechanism in which both 
leaving group and nucleophile participate in the reaction coordinate (272). Quantum 
mechanics/molecular mechanics (QM/MM) simulation study of the hydrolysis of NAD+ 
by PARP-1 showed that the cleavage of nicotinamide–ribosyl bond proceeds through a 
dissociative SN2 mechanism via an oxocarbenium-like transition state structure (or 
intermediate), in agreement with previous linear free energy and KIE studies (273). 
Moreover, Lim et al. also performed density functional theory (DFT) calculations 
combined with continuum dielectric methods to systematically assess the roles of 
pyrophosphate, the nucleophilicity of different attacking nucleophiles, and the medium in 
affecting the NAD+ non-redox reaction pathways and demonstrated their contributions to 
accelerating the reaction in general (274). 
Experimental evidence regarding the NAD+ substrate scope of poly(ADP-
ribosyl)ation reaction is somewhat limited for PARP-1. Radiolabeled adenosine 
deoxyribose analogues of NAD+ have been enzymatically synthesized in the 80s in order 
to characterize the mechanism of chain elongation catalyzed by PARP-1 (275). While 3′-
deoxy-NAD+ can be incorporated into oligomeric PAR polymers (247), 2′-deoxy-NAD+ 
was not a substrate for PARP-1 as no radiolabeled protein was detected following the 
incubation. Instead, it was shown to be a noncompetitive inhibitor for PARP-1 with a Ki 
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value of 32 μM (275). This compound, however, could be processed by an arginine-
specific mono-ADP-ribosyltransferase from turkey erythrocytes (276).  
In order to gain further insight into the reaction mechanism of each step of 
poly(ADP-ribosyl)ation, fluorinated NAD+ analogues were designed and synthesized in 
our laboratory to study the PAR polymer formation. Fluorine-containing compounds are 
useful small molecule probes to elucidate enzymatic reaction mechanisms (277). The 
electronegativity and van der Waals radius of fluorine render it an effective hydroxyl 
group mimic. Our interest mainly lies in examining the stepwise mechanism of 
poly(ADP-ribosyl)ation during PAR polymer growing. Replacement of the 2′-hydroxyl 
group of the adenosine ribose with fluorine (2′-deoxy-2′-fluororibo-NAD+, 2AF-NAD+) 
is expected to prevent chain elongation (Figure 3-1). Likewise, replacement of the 2″-
hydroxyl group of the NMN ribose with fluorine (2″-deoxy-2″-fluororibo-NAD+, 2NF-
NAD+) could potentially block branching reaction, generating linear PAR polymers 
(Figure 3-1). In this chapter, fluorinated NAD+ analogues were synthesized and detailed 
characterizations of the reaction outcomes with human PARP-1 were carried out with our 
focus set on 2NF-NAD+, since the biological significance of the branching reaction has 
not been fully addressed. The data indicate that 2NF-NAD+ is not a substrate for PARP-1, 
whereas 2AF-NAD+ has minor inhibitory effect on PAR formation. This result, however, 
is consistent with the proposed catalytic mechanism of ADP-ribosyltransferase reaction 
that an oxocarbenium-like transition state is formed during enzyme catalysis. A fluorine 
atom present at the C2 position of the nicotinamide ribose hampers the formation of such 
intermediate, rendering no catalytic turnover of the compound. 
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Figure 3-1. Structures of NAD+ analogues as mechanistic probes for PARP-1. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Expression and purification of human NMNAT-1 in E. coli 
The cDNA encoding human nicotinamide/nicotinate mononucleotide 
(NMN/NaMN) adenylyltransferase-1 (NMNAT-1), a gift from Dr. Hong Zhang in UT 
Southwestern Medical Center, was subcloned into pET-28b(+) vector (Novagen) by Dr. 
Peng Gao. Expression of the protein was carried out in Escherichia coli (E. coli) BL21-
CodonPlus strain (Stratagene). A glycerol stock of cells transformed with NMNAT-
1/pET-28b(+) was re-streaked onto a Luria-Bertani (LB) agarose plate containing 50 
μg/mL ampicillin and incubated at 37 °C overnight. A single colony was selected to 
produce a 10 mL, overnight small culture subsequently used to inoculate a 1 L large 
culture of LB medium containing the same selection antibiotic. Cells were grown at 37 
°C with shaking at 200 rpm until OD600 reached 0.6. Protein expression was induced by 
the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 
1.0 mM, and the cells were allowed to grow for an additional 12-18 h at 18 °C with 
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shaking at 125 rpm. Cells were then harvested by centrifugation at 4500 × g for 30 min 
and stored at −80 °C until lysis. 
All the protein purification procedures were performed at 4 °C. Thawed cells 
were re-suspended in lysis buffer containing 50 mM sodium phosphate, 300 mM NaCl, 
10 mM imidazole, 1 mM β-mercaptoethanol and 10% glycerol at pH 8.0. Sonication for 
ten 10-sec bursts with 30-sec cooling interval was used to completely disrupt cells. Cell 
debris was removed by centrifugation at 16,000 × g for 30 min, and the supernatant was 
incubated with Ni-NTA agarose resin (Qiagen) on a tube rotator for 1 h. The lysate 
mixture was transferred onto a column, gravity drained, and washed with lysis buffer. 
The His6-tagged NMNAT-1 protein was then eluted with elution buffer (lysis buffer with 
250 mM imidazole). The desired fractions were checked by Bradford reagent (Bio-Rad), 
pooled, and dialyzed against lysis buffer. Purity of the protein was analyzed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Purified His-tagged 
NMNAT-1 was aliquoted, flash-frozen in liquid nitrogen, and stored at −80 °C. 
 
3.2.2 NMNAT-1 activity assay  
To test the activity of purified human NMNAT-1, a high-performance liquid 
chromatography (HPLC)-based assay was developed to monitor the production of NAD+ 
in the presence of NMN, ATP, and NMNAT-1. Briefly, a 200-μL reaction mixture 
containing 120 μM NMN, 10 mM ATP, 30 μM purified NMNAT-1, 2 units inorganic 
pyrophosphatase, 10 mM MgCl2, and 50 mM sodium phosphate at pH 7.4 was incubated 
at 37 °C for 2 h. The reaction mixture was filtered through a Microcon centrifugal filter 
unit YM-10 (EMD Millipore) to remove the enzyme. The filtrate was subjected to HPLC 
analysis using System Gold HPLC (Beckman Coulter) equipped with a Luna C18(2) 5 
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μm 250 × 4.6 mm analytical column (Phenomenex). The sample was eluted with the 
mobile phase consists of 10 mM ammonium acetate (solvent A) and acetonitrile (solvent 
B). The gradient started from 0 to 10% B over 20 min, 10 to 70% B over 2 min, and 70 to 
0% B over 2 min before re-equilibration for 6 min. The flow rate was 1 mL/min and the 
eluent was monitored by UV absorbance at 260 nm. Product peaks were verified by co-
elution with standards.  
 
3.2.3 Chemoenzymatic synthesis of fluorinated NAD+ analogues 
2NF-NAD+ was chemoenzymatically synthesized according to the scheme shown 
in Figure 3-2 with the input from Dr. Chi-Hau Chen. The fluorinated NMN moiety 
(compound 6) was chemically synthesized with the assistance of Richiro Ushimaru. 
Enzymatic coupling of 6 with ATP using NMNAT-1 gave the final product 2NF-NAD+. 
 
 
Figure 3-2. Synthetic scheme for 2NF-NAD+. 
Synthesis of compound 5 
D-Arabinose was selectively protected to leave 2′-hydroxyl available. Fluorine 
was introduced by tetra-n-butylammonium fluoride (TBAF), affording compound 3 with 
1) TBDPSCl
    imidazole
2) 2,2-dimethoxypropane
    p-TsOH
3) TBAF
HO O
OH
OH
OH
OHO
OH
O O OBnO
OBn
OH
OMe O
BnO
OBn
OMe O
AcO
OAc
OAc
F F
OHO
OH F
N
O
NH2
OO
OH F
N
O
NH2
P
O
O
OH
OO
OH F
N
O
NH2
P
O
O
OO
OH OH
PO
O
N
NN
N
NH2O
1) BnBr
2) CSA
1) H2, Pd/C
    HCO2H
2) Ac2O, H2SO4
1) Tf2O
2) TBAF
N
N
O
TMS
TMS
TMSOTf
CF3CO2
diphosphoryl chloride
m-cresol
ATP
NMNAT-1
D-Arabinose
1)
2)  NH3, MeOH
1 2
1
3 4
5 6 2NF-NAD+
 80 
a ribose configuration. Change of protecting group to acetyl moiety at the anomeric 
position enhanced its reactivity and facilitated the installation of nicotinamide base. The 
resulting compound 5 is a mixture of α- and β-nucleosides and the desired β-form was 
further purified by HPLC using a Nucleosil C18 5 μm 250 × 10.0 mm semi-preparative 
column (Phenomenex) and a gradient elution consists of 0.1% TFA in water (solvent A) 
and 0.1% TFA in acetonitrile (solvent B). Following injection, the column was eluted 
with 0 to 5% B over 15 min and washed with 100% B before re-equilibrating back to 
100% A for 4 min. The flow rate was 4 mL/min and the eluent was monitored by UV 
absorbance at 260 nm. Peak corresponding to the β-form of compound 5 (retention time 
~7 min) was collected, neutralized with saturated sodium bicarbonate, lyophilized and 
verified by NMR and ESI-MS analysis (278). 
Synthesis of compound 6 
Selective phosphorylation of the primary hydroxyl group of 5 was carried out 
according to the literature (279). The resulting nucleotide 6 was purified by semi-
preparative HPLC similar to 5. The mobile phase consists of 10 mM ammonium acetate 
(solvent A) and acetonitrile (solvent B). The gradient elution was 0 to 10% B over 10 
min. Peak corresponding to 6 (retention time ~3.5 min) was collected, lyophilized, and 
verified by NMR and ESI-MS analysis (278). 
Synthesis of 2NF-NAD+ 
The synthesis of 2NF-NAD+ was accomplished using an enzymatic coupling 
reaction catalyzed by NMNAT-1 between 6 and ATP. The reaction was carried out 
according to the literature with some modifications (278). Purified NMNAT-1 was added 
(final concentration 30 μM) to a 1-mL reaction containing 3.8 mM compound 6, 10 mM 
ATP, 20 units inorganic pyrophosphatase, 10 mM MgCl2, and 50 mM sodium phosphate 
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at pH 7.4. The reaction mixture was incubated at 37 °C for 1 h and then quenched by 
adding 3 μL 0.1% TFA. Quenched reaction was filtered through a Microcon centrifugal 
filter YM-10 unit to remove proteins. The filtrate was subjected to semi-preparative 
HPLC purification following the same procedure for compound 5 except for the gradient 
elution starting from 0 to 5% B over 10 min. Peak corresponding to 2NF-NAD+ 
(retention time ~9.3 min) was collected, lyophilized, and verified by NMR and ESI-MS 
analysis (278). 
Synthesis of 2AF-NAD+ 
The synthesis of 2AF-NAD+ (Figure 3-1) was accomplished by Dr. Peng Gao. 
 
3.2.4 Cloning, expression, and purification of human full-length PARP-1 and the 
E988Q mutant using baculovirus expression vector system in insect cells 
The human PARP-1 gene was cloned from PARP-1/pET-28b(+) into the NdeI 
and XhoI restriction sites of an intermediate pFastBac HT B/MBP-Tev vector generated 
in our laboratory by Dr. Yung-nan Liu from the pFastBac HT B vector (Invitrogen). The 
pFastBac HT B/MBP-Tev vector contains an engineered decahistidine-tagged maltose-
binding protein (MBP, molecular weight ~42.5 kDa) sequence followed by a tobacco 
etch viruse (TEV) protease cleavage site N-terminal to the gene of interest for expression. 
The resulting pFastBac HT B/MBP-Tev-PARP plasmid was amplified in E. coli DH5α 
competent cells (Stratagene) for downstream purpose. E988Q mutant construct was 
generated in house by Dr. Zhihua Tao using site-directed mutagenesis (72) and followed 
by the same procedures mentioned above. 
To generate the recombinant baculovirus shuttle vector “bacmid” for the MBP-
Tev-PARP construct, MAX Efficiency DH10Bac E. coli competent cells (Invitrogen) 
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were transformed with pFastBac HT B/MBP-Tev-PARP according to the manufacturer’s 
instructions for the Bac-to-Bac Baculovirus Expression System. Successful transformants 
were selected by blue/white colony screening on LB agar plates containing 50 μg/mL 
kanamycin, 7 μg/mL gentamicin, 10 μg/mL tetracycline, 100 μg/mL Bluo-gal, and 40 
μg/mL IPTG. Following the incubation of the streaked LB agar plates at 37 °C for 48 h, 
white colonies were selected, re-streaked on a fresh LB agar plate containing the same 
additives, and incubated at 37 °C overnight to confirm the white colony phenotype. A 
single white colony was then used to inoculate an LB medium containing 50 μg/mL 
kanamycin, 7 μg/mL gentamicin, and 10 μg/mL gentamicin. The liquid culture was 
incubated at 37 °C overnight with shaking at 250 rpm. The resulting recombinant bacmid 
DNA was subsequently purified using the Purelink HiPure Plasmid DNA Miniprep Kit 
(Invitrogen) and confirmed by PCR based on the manufacturer’s protocol. 
The bacmid DNA containing MBP-fused PARP-1 gene was used to transfect Sf21 
insect cells using Cellfectin II Reagent (Invitrogen). When the cells displayed signs of 
late stage infection (cytopathic effect) roughly 72-96 h after transfection, the medium was 
collected by centrifugation at 1,000 × g for 5 min. The resulting P1 viral stock was then 
used to generate P2 viral stock by infecting Sf21 cells grown in suspension. 
For the expression of MBP-PARP-1 fusion protein, P2 viral stock was used to 
infect Sf21 insect cells grown in serum-free SF-900 II SFM medium at 27 °C with 
shaking at 100 rpm. At 72 h post infection, the infected cells were harvested by 
centrifugation at 4,000 × g for 10 min. Cells were re-suspended and washed with PBS 
twice and stored at −80 °C until further usage. 
Protein purification was carried out at 4 °C as follows. Harvested cells were 
thawed and re-suspended in lysis buffer containing 20 mM HEPES, 1 M NaCl, 10 mM 
imidazole, 1% Triton X-100, 1 mM β-mercaptoethanol, and 10% glycerol at pH 7.5. 
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Cells were disrupted by sonication and debris was removed by centrifugation at 4,000 × g 
for 20 min. The resulting supernatant was incubated for 1 h on a tube rotator with 10 mL 
Ni-NTA agarose resin (Qiagen) which had been pre-equilibrated with the lysis buffer. 
The mixture was then loaded onto a column for gravity drainage and washed extensively 
with at least 10× column volume wash buffer (lysis buffer containing 20 mM imidazole). 
To facilitate the washing process for large-scale preparation, the mixture could be 
centrifuged at 500 × g for 3 min and buffer-exchanged with wash buffer twice before 
loading onto the column for gravity drainage. The MBP fusion protein was eluted with 
elution buffer (lysis buffer containing 250 mM imidazole and 300 mM NaCl). Fractions 
containing desired protein were checked by Bradford reagent (Bio-Rad), pooled and 
dialyzed against 2 × 1 L lysis buffer. His6-tagged TEV protease was added into the 
protein solution to a final concentration of 5% (w/w) 2 h after the start of dialysis, for the 
cleavage of the His10-MBP tag. The mixture was continued to undergo dialysis with 1 L 
fresh buffer for 24 h at 4 °C. 
To remove the cleaved MBP tag from the non-tagged protein, the protein mixture 
was slowly passed through a column containing 10 mL Ni-NTA agarose resin. The 
protein recovered in the flow through was concentrated using an Amicon Ultra-15 
centrifugal filter unit with a 10-kDa cut-off (EMD Millipore). The desired protein 
construct contains two additional amino acid residues, glycine followed by histidine, at 
the protein N-terminus owing to the engineered TEV cleavage sequence. Depending on 
specific experiment, further purification was performed by size-exclusion 
chromatography using AKTA FPLC system equipped with a Superdex 200 column (GE 
Healthcare). The elution buffer contains 10 mM sodium phosphate, 100 mM NaCl, and 
10% glycerol at pH 7.5. Purified protein was aliquoted, flash-frozen in liquid nitrogen, 
and stored at −80 °C. 
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3.2.5 PARP-1 automodification assay 
In vitro PARP-1 automodification assay was carried out by adding PARP-1 (final 
concentration 0.5-5 μM) to a reaction mixture containing varying concentrations of 
NAD+ or NAD+ analogues in the 10-μL PARP reaction buffer (25 μg/mL calf thymus 
DNA (Sigma-Aldrich), 250 μM dithiothreitol (DTT), 10 mM MgCl2, 100 mM Tris-HCl 
at pH 8.0). The mixture was incubated at room temperature for 30 to 60 min and then 
quenched by 2× SDS-PAGE loading buffer. To assess the effect of fluorinated NAD+ 
analogues on the wild-type poly(ADP-ribosyl)ation reaction, either a mixture of NAD+ 
and NAD+ analogues was included in the same reaction, or a 30-min pre-incubation of 
NAD+ analogues with PARP-1 and other reaction components was performed before the 
addition of natural NAD+ to initiate poly(ADP-ribosyl)ation. The reaction was analyzed 
by SDS-PAGE and visualized by SYPRO Ruby protein gel stain (Invitrogen) or Western 
blotting. The blots were probed with anti-PAR polymer monoclonal antibody (Trevigen) 
followed by incubation of horseradish peroxidase-conjugated anti-mouse IgG secondary 
antibody (Sigma-Aldrich), and the protein bands were visualized using Amersham ECL 
Prime Western Blotting chemiluminescence substrate (GE Healthcare). 
A radioactivity-based PARP-1 automodification assay was also adopted to 
achieve higher detection sensitivity. Total volume of 6 μL reactions were conducted 
under the same condition described above in the presence of a mixture of cold NAD+ and 
[adenylate-32P]NAD+ (32P-NAD+, American Radiolabeled Chemicals). The ratio of NAD+ 
to 32P-NAD+ was 0.1 mM–0.1 µCi µL−1. The samples were resolved by a 16 × 16 cm 
SDS-PAGE gel, exposed on a storage phosphor screen (GE Healthcare) and detected by 
Typhoon FLA 9500 (GE Healthcare). Gel images were processed by ImageJ (National 
Institutes of Health). 
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3.2.6 Sequencing gel-based poly(ADP-ribose) polymer analysis 
Characterization of PAR polymers generated by PARP-1 automodification in the 
presence of fluorinated NAD+ analogues was carried out according to the literature with 
some modifications (64). Briefly, a 100-µL automodification reaction containing varying 
concentrations of fluorinated NAD+ analogues were pre-incubated with 0.2 µM PARP-1 
in the PARP reaction buffer (see Section 3.2.5) at room temperature for 30 min prior to 
the addition of 100 µM NAD+ and 0.1 µCi 32P-NAD+. The reaction was allowed to 
proceed for 10 min before quenching by equal volume of 20% (w/v) trichloroacetic acid 
(TCA). Protein precipitates were collected by centrifugation and washed twice with ice-
cold ethanol. The precipitates were then digested in a 30-µL solution containing 0.5 M 
KOH and 50 mM EDTA at 37 °C for 15 min. After base digestion, the solution was 
brought to neutral pH by adding Tris-HCl buffer. Cleaved PAR polymers were extracted 
by equal volume of phenol/chloroform/isoamyl alcohol (25:24:1, v/v/v, saturated with 10 
mM Tris, pH 8.0 and 1 mM EDTA). The aqueous layer was collected and the extraction 
was repeated twice. The combined aqueous layer was mixed with 2× PAR loading buffer 
(40% urea, 25 mM NaCl, 4 mM EDTA, 0.02% bromophenol blue, and 0.02% xylene 
cyanol) and resolved by 20% Tris-borate-EDTA PAGE system followed by 
phosphorimaging. Gel images were processed by ImageJ (National Institutes of Health). 
 
3.2.7 HPLC-based poly(ADP-ribose) polymer analysis 
For HPLC-based PAR polymer analysis, nonradioactive NAD+ was used. A 300-
µL automodification reaction was set up as described in Section 3.2.6, except for using 1 
µM PARP-1 and 1 mM NAD+, or a mixture of 500 µM NAD+ and 500 µM fluorinated 
NAD+ analogues. A solution of 50 µg/mL histone H1 was also included to enhance 
overall PAR production. Steps leading to the generation of aqueous solution containing 
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free PAR polymers after extraction by organic solvent were followed according to 
Section 3.2.6. PAR polymers were precipitated at −20 °C overnight by adding ethanol to 
a final concentration of 70% (w/w). The precipitates were collected by centrifugation at 
16,000 × g, washed by ether, dried by speedvac, and stored at −20 °C until further 
process.  
To digest the PAR polymers into monomeric subunits (Figure 1-5), the pellets 
were first re-dissolved in 56 µL 0.1 M ammonium bicarbonate and 2 mU 
phosphodiesterase (PDE) was added to the solution for 2 h incubation at 37 °C. Alkaline 
phosphatase (AP) was added subsequently to convert digestion products into their 
corresponding nucleoside forms. The digestion was allowed to proceed overnight at 37 
°C. After removing enzymes by YM-10 membrane filtration, the filtrate was subjected to 
C18 analytical HPLC analysis using 10 mM ammonium acetate (solvent A) and methanol 
(solvent B) as mobile phase components. The gradient program started from 7 to 14% B 
over 35 min. The flow rate was 1 mL/min and the elution was monitored by UV 
absorbance at 260 nm. Product peaks were verified by co-elution with standards and 
collected for ESI-MS analysis. 
 
3.2.8 Analysis of PARP-1 initiation reaction using HPLC 
To confirm if the initiation step occurred during protein poly(ADP-ribosyl)ation, 
automodification reaction (50 µL) of PARP-1 or the E988Q mutant was set up according 
to the same procedures described in Section 3.2.5, in the presence of 500 µM NAD+ or 
NAD+ analogues. The reaction was incubated at 37 °C for 1 h. PAR polymer was then 
cleaved by the addition of purified PARG enzyme (kindly provided by Dr. Yung-nan 
Liu) for overnight incubation at 37 °C, leaving the proximal ADP-ribose attached to 
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proteins. The samples were passed through a YM-10 filtering unit to filter out ADP-
ribose produced by PARG digestion. The filtrate (sample a) was saved for subsequent 
C18 analytical HPLC analysis. After washing with 0.1 M ammonium bicarbonate, the 
remaining proteins were further digested with PDE for 3 h followed by AP for 1 h at 37 
°C. Proteins were again filtered out by YM-10 filtering unit, and the filtrate (sample b) 
was subjected to C18 analytical HPLC analysis using 10 mM ammonium acetate (solvent 
A) and acetonitrile (solvent B) as mobile phase. The gradient elution were 0 to 10% B 
over 20 min and 7 to 12% B over 25 min for sample a and b, respectively. The flow rate 
was 1 mL/min and the elution was monitored by UV absorbance at 260 nm. Product 
peaks were verified by co-elution with standards. 
 
3.2.9 NAD+-dependent redox reaction assay 
To test if fluorinated NAD+ analogues can serve as redox cofactors, NAD+-
dependent oxidation of ethanol to acetaldehyde catalyzed by alcohol dehydrogenase 
(ADH) from yeast (YADH) was used as the model reaction. A 100-µL solution contains 
0.33 M ethanol, 8.3 mM NAD+ or NAD+ analogues, and 50 mM sodium pyrophosphate, 
pH 9.2. The reaction was initiated by adding 1 µL YADH (2 µg/mL in 0.1 M sodium 
phosphate, pH 7.5 and 0.1% BSA) and monitored continuously fore every 10 sec by UV 
absorbance at 340 nm using Agilent 8453 Spectrophotomer (Agilent Technologies) for 
350 sec. Reactions using 2NF-NAD+ as cofactor was monitored by NanoDrop (Thermo 
Scientific) before and 350 sec after the addition of the enzyme. 
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3.3 RESULTS 
3.3.1 Chemoenzymatic synthesis of fluorinated NAD+ analogues 
The key steps to synthesize 2NF-NAD+ are the preparation of the fluorinated 
NMN moiety in the ribose configuration, and the formation of pyrophosphate linkage 
between NMN and AMP. The fluorinated NMN moiety was prepared chemically starting 
from D-arabinose. After a series of selective introductions of protecting groups, 
nucleophilic fluorination of compound 2 at 2′ position was carried out using triflic 
anhydride and TBAF, generating compound 3 with ribose configuration. Changing from 
methoxy group to acetyl group at the anomeric carbon increased the reactivity of 
compound 4 for the introduction of nicotinamide base. The reaction to generate 
nucleoside 5 with exclusive β-configuration was performed according to the literature 
(280). However, a mixture α- and β-form was observed by the crude NMR of the 
reaction, potentially due to the substitution of fluorine for the hydroxyl group at 2′-
position. The desired β-form was then purified by semi-preparative HPLC and converted 
to nucleotide 6 by phosphorylation of the primary alcohol. 
The final coupling of the fluorinated NMN moiety (6) with AMP was 
accomplished by the enzyme NMNAT-1. To test the activity of in vitro overexpressed 
NMNAT-1, the production of NAD+ was examined using natural β-NMN and ATP. In 
the presence of enzyme, a peak at ~11.6 min was observed, which co-eluted with NAD+ 
(Figure 3-3), suggesting that the purified NMNAT-1 was active. With the active enzyme 
in hand, the coupling of fluorinated NMN (6) with ATP was conducted, and the product 
was purified by semi-preparative HPLC. As shown in Figure 3-4, the peak eluted at ~9.2 
min was collected and subjected to ESI-MS and NMR analysis. The data are consistent 
with the chemical structure of 2NF-NAD+ (see Appendix). The reaction was not complete 
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even in the presence of ~2.6-fold molar excess of ATP, and compound 6 can be 
recovered for further conversion. 
 
 
Figure 3-3. HPLC analysis of NMNAT-1 activity assay. (a) Mixture of chemical 
standards. NAM, nicotinamide. (b) ATP. (c) Reaction in the absence of 
NMNAT-1. (d) Reaction in the presence of NMNAT-1. (e) Co-injection of 
the reaction (trace d) with AMP. (f) Co-injection of the reaction (trace d) 
with NAD+. (g) NMNAT-1 only. 
 
 
Figure 3-4. Semi-preparative HPLC chromatograms of the production of 2NF-NAD+ by 
NMNAT-1-catalyzed reaction. (a) 10-μL injection of the reaction. (b) 400-
μL injection of the reaction. 
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2AF-NAD+ has been synthesized in our laboratory previously, and the compound 
was verified by ESI-MS. 
 
3.3.2 Poly(ADP-ribosyl)ation of PARP-1 using fluorinated NAD+ analogues 
To test if fluorinated NAD+ analogues are substrates for PARP-1, in vitro 
poly(ADP-ribosyl)ation reaction of PARP-1 was carried out and resolved by SDS-PAGE. 
Western blotting using anti-PAR monoclonal antibody was performed to detect the 
formation of PAR polymer, whereas PARP-1 protein was stained by SYPRO Ruby dye. 
The results of PARP-1 automodification reactions using either NAD+ and/or 2NF-
NAD+ as substrates are shown in Figure 3-5. PARP-1 was poly(ADP-ribosyl)ated in the 
presence of NAD+, as revealed by anti-PAR immunoblotting (lane 2-5, Figure 3-5A) and 
the smear in the protein stain (lane 1-5, Figure 3-5B). However, no PAR polymer was 
formed in the presence of 2NF-NAD+ alone, and no protein smear was observed (lane 6-
9, Figure 3-5). Longer exposure of the gel did not show any PAR signal. To further 
confirm the observation, similar reactions with increased PARP-1 concentration was 
carried out. Neither PAR polymer signal was detected, nor protein band shift was 
observed (Figure 3-5C). The results suggest that no PAR polymer was produced by 
PARP-1 in the presence of 2NF-NAD+ alone. 
To assess if 2NF-NAD+ has any effect on native poly(ADP-ribosyl)ation, 
automodification of PARP-1 was conducted using a mixture of NAD+ and 2NF-NAD+, or 
pre-incubation of PARP-1 with 2NF-NAD+ prior to the addition of NAD+. All reactions 
showed comparable level of poly(ADP-ribosyl)ation as those using NAD+ alone (lane 10-
14, Figure 3-5A, B; lane 8-12, Figure 3-5C). Reactions with higher molar ratio of 2NF-
NAD+ to NAD+ (up to 20:1) did not show significant difference of protein smear as 
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compared to reactions using NAD+ only (Figure 3-5D). The results indicate that 2NF-
NAD+ has minimal perturbation on native poly(ADP-ribosyl)ation reaction. 
 
  
Figure 3-5. Poly(ADP-ribosyl)ation of PARP-1 using NAD+ or 2NF-NAD+ as 
substrates. (A) Automodification reactions of 0.5 µM PARP-1 detected by 
anti-PAR monoclonal antibody. Lane 1, no NAD+; lanes 2-5, increasing 
NAD+ concentrations of 5, 10, 50, 100 µM, respectively; lanes 6-9, 
increasing 2NF-NAD+ concentrations of 5, 10, 50, 100 µM, respectively; 
lanes 10-14, increasing 2NF-NAD+ concentrations of 5, 10, 50, 100, 200 µM 
respectively in the presence of 50 µM NAD+. M, molecular weight marker. 
(B) Same reactions performed in (A) detected by SYPRO Ruby stain. (C) 
Automodification reactions of 5 µM PARP-1. Lane 1, no NAD+; lanes 2-4, 
increasing NAD+ concentrations of 50, 100, 200 µM, respectively; lanes 5-7, 
increasing 2NF-NAD+ concentrations of 50, 100, 200 µM, respectively; 
lanes 8-12, pre-incubation of 50, 100, 200, 500, 1000 µM 2NF-NAD+, 
respectively for 30 min before the addition of 200 µM NAD+. Top, anti-PAR 
Western blot. Bottom, SYPRO Ruby stain. (D) Automodification reactions 
of 1 µM PARP-1. Lane 1, no NAD+; lane 2, 50 µM NAD+; lanes 3-7, 
increasing 2NF-NAD+ concentrations of 10, 50, 100, 500, 1000 µM, 
respectively in the presence of 50 µM NAD+. 
To gain further insight into the effect of 2NF-NAD+ on poly(ADP-ribosyl)ation, 
radioactivity-based automodification reactions were performed to achieve higher 
detection sensitivity. In the presence of 32P-NAD+, PARP-1 was poly(ADP-ribosyl)ated 
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and shifted toward the gel interface. Poly(ADP-ribosyl)ation still occurred as the 
concentration of 2NF-NAD+ increases, and the intensity did not change significantly 
(Figure 3-6). However, more ADP-ribose was produced, suggesting that NAD+ 
hydrolysis could be more efficient than PAR polymer elongation in the presence of 2NF-
NAD+.  
 
 
Figure 3-6. Radioactivity-based PARP-1 automodification reactions in the presence of 
2NF-NAD+. Lane 1, NAD+ only; lane 2, PARP-1 + 50 µM NAD+; lanes 3-7, 
increasing 2NF-NAD+ concentrations of 10, 50, 100, 500, 1000 µM, 
respectively in the presence of 50 µM NAD+. Interface indicates the 
boundary between the stacking and the separating gel. ADPR, ADP-ribose. 
2AF-NAD+, another fluorinated analogue with fluorine atom substituted at the C2 
position of the adenosine ribose ring, was assessed for its ability to poly(ADP-ribosyl)ate 
PARP-1 in a similar way to 2NF-NAD+. PARP-1 incubated with 2AF-NAD+ alone was 
not able to generate PAR polymers detected by anti-PAR Western blot (lane 2, Figure 3-
7). 2AF-NAD+ also did not have significant effect on the native poly(ADP-ribosyl)ation 
reaction, as protein smear was observed for all reactions up to 20-fold molar excess of the 
analogue (lane 3-7, Figure 3-7). These results suggest that no PAR polymers were formed 
1""""""""2""""""""3""""""""4""""""""5""""""""6"""""""7"""""""
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in the presence of 2AF-NAD+ alone, and no significant effect of 2AF-NAD+ on PARP-1 
automodification in the presence of natural substrate NAD+. 
 
 
Figure 3-7. Poly(ADP-ribosyl)ation of PARP-1 using NAD+ or 2AF-NAD+ as 
substrates. Lane 1, PARP-1 only; lane 2, 25 µM 2AF-NAD+; lanes 3-7, 
increasing 2AF-NAD+ concentrations of 0, 10, 50, 100, 500 µM, 
respectively in the presence of 25 µM NAD+. Top, anti-PAR 
immunoblotting. Bottom, SYPRO Ruby stain. M, molecular weight marker. 
 
3.3.3 PAR polymer analysis 
PARP-1 incubated with fluorinated NAD+ analogues alone were not able to 
produce PAR polymers, but the possibility that these analogues can be incorporated into 
the growing polymer in the presence of natural NAD+ still cannot be ruled out. If 2NF-
NAD+ was incorporated into the PAR polymer, the composition and branching frequency 
of the polymer could be altered. Therefore, detailed analyses of the PAR polymer in the 
presence of fluorinated NAD+ analogues were conducted. 
To estimate the size distribution of the in vitro synthesized PAR polymers, a 
modified sequencing gel-based assay was adopted. PARP-1 automodification reactions 
were performed in the presence of 32P-NAD+ and fluorinated NAD analogues. PAR 
polymers attached on the proteins were chemically cleaved and purified with a method 
similar to the purification of nucleic acids. Radiolabeled PAR polymers were resolved on 
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a TBE-buffered PAGE gel and visualized by phosphorimaging analysis. Radioactivity 
can be observed at the origin of each well, representing highly branched PAR polymers 
which cannot enter into the gel. A ladder of PAR polymers were observed according to 
their size, with the shortest one migrated to the bottom of the gel. 2NF-NAD+ seemed to 
have minimal effect on the distribution of PAR polymers (lane 2-4, Figure 3-8), whereas 
reduced level of highly branched polymers as well as linear polymers were observed with 
increasing concentrations of 2AF-NAD+ (lane 6-8, Figure 3-8). 
 
 
Figure 3-8. PAR polymer analysis using modified sequencing PAGE gel in the presence 
of 32P-NAD+. Lanes 1 and 5, 100 µM NAD+ only; lanes 2-4, increasing 2NF-
NAD+ concentrations of 50, 100, 500 µM, respectively in the presence of 
100 µM NAD+; lanes 6-8, increasing 2AF-NAD+ concentrations of 50, 100, 
500 µM, respectively in the presence of 100 µM NAD+; lane 9, NAD+ only. 
The composition of PAR polymers can be analyzed by digesting the polymers 
with PDE and AP, producing nucleoside version of AMP, PR-AMP and PR2-AMP 
(Figure 1-5). The resulting monomeric units can be separated by HPLC. If any 
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fluorinated analogue was incorporated into the growing polymer, a different elongation 
unit should be detected. 
 
 
Figure 3-9. Analyses of the composition of PAR polymers. (A) HPLC profiling of 
monomeric units derived from enzymatic digestion of PAR polymers. (a) 
Samples derived from PARP-1 automodification using 1 mM NAD+. (b) 
Samples derived from PARP-1 automodification using 500 µM NAD+ and 
500 µM 2NF-NAD+. (c) Co-injection of a and b. Ado, adenosine; R-Ado, 
ribosyladenosine; X, unknown peak. (B) ESI-MS analysis of the peak 
denoted with an asterisk (*) in A. (C) Chemical structures of 
ribosyladenosine (left) and the fluorinated ribosyladenosine (right).  
The result of HPLC analysis was shown in Figure 3-9A. Enzymatic digestion of 
samples derived from native PAR polymers gave UV-detectable adenosine (terminal 
unit) and ribosyladenosine (elongation unit) (trace a). The amount of branching unit was 
below UV detection limit. Enzymatic digestion of PAR polymers in the presence of a 
mixture of NAD and 2NF-NAD also gave similar profile (trace b). Co-injection of trace a 
and b resulted in the same HPLC profile (trace c). To confirm the identity of the asterisk 
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peak (retention time ~27.6 min) and to rule out the possibility of peak overlapping 
between ribosyladenosine and its fluorinated analogue, the peak was collected and 
submitted to ESI-MS analysis. The result is consistent with ribosyladenosine and no 
signals corresponding to its fluorinated analogue were observed (calculated [M+H]+ = 
400.2, found 400.1, Figure 3-9B). 
 
3.3.4 Analysis of the initiation step of poly(ADP-ribosyl)ation by PARP-1 
Protein poly(ADP-ribosyl)ation reaction can be dissected into three steps: 
initiation, elongation, and branching. Based on the results presented in the previous 
sections, incubation of PARP-1 with either 2NF-NAD+ or 2AF-NAD+ alone was not able 
to produce PAR polymers derived from these NAD+ analogues. However, the methods 
used to detect PAR polymer formation (anti-PAR immunoblotting and protein smear 
detection) did not provide information regarding the initiation reaction, that is, a single 
ADP-ribose (or its fluorinated version) unit attaching onto the protein. The absence of 
PAR polymer formation does not necessarily mean that initiation reaction, or mono-
ADP-ribosylation of PARP-1 does not occur. To provide evidence for the occurrence of 
initiation step of PARP-1 poly(ADP-ribosyl)ation, an HPLC-based method was 
developed to monitor the production of adenosine, which is derived from enzymatic 
digestion of the proximal ADP-ribose unit attached to the protein after initial mono-ADP-
ribosylation. The E988Q mutant of PARP-1, which only catalyzes mono-ADP-
ribosylation reaction, was included as a positive control. Reactions omitting either PARP-
1 or substrate NAD+s further served as negative controls to account for background signal 
during sample process. After 30-min incubation of the reaction mixtures, the modified 
proteins were separated from the remaining solution by passing through a molecular 
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weight cutoff centrifugal unit. Both the proteins and the filtrate were saved for HPLC 
analyses to examine the possibility of any NAD+ substrate turnover. The modified 
proteins were treated with PARG to trim PAR polymers down to one ADP-ribose unit. 
Subsequent digestion with PDE and AP released the adenosine moiety from the protein-
proximal ADP-ribose. The filtrate was analyzed by HPLC directly without further 
treatment. 
The HPLC traces from the enzymatic digestion of modified proteins are shown in 
Figure 3-10A. A peak eluted at ~7.2 min in trace a was confirmed to be adenosine, as 
expected for PARP-1 automodification using NAD+. A larger peak of adenosine was 
observed in trace d for the reaction of E988Q and NAD+. This is consistent with the 
notion that the mutant can only catalyze mono-ADP-ribosylation. A relatively small peak 
corresponding to adenosine was observed for PARP-1 or E988Q incubated with 2NF-
NAD+ (trace b and e), as well as reactions with PARP-1 proteins (trace c and f) or 
substrate NAD+s alone (trace g and h). The results indicate that there is residual amount 
of NAD+ remained on the membrane of the centrifugal unit, or binding to the proteins 
even after buffer wash. Therefore, analyses of modified proteins are not sufficient to 
conclude that there is turnover of 2NF-NAD+ or not. 
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Figure 3-10. HPLC analysis of the initiation step of poly(ADP-ribosyl)ation catalyzed by 
PARP-1 or its mutant E988Q. (A) Samples derived from enzymatic 
digestion of the modified PARP-1 or control reactions omitting either 
PARP-1 or substrate NAD+s. (B) Samples derived from the remaining 
filtrate after removing PARP-1 which had undergone automodification. 
Reaction conditions for each trace are as follows: (a) PARP-1 with NAD+, 
(b) PARP-1 with 2NF-NAD+, (c) PARP-1 only, (d) E988Q with NAD+, (e) 
E988Q with 2NF-NAD+, (f) E988Q only, (g) NAD+ only, (h) 2NF-NAD+ 
only, (i) Chemical standard of adenosine and ADP-ribose in A and B, 
respectively. 
The HPLC traces from the filtrate of the reaction mixtures are shown in Figure 3-
10B. For the PARP-1 reaction with NAD+, almost all NAD+ was consumed and the 
production of ADP-ribose (retention time ~6.5 min) was observed due to the NAD+ 
hydrolysis side reaction (trace a). A small peak of NAD+ was eluted at ~11 min in the 
E988Q reaction filtrate (trace d), consistent with the fact that less turnover of NAD+ 
compared to wild-type PARP-1. However, a peak corresponding to 2NF-NAD+ was 
observed for both PARP-1 and the E988Q mutant (trace b and e). No ADP-ribose was 
noticed, suggesting that enzyme-catalyzed hydrolysis of 2NF-NAD+ did not take place 
under the experimental condition. Enzyme only controls omitting substrate NAD+s 
indicated no small molecule contamination (trace c and f), therefore the small peaks 
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observed in Figure 3-8A trace c and f should be derived from residual NAD+s bound to 
the membrane of the centrifugal unit. Together with the HPLC analyses of modified 
PARP-1 proteins, it is concluded that no initiation step, i.e., mono-ADP-ribosylation of 
PARP-1 happened in the presence of 2NF-NAD+. 
 
3.3.5 Test of 2NF-NAD+ as a redox cofactor utilized by alcohol dehydrogenase 
Since the nicotinamide part is unchanged in the structure of 2NF-NAD+, its ability 
to serve as a redox cofactor was assessed in a model redox reaction catalyzed by alcohol 
dehydrogenase (ADH) from yeast (YADH). In control reaction using NAD+ as the 
cofactor, the oxidation of ethanol to acetaldehyde was continuously monitored by UV 
absorbance at 340 nm, reflecting the reduction of NAD+ to NADH. The result of the 
kinetic experiment reveals that about 2 ng of YADH can reduce 0.00125 µmol of NAD+ 
per min, corresponding to an activity of 625 unit/mg enzyme (Figure 3-11A). 
Similar reaction was conducted using 2NF-NAD+ as the cofactor. However, the 
high UV background at 340 nm (> 1.0) prevented the monitor of 2NF-NAD+ reduction 
continuously. Instead, the whole spectra were monitored by NanoDrop before and after 
the reaction. No significant elevated absorbance at 340 nm was observed, indicating that 
no turnover of 2NF-NAD+ by this enzyme (Figure 3-11B). 
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Figure 3-11. Oxidation of ethanol to acetaldehyde catalyzed by alcohol dehydrogenase 
from yeast. (A) Progress curve of reaction using NAD+ as the cofactor 
monitored by UV absorbance at 340 nm. (B) UV spectra of samples using 
2NF-NAD+ as the cofactor. Square (n), before the addition of enzyme; 
diamond (u), 350 sec after the addition of enzyme.   
 
3.4 DISCUSSION 
3.4.1 2NF-NAD+ is not a substrate for PARP-1 automodification reaction 
Poly(ADP-ribosyl)ation consists of three steps: initiation, elongation, and 
branching, each of which involves the breakage of nicotinamide–ribose glycosidic bond 
and the transfer of ADP-ribose unit onto different nucleophilic acceptors. To provide 
insight into the mechanism of such complicated reaction, fluorinated NAD+ analogues 
substituted at different ribose hydroxyl groups were designed and synthesized as 
mechanistic probes for the individual steps of PARP-1-catalyzed poly(ADP-ribosyl)ation. 
Fluorinated NAD+ could be useful to stop poly(ADP-ribosyl)ation at different 
stages. Fluorine substitution at the C2 position of the nicotinamide ribose could prevent 
PAR polymer chain from branching, leading to linear polymers (Figure 3-12A). Fluorine 
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substitution at the C2 position of the adenosine ribose could stop chain elongation, 
generating mono-ADP-ribosylated proteins (Figure 3-12B). 
 
 
Figure 3-12. Expected outcomes of poly(ADP-ribosyl)ation of PARP-1 using fluorinated 
NAD+ analogues as substrates. (A) Linear PAR polymers generated from the 
reaction of 2NF-NAD+ with PARP-1. (B) Mono-ADP-ribosylation of 
PARP-1 by 2AF-NAD+. 
Since poly(ADP-ribosyl)ation is a protein posttranslational modification, it is not 
straightforward to isolate the enzymatic reaction products, which are heterogeneous PAR 
polymers. Instead, macromolecule-based methods were first chosen for the detection of 
protein-attached PAR polymers. PAR polymers can be visualized by Western blot 
analysis using anti-PAR antibody. Poly(ADP-ribosyl)ated proteins would have higher 
molecular weight than the unmodified ones. Moreover, the modified proteins would have 
different molecular weight dependent on the size of the polymers. Therefore, poly(ADP-
ribosyl)ated protein species with different molecular weight could be resolved on an 
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SDS-PAGE gel, forming a smear as detected by sensitive protein stain such as SYPRO 
Ruby stain. In addition to staining, poly(ADP-ribosyl)ated proteins can be directly 
visualized by radioactivity-based imaging technique when using 32P-NAD+ as a substrate. 
All of the abovementioned methods were used to detect the formation of PAR polymers 
in the presence of fluorinated NAD+ analogues.  
2NF-NAD+ was incubated with PARP-1 to see if PAR polymers can be produced. 
Western blot analysis as well as SYPRO Ruby stain indicated no PAR polymers were 
produced, as no signal was detected by anti-PAR immunoblot (Figure 3-5A), and the 
resulting PARP-1 protein maintained its original molecular weight (Figure 3-5B). 
It is a discouraging finding that 2NF-NAD+ could not be processed by PARP-1, 
but it may still be able to compete with NAD+ and perturb native poly(ADP-ribosyl)ation, 
or it can be incorporated into the growing polymers once the initiation has been primed 
by natural NAD+. To assess any potential effect of 2NF-NAD+ on PARP-1 poly(ADP-
ribosyl)ation, competition and pre-incubation experiments were set up. Increasing molar 
ratio of 2NF-NAD+ to NAD+ up to 20-fold or changing the amount of enzyme to facilitate 
the detection showed no significant effect on poly(ADP-ribosyl)ation (Figure 3-5), even 
with radioacitivity-based assay (Figure 3-6). Pre-incubation of 2NF-NAD+ with PARP-1 
also failed to hinder the formation of native PAR polymer chains (Figure 3-5C). These 
results ruled out the possibility of the covalent modification of the active site base Glu-
988 by 2NF-NAD+, which has been observed in the case of bovine CD38, an ADP-
ribosyl cyclase (281-284). 
Although no significant change of poly(ADP-ribosyl)ation of PARP-1 was 
observed using protein-based detection methods, direct analysis of the enzymatic reaction 
products was also carried out in order to unambiguously verify any possible incorporation 
of 2NF-NAD+ into PAR polymers. To do so, PAR polymers produced using a mixture of 
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NAD+ and 2NF-NAD+ were purified and analyzed by a modified DNA sequencing PAGE 
method. By doping with radiolabeled NAD+, PAR polymers can be directly visualized by 
phosphorimaging. The result, however, showed insignificant change of the polymer 
distribution pattern in the presence of 2NF-NAD+, suggesting that polymer length or 
branching frequency was not altered by 2NF-NAD+ (Figure 3-8). 
To provide chemical evidence of the composition of PAR polymers in the 
presence of 2NF-NAD+, polymers were again purified from large-scale in vitro PARP-1 
automodification reaction, and further digested by PDE and AP, generating terminal, 
elongation, and branching unit which can be monitored by analytical HPLC. The result 
confirmed the production of PAR polymers in the presence of equimolar of NAD+ and 
2NF-NAD+, but ESI-MS analysis of the isolated elongation unit only showed signals 
consistent with ribosyladenosine, the natural elongation unit (Figure 3-9). These results 
concluded that 2NF-NAD+ cannot be processed by PARP-1, nor it can be incorporated 
into the growing polymer to modulate polymer pattern.  
Despite the fact that 2NF-NAD+ cannot be used in the elongation or branching 
step of poly(ADP-ribosyl)ation, one remaining possibility is that PARP-1 can be mono-
ADP-ribosylated by 2NF-NAD+, which means the initiation step is operating. To test this 
hypothesis, a novel HPLC-based assay suitable for the analysis of the initiation step of 
poly(ADP-ribosyl)ation reaction was developed. The rationale behind this assay is that 
mono-ADP-ribosylated proteins can be verified by producing adenosine from the ADP-
ribose unit attached on the proteins. All other components present in the reaction mixture 
after removing the proteins were also subjected to HPLC analysis to capture any 
production of small molecules derived from the turnover of 2NF-NAD+. Taking 
advantage of its mono-ADP-ribosylation activity, the PARP-1 mutant E988Q was also 
included as a positive control for the assay. Adenosine was detected for both PARP-1- 
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and E988Q-catalyzed reactions using NAD+ as a substrate, confirming the assay was 
functional. A small peak eluted around the adenosine region was observed for both 
reactions using 2NF-NAD+ as a substrate and negative controls (Figure 3-10A). Further 
analysis of the filtrate demonstrated that the adenosine should come from residual 
binding of NAD+ to the filtering unit, and 2NF-NAD+ remained intact after incubation 
with PARP-1 or E988Q, as opposed to NAD+ which had been (partially) converted to 
ADP-ribose (Figure 3-10B). These results suggest that 2NF-NAD+ is not a substrate for 
PARP-1-catalyzed poly(ADP-ribosyl)ation at all steps, i.e., initiation, elongation, and 
branching. 
 
3.4.2 2NF-NAD+ cannot serve as a redox cofactor for yeast alcohol dehydrogenase 
To explore the competence of fluorinated NAD+ analogues as redox cofactors, 
ethanol oxidation catalyzed by ADH from yeast was chosen as the model reaction. 
Despite the intact nicotinamide ring, 2NF-NAD+ could not serve as a redox cofactor for 
yeast alcohol dehydrogenase (Figure 3-11). Modification of the nicotinamide ribose of 
NAD+ has been demonstrated to affect both the redox potential of the pyridinium ring and 
the binding of the cofactor to the dehydrogenases (285). It is unclear to what aspect that 
the effect of fluorine substituent at the C2 position may have. However, the result is in 
accordance with the notion that perturbation of the microenvironment of the NMN 
moiety may have greater impact on the redox properties of NAD+. Novel NAD+ 
analogues with modifications at the AMP moiety have been successfully prepared and 
proved to be useful in engineering bioorthogonal redox systems (286). 
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3.4.3 2AF-NAD+ has minor inhibitory effect on PARP-1 poly(ADP-ribosyl)ation 
NAD+ analogues with modification on the adenosine ribose have been explored 
only to the scope of deoxy-analogues in the past according to the literature. 2′-Deoxy-
NAD+ was not a substrate for PARP-1, whereas 3′-deoxy-NAD+ only gave rise to mono-
ADP-ribosylated or oligo-modified proteins (247, 275, 276). 2AF-NAD+ has been 
synthesized in our laboratory, and here its effect on poly(ADP-ribosyl)ation was tested. 
In the presence of 2AF-NAD+ alone, no PAR polymers were produced (Figure 3-7). 
However, a minor inhibitory effect on the formation of native PAR polymers was 
observed in the radioactivity-based experiment (Figure 3-8). The presence of 2AF-NAD+ 
functioning as a polymer chain terminator could reduce the overall level of PAR 
polymers being produced. In addition, these results did not rule out the possibility that 
2AF-NAD+ can be processed by PARP-1 during the initiation step of poly(ADP-
ribosyl)ation, generating mono-ADP-ribosylated proteins. Consistent with this 
hypothesis, a paper published recently reported the successful labeling of PARP-1 and 
histone H1.2 in vitro using clickable NAD+ analogues bearing 2′-deoxy or 2′,3′-
dideoxyadenosine moiety (249). Therefore, with further experiments to confirm the 
mono-ADP-ribosylation ability of 2AF-NAD+, novel NAD+ analogues can be designed in 
order to simplify the heterogeneous poly(ADP-ribosyl)ation reaction. 
 
3.4.4 Mechanistic implication  
The consequence of non-turnover of 2NF-NAD+ by PARP-1 and the inhibitory 
effect of 2AF-NAD+ limited the use of these fluorinated NAD+ analogues in poly(ADP-
ribosyl)ation reaction. Nonetheless, a mechanistic rationale can still be formulated based 
on the current experimental data. The substitution of fluorine for hydroxyl group at the 
C2 position of the nicotinamide ribose ring may have significant electron-withdrawing 
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effect, which in turn destabilizes the oxocarbenium intermediate, or increases the energy 
of the oxocarbenium-like transition state. The result is the inability of PARP-1 to break 
the nicotinamide–ribosyl bond of 2NF-NAD+. Furthermore, fluorine substitution could 
disrupt the hydrogen bond stabilization effect provided by the catalytic glutamate residue. 
This may also decrease the binding affinity of this compound for PARP-1, but it is purely 
speculative at this point. Reduced binding affinity of 2NF-NAD+ could explain the poor 
inhibitory effect of this compound in the presence of natural NAD+, and the fact that the 
compound was not hydrolyzed by PARP-1 neither. 
Significantly reduced rate of enzymatic hydrolysis of 2NF-NAD+ has been 
observed for NAD+-glycohydrolases (270, 287). The formation of an alkoxide-like 
hydroxyl group possessing partially anionic character was proposed to facilitate the 
reaction to proceed. Similar catalytic mechanism has also been proposed for the 
diphtheria toxin-catalyzed ADP-ribosylation diphthamide (272). The experimental data 
provided in this chapter are consistent with the mechanism that an oxocarbenium 
intermediate, or an oxocarbenium-like transition state is formed during the catalysis. 
Catalytic residue Glu-988 may provide necessary stabilization effect through hydrogen 
bonding to the 2′-hydroxyl group of the nicotinamide ribose. Both hydroxyl groups on the 
adenosine ribose ring are important for the elongation/branching step, as the reduced 
PAR polymer formation was observed herein and in the literature (247, 249, 275). 
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Chapter 4. Characterization of Poly(ADP-ribose)–Protein Linkages 
4.1 INTRODUCTION 
PARP-1 is known to be the major acceptor for poly(ADP ribosyl)ation, and the 
automodification sites were thought to be confined within domain D (Figure 1-11). The 
exact amino acid residues to which the PAR polymer is attached remain largely unknown 
owing to the difficulty in the characterization of such heterogeneous biopolymers. 
Previous group member Dr. Zhihua Tao had initiated an effort into the identification of 
automodification sites in PARP-1 by MS (72). Using the E988Q mutant which only 
catalyzes mono-ADP-ribosylation reaction, domain D protein construct was found to be 
the primary site for modification in vitro by the mutant enzyme. Tryptic digestion of the 
purified, mono-ADP-ribosylated protein followed by MS analysis revealed that Asp-387, 
Glu-488, and Glu-491 are the ADP-ribosylation sites. Unexpectedly, PARP-1 with 
domain D deleted is still catalytically active, and full length PARP-1 carrying point 
mutations of the aforementioned three residues can still undergo self-modification. These 
results suggest that there exist additional modification sites beyond domain D. 
Recently, Hottiger et al. reported that PARP-1 bearing three lysine-to-arginine 
point mutations within domain D has a significantly reduced level of automodification. It 
was also found that additional mutations of eight glutamate to glutamine located between 
residues 484 to 557 in PARP-1 with deleted BRCT domain (which is a part of domain D) 
did not alter the automodification signal (12). Therefore they argued that lysine is the true 
acceptor for PAR polymers rather than glutamate or aspartate. In order to identify other 
potential automodification sites in PARP-1, and to verify that lysine can also be an 
acceptor for PAR polymer, MS techniques were adopted to locate the possible ADP-
ribosylation sites in PARP-1 peptides and domains.  
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As described in this chapter, synthetic peptides containing previously reported 
automodification sites were not modified by PARP-1 or the E988Q mutant based on 
HPLC and MS analysis. These findings suggest that short peptides may not be able to 
compete with full-length protein as PARP-1 substrates. Direct MS analysis the in vitro 
automodification of PARP-1 confirmed that there are ADP-ribosylation sites present 
within domains A and B. Experiments to probe the chemical nature of poly(ADP-
ribose)–protein linkage were also performed. For poly(ADP-ribosyl)ated proteins, the 
failure of detection of carbonyl groups derived from Amadori rearrangement of the ADP-
ribose–lysine linkage suggests that lysine residues in domain D may not necessarily be 
the true modification sites. Instead, they may be important for catalysis in terms of 
maintaning the protein structure and/or binding with DNA. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Cloning, expression, and purification of human PARP-1 fragments in E. coli 
The gene encoding domain D of human PARP-1 (residues 374–525) was cloned 
into pET-28b(+) (Novagen) at the NdeI and HindIII restriction sites by Dr. Zhihua Tao 
(72). Protein expression and purification were carried out essentially the same as 
described in the original paper. A 10-mL overnight culture of E. coli Rosseta2 
BL21(DE3) (Stratagene) transformed with D/pET-28b(+) was used to inoculate 1 L LB 
medium containing 50 μg/mL kanamycin. The cells were grown at 37 °C with shaking at 
250 rpm until OD600 reached 0.6. Protein expression was then induced by the addition of 
IPTG to a final concentration of 0.2 mM, and the cells continued to grow for an 
additional 24 h at 18 °C with shaking at 125 rpm. Cells were harvested and re-suspended 
in lysis buffer containing 20 mM HEPES, 300 mM NaCl, 10 mM imidazole, and 10% 
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glycerol at pH 7.5. Sonication was used to disrupt cells. After removal of cell debris by 
centrifugation, the supernatant was incubated with pre-equilibrated Ni-NTA resin on a 
tube rotator at 4 °C for 1 h. The mixture was then loaded onto a column and washed with 
lysis buffer. The N-terminal His6-tagged domain D was then eluted with elution buffer 
(lysis buffer with 250 mM imidazole). Fractions containing the desired protein were 
pooled and dialyzed against 3 × 1 L lysis buffer. Purified domain D was aliquoted, flash-
frozen in liquid nitrogen, and stored at −80 °C. 
DNA encoding domains A and B (AB) of human PARP-1 (residues 1–232) was 
cloned into the MalE-pET vector generated in house by Dr. Peng Gao at the NdeI and 
XhoI restriction sites. Construction of the MalE-pET vector was achieved by engineering 
a pET-24b(+) vector (Novagen) with an decahistidine MBP tag followed by a TEV 
cleavage site, similar to the pFastBac HT B/MBP-Tev vector (see Section 3.2.4). 
AB/MalE-pET was used to transform E. coli BL21 CodonPlus (DE3)-RP competent cells 
(Stratagene) for protein expression. Conditions for protein expression were the same as 
described for domain D. Harvested cells were re-suspended with lysis buffer containing 
20 mM HEPES, 1 M NaCl, 10 mM imidazole, 1 mM β-mercaptoethanol, and 10% 
glycerol at pH 7.5. The remaining purification steps were similar to those described for 
MBP-tagged full-length PARP-1 (see Section 3.2.4). 
 
4.2.2 ADP-ribosyl)ation of peptide substrates by the E988Q mutant 
The reaction was performed according to the literature with some modifications 
(72). Briefly, a 50-μL reaction containing 2 μM E988Q, 1 mM synthetic peptides (Table 
4-1, American Peptide Company), 100 μM or 1 mM NAD+, 50 μg/mL calf thymus DNA 
or GGAATTCC 8-mer double-strand DNA, 250 μM DTT, 100 mM Tris-HCl, pH 8, and 
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10 mM MgCl2 was incubated at 37 °C for 30 min. The reactions using PARP-1 as the 
enzyme were further treated with PARG before filtering out the proteins with YM-10 
centrifugal unit (10-kDa cutoff). The filtrate was subject to C18 analytical HPLC analysis 
using 0.1% trifluoroacetic acid in water (TFA, solvent A) and 0.1% TFA in acetonitrile 
(solvent B) as mobile phase components. The flow rate was 1 mL/min and the elution 
was monitored by UV absorbance at both 214 nm and 260 nm. Samples were also 
directly submitted for MS analysis.  
 
Peptide Sequence Molar Mass m/z=+1 m/z=+2 m/z=+3 
P1 AD387KPLSNMK 1003.18 1003.50 502.27 335.18 
P2 KAE488PVE491VVAPR 1194.39 1194.68 597.85 398.90 
PK1 GK498SGAALSK505KSK508 1161.40 1161.70 581.35 387.90 
PK2 SEK521RMK524LTLK 1233.60 1233.73 617.37 411.92 
Table 4-1. Peptides used in the PARP-1 heteromodification reactions. Amino acid 
residues that are possible modification sites are underlined and in boldface; 
numbers represent the corresponding amino acid residue number of human 
PARP-1. 
 
4.2.3 Poly(ADP-ribosyl)ation of PARP-1 and PARP-1 domains 
PARP-1 domains AB or D (10 μM) were poly(ADP-ribosyl)ated by 1 μM PARP-
1 in the presence of 100 μM NAD+, 10 μg/mL GGAATTCC 8-mer double-strand DNA, 
250 μM DTT, 100 mM Tris-HCl, pH 8, and 10 mM MgCl2 at 37 °C for 90 min. Under 
specific conditions, enzyme and substrate concentration will be stated otherwise. For MS 
analysis, the reactions were treated with PARG for an additional 1 h before sample 
cleaning. Automodification of PARP-1 followed by PARG treatment was also conducted 
for the same analysis. 
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4.2.4 MS analysis of ADP-ribosylated peptides or proteins 
Protein disulfide bonds were reduced by incubation with equimolar amounts of 
DTT followed by alkylation with iodoacetamide at room temperature. Trypsin digestion 
was carried out at a 20:1 (w/w) ratio of protein to enzyme (Promega) at 37 °C overnight. 
The digest sample was then cleaned using a C18 spin column (Pierce) prior to nano LC-
MS/MS analysis. 
Samples were analyzed using an Orbitrap Elite dual-pressure linear ion trap mass 
spectrometer (Thermo Scientific) equipped with a Dionex UltiMate 3000 RSLCnano LC 
system (Thermo Scientific). Tryptic peptides of the protein digest were separated using 
an in-house C18 packed nanotip column (New Objective) at a 0.3 µL/min flow rate. The 
following mobile phases were used: LC-grade water with 0.1% formic acid (solvent A) 
and LC-grade acetonitrile with 0.1% formic acid (solvent B). After injection of 1 µg of 
total protein onto the column, mobile phases were applied using a 60-min linear gradient 
from 3% to 40% B, followed by a 10-min increase to 90% B. CID (collision-induced 
dissociation) spectra were acquired using an isolation width of 2 Da and a q value of 0.25 
during a 10 ms activation period (35% normalized collision energy, NCE). Data was 
analyzed using Mass Matrix to determine the sequence coverage of proteins. The 
peptide/protein MS experiments were performed by Julia Aponte, a graduate student in 
Dr. Jennifer Brodbelt’s laboratory in the Department of Chemistry, UT-Austin. 
 
4.2.5 Analysis of poly(ADP-ribose)–histone H1 chemical linkage 
To analyze the chemical nature of poly(ADP-ribose)–H1 linkage, H1 (20 μM, 
Calbiochem) was first poly(ADP-ribosyl)ated by PARP-1 (0.5 μM) in the presence of 
either 0.2 mM or 1 mM NAD+ and PARP-1 reaction buffer (50 μg/mL GGAATTCC 8-
mer double-strand DNA, 250 μM DTT, 100 mM Tris-HCl, pH 8, and 10 mM MgCl2), at 
 112 
37 °C for 15 min. The reactions mixtures were divided into four sets for 1-h further 
treatment with water, PARG, 0.9 M NH2OH, pH 7, and 0.45 M KOH/45 mM EDTA, 
respectively. For the NH2OH and KOH/EDTA treatment sets, proteins were concentrated 
by YM-10 filtering unit. The samples were resolved by SDS-PAGE and probed with anti-
PAR monoclonal antibody (Trevigen). 
 
4.2.6 Model studies of peptide glycation by ADP-ribose 
Peptides PK1 or PK2 (1 mM) were incubated with 1 mM ADP-ribose in 50 mM 
potassium phosphate buffer (pH 7.5) at 37 °C for 1 h. The reactions were analyzed by 
C18 HPLC according to the method described in Section 4.2.2. 
 
4.2.7 Model studies of protein glycation by ADP-ribose 
BSA and histone H1 were used as model substrates for protein glycation by ADP-
ribose. The reactions were carried out according to the literature with some modifications 
(288). Briefly, BSA (1.5 mg/mL, Thermo Scientific) or H1 (1.0 mg/mL) was incubated 
with 1 mM ADP-ribose in 50 mM potassium phosphate buffer (pH 7.5) at 37 °C for 
either 1 d or 7 d in dark. The samples were further reacted with solution containing 5 mM 
2,4-dinitrophenylhydrazine (DNP) in 10% TFA, 2 M Tris-HCl, and 30% glycerol at room 
temperature for 1 h. Proteins were resolved by SDS-PAGE, stained with Coomassie Blue 
or probed with anti-DNP antibody (Novex). 
 
4.2.8 Detection of protein carbonylation by DNP derivatization 
Both the protein glycation reactions (Section 4.2.7) and poly(ADP-ribosyl)ation 
reactions of PARP-1 and domain D were analyzed for protein carbonylation. Glycation of 
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BSA or H1 was carried out as described in Section 4.2.7. Poly(ADP-ribosyl)ation of 50 
μM domain D using 5 μM PARP-1, or automodification of 10 μM PARP-1 was 
performed following similar procedures described in Section 4.2.3, with additional 
PARG treatment. Derivatization of protein carbonyl groups with DNP was carried out as 
described in Section 4.2.7. Proteins were analyzed by analytical HPLC equipped with a 
300 × 7.8 mm Bio-Sil SEC 125-5 gel filtration column (Bio-Rad) with isocratic elution 
using 200 mM sodium phosphate buffer, pH 6.5. The flow rate was 1 mL/min and the 
elution was monitored by UV absorbance at both 280 nm and 360 nm. 
 
4.3 RESULTS 
4.3.1 No modification of peptides substrates by the E988Q mutant  
To verify that Asp-387, Glu-488, and Glu-491 are the automodification sites of 
PARP-1 as reported by Dr. Zhihua Tao (72) and other potential lysine automodification 
sites, synthetic peptides bearing these residues were used as substrates in ADP-
ribosylation reactions catalyzed by the E988Q mutant which only generated mono-ADP-
ribosylated species. The reactions were analyzed by HPLC at UV absorbance of 214 nm 
and 260 nm for peptide bonds and ADP-ribose, respectively. As shown in Figure 4-1, no 
change was observed for all four peptides under 214 nm absorbance, and no new peak 
appeared under 260 nm absorbance. The concentration of NAD+ of the reactions was 
raised from 100 μM to 1 mM to see if it may increase the yield of modified peptides. No 
new peak was produced in the presence of the enzyme, except for P2 (Figure 4-2A and B, 
trace c, arrow). However, the low abundance of the peak prevented further 
characterization. Based on HPLC chromatograms, short peptides seem to be poor 
substrates and could not be modified by the E988Q mutant. 
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Figure 4-1. HPLC chromatograms of poly(ADP-ribosyl)ation reaction of synthetic 
peptides by the E988Q mutant using 100 μM NAD+. The elution was 
monitored at (A) 214 nm and (B) 260 nm. (a) P1+E988Q (b) P1. (c) 
P2+E988Q. (d) P2. (e) PK1+E988Q. (f) PK1. (g) PK2+E988Q. (h) PK2. 
 
  
Figure 4-2. HPLC chromatograms of poly(ADP-ribosyl)ation reaction of synthetic 
peptides by the E988Q mutant using 1 mM NAD+. The elution was 
monitored at (A) 214 nm and (B) 260 nm. (a) P1+E988Q (b) P1. (c) 
P2+E988Q. (d) P2. (e) PK1+E988Q. (f) PK1. (g) PK2+E988Q. (h) PK2. 
The same reactions were subject to MS analysis to capture any modified peptides 
in solution. Samples were either separated by passing through a LC column or directly 
injected into ESI-MS instrument. Disappointedly, none of the samples showed MS 
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signals corresponding to the modified peptide, even for the P2 reaction (Figure 4-3). 
These results suggest that short synthetic peptides may not be suitable substrates for the 
E988Q mutant. 
 
 
Figure 4-3. ESI-MS spectra of directly infused samples containing (A) P2+E988Q and 
(B) P2. The observed m/z values of different charge states of P2 are labeled. 
The calculated values can be found in Table 4-1. 
 
4.3.2 MS analysis of poly(ADP-ribosyl)ated PARP-1 constructs 
Since synthetic peptides were not modified by the PARP-1 E988Q mutant, MS 
analysis of poly(ADP-ribosyl)ated proteins was conducted to directly locate the 
automodification sites. Both automodification of PARP-1 and heteromodification of 
PARP-1 domains AB and D were carried out in vitro. The reaction mixtures were treated 
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with PARG to afford mono-ADP-ribosylated species before trypsin digestion. Tryptic 
digest was cleaned up by C18 spin column and subject to LC-MS analysis. The sequence 
coverage of the full-length PARP-1 was 70%, but peptides having ADP-ribose attached 
(Δm/z = 541) were poorly fragmented (Figure 4-4). This complicates the assignment of 
ADP-ribosylation sites to specific amino acid residue. Domains AB and D modified in 
trans also had decent sequence coverage, but similar problems existed for both 
constructs. Nonetheless, several modification sites could be found in these domains, 
suggesting that domain D is not the sole automodification center (Table 4-2). 
 
 
Figure 4-4. CID MS/MS spectra of a modified peptide derived from poly(ADP-
ribosyl)ated PARP-1 tryptic digest. m/z values of fragmented ions are 
indicated. b ion is the N-terminal part of the molecule cleaved at the peptide 
bond, and y ion is the complementary C-terminal portion. Asterisks denote 
potential ADP-ribosylation sites. 
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Peptide Modified residue Domain 
MAIMVQSPMFDGK* K47 A 
KTAEAGGVTGK* K97 A 
GQDGIGSKAEK* K108 A 
TLGDFAAE*YAKSNR E116 A 
TLGDFAAEYAK*SNR K119 A 
GCME*K*IE*K*GQVR E130, K131, E133, K134 A 
GQVRLSKK* K144 A 
QLPGVKSE*GK* E205, K207  B 
RKGDEVDGVDEVAK* K221 B 
AE*PVE*VVAPR E488, E491 D 
Table 4-2. Peptide ions bearing potential PARP-1 automodification sites identified by 
CID-MS/MS. Modification sites are labeled with asterisks, underlined and 
boldfaced. 
 
4.3.3 Chemical nature of poly(ADP-ribose)–H1 linkage 
Probing the chemical nature of poly(ADP-ribose)–protein linkage could 
potentially shed light on the type of amino acid residues to which PAR polymer is 
attached. PARP-1 and histone H1 were first poly(ADP-ribosyl)ated in vitro and the 
resulting poly(ADP-ribosyl)ated species were subject to different types of treatment. 
PARG cleaves the PAR polymers from the proteins, leaving one ADP-ribose attached. 
Neutral hydroxylamine could only cleave ester bond, but not Schiff base or hemiaminal, 
whereas strong base could cleave both types of linkage. The samples were resolved by 
SDS-PAGE and visualized by either Coomassie stain or anti-PAR immunoblotting. 
As shown in Figure 4-5A, poly(ADP-ribosyl)ation of 113-kDa PARP-1 or 30-kDa 
H1 created a smear of proteins, and the PAR signal became stronger in the presence of 
H1 (lane 2) and higher NAD+ concentration (lane 3). The protein band of PARP-1 shifted 
toward the gel interface (Figure 4-5B, land 1–3), and the smear of H1 was visible at 1 
 118 
mM NAD+ (lane 3), consistent with the trend revealed by anti-PAR immunoblotting. 
PARG treatment almost completely eliminated the PAR signals (Figure 4-5A, lane 4–6), 
and protein bands of PARP-1 and H1 shifted back to the unmodified molecular weight 
(Figure 4-5B, lane 4–6). Neutral hydroxylamine treatment partially reduced the PAR 
signals from PARP-1, and the H1 bands became visible (Figure 4-5A, lane 7–9). Samples 
treated with strong base, however, displayed far less PAR signals as compared to 
hydroxylamine treatment (Figure 4-5A, lane 10–12). The data suggest that there are at 
least two types of chemical linkage existing between the PAR polymer and the protein. 
One of them could be an ester linkage, which is sensitive to both hydroxylamine and base 
treatment. Another could be a Schiff base or hemiaminal linkage involving reactive 
amines and the reducing end of ADP-ribose. This is also in line with early observations 
that in addition to Glu and Asp, lysine residues could be the acceptors for PAR polymers. 
 
 
Figure 4-5. Analysis of poly(ADP-ribosyl)ated PARP-1 and H1 by enzymatic or 
chemical treatment. (A) Anti-PAR Western blot. (B) Coomassie stain. Lanes 
1, 4, 7, and 10, 0.5 μM PARP-1+1 mM NAD+; lanes 2, 5, 8, and 11, 0.5 μM 
PARP-1+20 μM H1+0.2 mM NAD+; lanes 3, 6, 9, and 12, 0.5 μM PARP-
1+20 μM H1+1 mM NAD+. Specific treatment is indicated above the lanes. 
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4.3.4 ADP-ribose glycated proteins, but not poly(ADP-ribosyl)ated ones, contain 
protein carbonyl groups 
The observation of PAR–protein linkage other than ester bond raises the 
possibility that lysine could also serve as the acceptor for PAR polymers. To verify the 
chemical nature of lysine-linked ADP-ribose, model studies of ADP-ribose–protein 
conjugates were carried out using peptides containing reported lysine automodification 
sites of PARP-1. Peptides incubated with equimolar of ADP-ribose at 37°C for 1 h did 
not give any newly modified products as detected by HPLC (Figure 4-6). The result 
could be interpreted as either the non-reactivity of these peptides toward ADP-ribose, or 
that the reaction proceeded too slowly to be detected within one hour’s incubation. 
 
 
Figure 4-6. HPLC chromatograms of nonenzymatic ADP-ribose glycation reactions of 
model peptides monitored at 214 nm. (a) PK1. (b) PK1+ADP-ribose. (c) 
PK2. (d) PK2+ADP-ribose. 
Protein substrates BSA and H1 were also utilized in the model study of 
nonenzymatic ADP-ribose conjugation reaction (289). BSA or H1 was incubated with 
50-fold molar excess of ADP-ribose at °C in dark for either 1 day or 7 days. The reaction 
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mixtures were then derivatized with DNP to capture protein carbonyl groups resulting 
from the potential Amadori rearrangement product from the proximal ADP-ribose–lysine 
linkage (see Figure 4-10). For comparison, automodification of PARP-1 and 
heteromodification of domain D were also conducted to enzymatically generate PAR–
protein linkages. The poly(ADP-ribosyl)ated proteins were subject to the same 
derivatization procedure to label enzymatic reaction-generated protein carbonyl groups. 
The DNP-labeled proteins were subsequently probed with anti-DNP antibody. 
The SDS-PAGE of the resulting protein samples are shown in Figure 4-7. As 
expected, PARP-1 and domain D (~16 kDa) had smear band shifted upward from the 
unmodified protein bands (lane 1, 2). BSA, on the other hand, also had tailing bands 
below its original molecular weight (66 kDa) (lane 3, 4). The tailing effect could be due 
to prolonged incubation time, causing proteins to degrade. Similar observation can be 
seen for H1 (lane 5, 6). When probing the DNP-labeled protein samples, none of them 
showed ECL signal (data not shown). Changing the antibody concentration and adjusting 
the derivatization procedures did not improve the situation. It is therefore possible that 
either the derivatization reaction did not work, or the anti-DNP antibody is not suitable 
for Western Blot detection. 
To ensure that the DNP derivatization reaction works as expected, and to detect 
protein carbonyl groups more directly, the DNP-labeled proteins from the above 
experiments were analyzed by HPLC equipped with a protein gel filtration column. By 
monitoring the elution profile at both 280 nm and 360 nm, overlapping peaks would 
indicate DNP-labeled protein species. Figure 4-8 shows the gel filtration elution profiles 
of the protein samples. Each entry (a or a′) consists of two traces, with the one having 
more peaks between 5 and 12.5 min being monitored at 360 nm, and the other one 
monitored at 280 nm. Each pair of entries (a and a′) are samples generated under the 
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same reaction condition (enzymatic or nonenzymatic) as designated in the figure legend. 
Entries with “prime” symbols are samples derivatized with DNP, whereas the plain 
alphabets represent controls without derivatization. From entries c′, d′, e′ and f′, it is 
evident that a peak around 11 min showed up in both 360 nm (DNP absorption) and 280 
nm (protein) traces (arrows in the light green area), and the peak was absent in the control 
samples without derivatization (entry c, d, e and f). The retention time of the peak is 
consistent with BSA or H1. This result clearly illustrates the existence of carbonyl groups 
on the ADP-ribose glycated proteins, and the DNP derivatization protocol is functional. 
On the contrary, enzymatic poly(ADP-ribosyl)ated PARP-1 and/or domain D did not 
display any noticeable overlapping peaks from both 360 nm and 280 nm absorption 
traces (entry a′ and b′). Therefore, the data suggest that enzymatic protein poly(ADP-
ribosyl)ation within one hour may not necessarily occur on the lysine residues, or the 
abundance was too low to be detected using DNP derivatization protocol. 
 
 
Figure 4-7. SDS-PAGE gel of enzymatically poly(ADP-ribosyl)ated proteins and 
nonenzymatic ADP-ribose glycation of proteins. Lane 1, 5 μM PARP-1+50 
μM domain D+0.5 mM NAD+; lane 2, 10 μM PARP-1+0.5 mM NAD+; lane 
3, BSA+ADP-ribose, 1 d; lane 4, BSA+ADP-ribose, 7 d; lane 5, H1+ADP-
ribose, 7 d; lane 6, H1+ADP-ribose, 1 d. M, molecular weight marker. 
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Figure 4-8. HPLC chromatograms of DNP-labeled protein species from enzymatic 
poly(ADP-ribosyl)ation or nonenzymatic ADP-ribose glycation reactions. 
For each entry, traces with more obvious peaks between 5 to 12.5 min were 
monitored at 280 nm. Arrows in the light green highlighted area indicate 
overlapping peaks from both 280 nm and 360 nm absorbance. Traces with 
“prime” symbols represent samples undergone DNP derivatization, whereas 
unlabeled alphabets represent controls. (a) and (a′), PARP-1+D+NAD+. (b) 
and (b′), PARP-1+NAD+. (c) and (c′), BSA+ADP-ribose, 1 d. (d) and (d′), 
BSA+ADP-ribose, 7 d. (e) and (e′), H1+ADP-ribose, 1 d. (f) and (f′), 
H1+ADP-ribose, 7 d. 
 
4.4 DISCUSSION 
4.4.1 Synthetic peptides are not PARP-1 substrates 
Defining the amino acid residues undergone posttranslational modification is of 
great importance to study the biological consequence of such molecular transformation. 
Surprisingly, the exact locations of the automodification sites of PARP-1, a pivotal 
nuclear protein involved in DNA repair and other cellular processes, remain largely 
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unknown. This challenging problem can be attributed to several biochemical properties 
unique to PARP-1. One example is the lack of defined amino acid residue or sequence 
consensus in the modification motif. This is distinctly different from other types of 
posttranslational modification such as phosphorylation, methylation, acetylation, 
ubiquitylation…etc. In addition, the resulting PAR polymer is heterogeneous in terms of 
size and structure, making structural characterization a daunting task. The negatively-
charged chemical nature of PAR polymer also complicates the analysis including MS. 
The facts that the large 113-kDa enzyme itself is the predominant acceptor of such 
modification, and the reaction is allosterically triggered by the presence of DNA, add 
another layer of complexity toward reconstitution of the reaction in vitro. Our previous 
group member, Dr. Zhihua Tao, had put substantial effort into the characterization of the 
automodification sites of PARP-1. The E988Q mutant of PARP-1, which only catalyzes 
mono-ADP-ribosylation reaction, was cleverly used to simplify the heterogeneous nature 
of PAR polymers. The data revealed that three amino acid residues, Asp-387, Glu-488, 
and Glu-491, located within domain D, are the primary modification sites by tandem MS 
analysis (72). PARP-1 with domain D deleted (ABCEF) was found to undergo 
automodifications as well, suggesting that ADP-ribosylation sites exist beyond domain D 
(72). To further verify these modification sites, synthetic peptides carrying these residues 
were used as substrates to test whether they can be poly(ADP-ribosyl)ated in trans. 
Without purification of the peptides, the MS spectra of the reaction mixture indeed 
showed ion patterns consistent with ADP-ribose attached onto these amino acid residues 
(72). 
In light of a recent report that, rather than glutamate or aspartate residues (12), 
Lys-498, Lys-521, and Lys-524 are the true automodification sites of PARP-1, synthetic 
peptides carrying these lysine residues were prepared and subject to similar reaction 
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condition as reported by Dr. Zhihua Tao. The reaction mixture was analyzed by HPLC in 
an attempt to detect modified species more definitely. MS analysis of ADP-ribosylated 
peptide can also provide information regarding the fragmentation patterns or 
characteristic ions of such posttranslational modifications.  
To our surprise, no modification reactions were observed for these peptide 
substrates, including the ones used in the previous publication (Figure 4-1 and 4-2). 
Direct infusion of the reaction mixtures into ESI-MS instrument did not show any signs 
of modification, neither (Figure 4-3). These results were perplexing at the first glance. 
But, it is possible that the modified peptide ions reported previously were actually 
derived from the enzyme E988Q itself rather than the peptide used in the reaction. Even 
under 500-fold molar excess of peptide to protein, with high concentrations of NAD+, no 
modification of peptides was observed. Another explanation could be that the LC 
program or the ESI-MS analysis is affecting the stability of such modification. Similar 
reactions were then analyzed by HPLC using 0.1% ammonium acetate as the main 
component of the mobile phase instead of 0.1% TFA, but no modified peptides was 
observed neither (data not shown). For MS analysis, the reaction mixtures after work-up 
were subject to LC separation before ionization or directly injected into the instrument. 
Neither of them gave ion signals corresponding to modified peptides. Therefore, it is 
concluded that short peptides (ca. 10-15 amino acids long) may not be efficient substrates 
for PARP-1 heteromodification. Direct analysis of poly(ADP-ribosyl)ated protein 
mixtures generated in vitro or in vivo, or using chemically synthesized ADP-ribosylated 
peptides (290, 291) should be considered for future characterization of this 
posttranslational modification. 
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4.4.2 Automodification sites of PARP-1 exist beyond domain D 
To circumvent the issue that short peptides are not modified by PARP-1, PARP-1 
domains and the protein itself were poly(ADP-ribosyl)ated, treated with PARG, and then 
subject to MS analysis. Traditional CID fragmentation method, despite having the 
potential to cause degradation of posttranslational modifications, can still provide useful 
information of the possible automodification sites. In fact, several lysine and glutamate 
residues beyond domain D were identified to be acceptors, although the exact location of 
modification still needs further verification in some cases (Figure 4-4 and Table 4-2). 
In order to successfully assign posttranslational modification to a specific amino 
acid residue by MS data, one should pay attention to sample preparation and the selection 
of the MS instrumentation. During the course of current studies, multiple laboratories 
also reported their work on the characterization of poly(ADP-ribosyl)ated proteome. 
Specific advancement of the reports will be discussed in the following paragraphs along 
with the comparison of the data presented herein. 
A well-defined m/z difference between the modified and unmodified ion is crucial 
for the analytic software to detect and identify the targeted modification. For poly(ADP-
ribosyl)ation, the strategy applied herein is to either use the E988Q mutant, which only 
catalyzes mono-ADP-ribosylation reaction, or digest the poly(ADP-ribosyl)ated species 
with PARG to get rid of the PAR polymers, leaving the proximal ADP-ribose attached to 
the protein. Either way would produce a modified protein (peptide) with a defined m/z 
difference, which is 541 Da for one ADP-ribose moiety. 
Quantity of the modified species may affect the quality of MS data. Low 
abundance of modified proteins/peptides may lead to overlook of the signals exerted from 
the modified species. Enrichment protocol to concentrate only the proteins carrying 
modifications could enhance the signal readouts. For poly(ADP-ribosyl)ated species, 
 126 
boronate resin had been demonstrated to be useful for the purification of PAR polymers 
(64). Similar protocol was thus applied here to enrich the poly(ADP-ribosyl)ated domains 
AB or D after in vitro reaction. Unfortunately, the MS results did not show significant 
improvement (data not shown). It is perhaps that the heteromodification reaction did not 
generate significant amount of modified domains AB or D so the enhancement after 
enrichment was only marginal. Some enrichment protocols used in the characterization of 
phosphoproteome had been proved useful to enrich poly(ADP-ribosyl)ated proteins after 
incubating with phosphodiesterase (73, 194). A recent publication described a novel 
strategy to characterize poly(ADP-ribosyl)ation proteome by combining the two methods 
mentioned above (195). Namely, modified proteins were first enriched by boronate resin 
column followed by elution of the proteins with hydroxylamine. Instead of using water, 
the researchers took advantage of the chemical sensitivity of Glu- or Asp-linked PAR 
polymers toward neutral hydroxylamine so that PAR-modified proteins eluted with 
hydroxylamine would produce a 15 Da m/z difference for each modification site 
distinguishable by MS. This process also reduced the heterogeneous PAR polymers into 
one defined chemical modification (hydroxamic acid derivatives of Glu- or Asp- residues 
bearing PAR polymers.) This method, being useful to identify ester linkages, is 
nonetheless unable to detect modifications of lysine-linked or other ADP-ribose–protein 
linkages. 
With a properly processed protein or peptide sample in hand, the fragmentation 
method employed by different MS instruments should also be considered. CID is the 
most common and universal method to generate fragmented ions. However, the high 
collision energy may cause some unstable modifications to be cleaved from the peptide. 
Moreover, the modification itself bearing an unstable chemical linkage (e.g., 
phosphodiester bond in the case of poly(ADP-ribose)) may be prone to degradation by 
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constant collisions with gas molecules. Other fragmentation methods such as electron 
transfer dissociation (ETD) (13, 292) have been suggested for the characterization of 
ADP-ribosylated peptides owing to their mild ionization process, but fewer peptide 
backbone fragmentation may occur, hampering the detailed sequence analysis of the 
tandem MS spectra. Instead of analyzing protease-digested peptides, an alternative is to 
adopt top-down MS analysis. Ultraviolet photodissociation (UVPD) (293) is an emerging 
MS technique to directly obtain sequence information from the whole protein without 
protease digestion. Due to the strong yet quick photon bombardment, this method could 
generate a more complete peptide backbone fragmentation pattern while preserving labile 
posttranslational modification at the same time. UVPD has been employed in the 
characterization of a protein tyrosine sulfotransferase (294). The feasibility of this novel 
MS technique was tested using poly(ADP-ribosyl)ated domain D (~16 kDa), but the 
results were inconclusive (data not shown). The application of UVPD in the 
characterization of the overall protein structure will be presented in chapter 5. 
Figure 4-9 summerizes the automodification sites identified in the current 
literature as well as in this study. Glu and Asp are the predominant residues being 
modified, and the automodification sites widespread throughout the entire protein, 
clustering at flexible the loop regions based on structural mapping (194, 195). Lysine 
residues and one arginine residue have been identified as the modification sites from in 
vitro reactions (73). Whether this is physiological relevant must await further 
examination. Due to the wide distribution of the automodification sites, identification of 
the modification “hot spot” or patterns under specific condition would be important to 
better correlate the respective physiological outcomes. Indeed, Poirier et al. found that 
the interdomain region connecting the BRCT domain and the WGR domain is the hot 
spot of automodification (295), consistent with the fact that it is in proximity to the active 
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site displayed in the near full-length PARP-1 crystal structure (200). Of note, Lys-498 
was found to be the acceptor site by MS in one report (73). 
 
 
 
Figure 4-9. Automodification sites of PARP-1 identified by MS experiments to date 
(72, 73, 112, 194, 195, 295). The location of each modification site is 
grouped according to PARP-1’s domain organization. Lysine or arginine 
residues reported in the literature are in red and boldfaced; lysine residues 
reported in this chapter are in blue and italic; glutamate residue reported in 
this chapter is in italic.  
 
4.4.3 Poly(ADP-ribose)–protein linkages exist in two types of chemical bonds  
Identification of the automodification sites of PARP-1 is always associated with 
the quest of knowing what the chemical nature of PAR–protein linkage is. Before the 
advancement of analytical instrumentation, chemical treatment is the standard way to 
gain structural information of biological samples. Hydroxylamine has been used to 
distinguish ADP-ribose–protein linkages in the early 80s (296). Current data shown in 
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Figure 4-5 suggest that there are two types of linkages present in the enzyme-catalyzed 
poly(ADP-ribosyl)ation reactions. One is hydroxylamine-labile, and the other one is 
hydroxylamine-resistant (Figure 4-10). The hydroxylamine-labile linkage is consistent 
with the nucleophilic attack of neutral hydroxylamine to the ribose–protein linkage 
(Figure 4-10A). The hydroxylamine-resistant linkage is most likely a non-ester bond 
formed between a protein nucleophile and the nicotinamide ribose of NAD+ (Figure 4-
10B). Lysine, arginine, and cysteine are all possible amino acid candidates involved in 
such linkage. 
 
 
Figure 4-10. Chemical structures of possible ADP-ribose–protein linkages found in 
poly(ADP-ribosyl)ated PARP-1. (A) Glu-linked ADP-ribose represents an 
ester bond linkage. Hydroxylamine treatment gives free ADP-ribose and 
hydroxamic acid derivative of Glu. (B) Lys-linked ADP-ribose undergoes 
Amadori rearrangement to generate a 2-ketoamine species. 
In the case of lysine–ADP-ribose linkage, tautomerization of the hemiaminal 
could lead to the production of 2-ketoamine, an Amadori rearrangement product. If 
poly(ADP-ribosyl)ation of lysine residues does take place, a reactive carbonyl group may 
present on the protein as a result of tautomerization. Such rearrangement has been 
characterized in detail for ADP-ribose-mediated protein glycation reaction (297). 
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Labeling the carbonyl group with a specific small molecule such as DNP could detect 
protein carbonylation derived from poly(ADP-ribosyl)ation of lysine.  
Model reactions of ADP-ribose glycated peptides or proteins were produced to 
serve as a positive control for the detection of protein carbonylation derived from ADP-
ribose-mediated glycation. Unfortunately, peptides containing reported PARP-1 lysine 
modification sites did not react with ADP-ribose under current experimental condition 
(Figure 4-6). Glycation of several other proteins and the derivatization with DNP seemed 
to work (Figure 4-7), but the detection of protein carbonylation using anti-DNP antibody 
did not show any signal. Alternatively, the glycated and DNP-derivatized proteins were 
directly analyzed by gel filtration HPLC, and the overlapping peak from the trace of both 
360 nm and 280 nm absorbance strongly suggested the existence of carbonyl groups in 
ADP-ribose-glycated BSA and H1 (Figure 4-8, entry c′, d′, e′, and f′). However, 
enzymatically poly(ADP-ribosyl)ated PARP-1 and domain D did not show any 
significant protein species bearing absorbance at 360 nm (Figure 4-8, entry a′ and b′). The 
low abundance of ADP-ribosylated lysine and the low occurrence of such modification 
underwent Amadori rearrangement all possibly contributed to the current observation. 
 
4.4.4 Interpretation of enzyme-catalyzed poly(ADP-ribosyl)ation of lysine residues 
Considering the data presented in this chapter together with the MS results 
reported in the literature, it is still difficult to draw a conclusion that PARP-1-catalyzed 
protein poly(ADP-ribosyl)ation can indeed take place on lysine residues. Mutagenesis of 
Lys-498, Lys-521, and Lys-524 to arginine abolishing modification does not necessarily 
imply these lysine residues are the true automodification sites. Instead, these residues 
could play important structural roles during catalysis, such as facilitating conformational 
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change or maintaining overall DNA binding affinity (199). Advanced MS techniques 
should be able to provide more definitive evidence to support the chemical nature of 
ADP-ribose–lysine linkage, but how to optimize experimental conditions to generate 
poly(ADP-ribosyl)ated proteins, both in vitro and in vivo, could be the key to resolve this 
problem. 
For in vitro reaction, it is clear that a streamline process of sample enrichment and 
derivatization are of tremendous importance to define the modified residues. However, an 
overlook of the “side effects” of such procedure could potentially complicate the 
analysis. For example, PARG treatment simplifies the PAR polymers to one ADP-ribose 
unit, but the remaining high concentration of ADP-ribose produced in the digestion 
mixture could potentially react with proteins nonenzymatically, generating ADP-ribose-
glycated species. Other types of digestion leading to reactive sugar species possessing 
reducing ends could all potentially react with protein free amines (lysine or arginine), 
especially in a highly enriched sample with high density of PAR polymers. 
Beyond the complication resulted from sample preparation, the endogenous 
NAD+ hydrolase activity of PARP-1 could also play a role in enzymatic poly(ADP-
ribosyl)ation. PARP-1’s activity is triggered by binding to DNAs, and the PAR polymers 
being produced can reach 200-400 units. Meanwhile, the accompanied NADase activity 
also increases as automodification proceeds (83), until the balance between the DNA 
affinity and the charge repulsion from the negatively-charged PAR polymers is broken. 
The local high concentration of ADP-ribose generated form NAD+ hydrolysis could also 
be reactive toward lysine residues in proximity. The high occurrence of lysine residues 
being identified as the acceptor (Table 4-2) in the current experimental setting may 
simply reflect the high concentration of free ADP-ribose produced from PARG treatment, 
or because of the usage of high NAD+ concentration to drive poly(ADP-ribosyl)ation 
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reaction, which creates a favorable condition for the NAD+ hydrolysis side reaction to 
occur, promoting nonenzymatic ADP-ribosylation of lysine. 
In addition to the above considerations, an assay designed for measuring the 
progress of enzymatic lysine ADP-ribosylation using defined substrates and chemicals 
would be beneficial. Structural studies of the enzyme–substrate complex with the 
substrate carrying a lysine residue in the active site of PARP-1 could also provide 
significant insight into this enigmatic process. 
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Chapter 5. Macromolecular Mechanism of Human PARP-1 
Automodification Reaction 
5.1 INTRODUCTION 
PARP-1 is a multi-modular protein containing three functional units: the DNA-
binding domain, the automodification domain, and the catalytic domain (178). These 
features dictate how PARP-1 works as a DNA-dependent ADP-ribosyltransferase, which 
itself can serve as a substrate and undergo automodification. In the presence of genotoxic 
stress, PARP-1 inside the cell nucleus quickly relocalizes to bind the damaged DNA, 
triggering PAR polymers formation mainly on PARP-1 itself and other nuclear proteins. 
This self-modification property of PARP-1 and the involvement of nonspecific, structural 
DNA recognition to induce enzyme activity raise interesting mechanistic questions about 
the stoichiometry (or molecularity) of DNA-dependent poly(ADP-ribosyl)ation of PARP-
1 in terms of “enzyme PARP-1,” “substrate PARP-1,” and DNA ligand. 
Early biochemical studies suggested that dimerization or even multimerization of 
PARP-1 could occur during catalysis (238, 298). A bimolecular, namely an 
intermolecular mechanism of PARP-1 automodification reaction was proposed by 
Alvarez-Gonzalez et al. based on the result of their kinetic study that the initial rate is 
proportional to the square of enzyme concentration (239). Meanwhile, the molecular 
mechanism of receptor tyrosine kinase (RTK) on cell membranes, particularly epidermal 
growth factor receptor (EGFR), was also established in the early 90s. It was shown that 
growth factor-induced EGFR dimerization triggers trans-phosphorylation of EGFR and 
stimulates the downstream signaling cascade (299). The characteristics of a RTK having 
an allosteric ligand and catalyzing self-modification (autophosphorylation) are analogous 
to DNA-induced PARP-1 automodification. It is thus not surprising that researchers in 
the PARP field would like to consider an intermolecular process for the PARP-1 
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posttranslational modification reaction. In addition, biophysical studies also suggested 
that dimerization of PARP-1 upon binding to specific DNA structure correlate with 
elevated enzyme activity (227, 241). Therefore, the model that PARP-1 acting as a 
catalytic dimer and the automodification process being intermolecular is well-
acknowledged in the PARP field. 
Even though PARP-1 dimerization during automodification appears to be a 
general belief, strong evidence supporting the bi-molecularity of poly(ADP-ribosyl)ation 
reaction is still lacking. It remains ambiguous whether the reaction is an uni-molecular 
event where a single PARP-1 protein acts as both enzyme and substrate, or a bi-
molecular event where the enzyme and the substrate are different proteins. Furthermore, 
recent solution structural studies using NMR and SAXS techniques failed to detect any 
dimerized species for various PARP-1 constructs including full-length PARP-1 (188, 
197, 198, 236). An X-ray crystal structure of a near full-length PARP-1 in complex with 
double-strand blunt-end DNA also revealed a monomeric form of the enzyme–DNA 
complex (200). However, a structure containing only the DNA-binding domain of PARP-
1 (FI and FII) was found to form a dimer at the end of an overhang DNA (235). Clearly, 
controversy about the active form of PARP-1 remains an issue to fully understand the 
DNA-induced PARP-1 automodification reaction. 
In this chapter, an in vitro poly(ADP-ribosyl)ation assay using two structurally 
distinguishable mutants of human PARP-1 was developed and used to investigate the 
macromolecular mechanism of PARP-1 automodification reaction. The feasibility of this 
assay is based on fact that the recombination of various domains in trans could produce a 
complementary full-length PARP-1 complex, which is capable of catalyzing poly(ADP-
ribosyl)ation, albeit with relatively weaker activity than the wild-type PARP-1 in a single 
polypeptide chain. In a typical experiment, a pair of PARP-1 constructs which have 
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different size and enzyme activity was used in the reaction in the presence of radioactive 
NAD+ and DNA. For example, an active enzyme could be mixed with an inactive enzyme 
in a reaction buffer containing hot NAD+ and DNA. Poly(ADP-ribosyl)ation could be 
catalyzed by the active enzyme or facilitated by the presence of other necessary domains 
in the solution. The reaction mixture was then treated with PARG to cleave the PAR 
polymers from the proteins, leaving only mono-ADP-ribosylated species. Finally, the 
proteins were resolved by SDS-PAGE and visualized by autoradiography. If the inactive 
protein constructs are ADP-ribosylated in trans only in the presence of a full-length 
active PARP-1, or a catalytically competent “PARP complex,” the results could support a 
model that PARP-1 automodification is mediated by an intermolecular process. 
The interplay between the PARP-1 domains is important for PARP-1 catalysis. 
Domain C, the third zinc finger-containing domain, has been shown to be essential for 
DNA-dependent PARP-1 automodification. Deletion of this domain largely abolished 
enzyme activity (187, 188). However, similar to the full-length PARP-1, discrepancy also 
exists between the reported monomeric NMR structure of domain C in solution (188) and 
the dimeric X-ray structure of domain C in crystal (187). Herein, a top-down MS-based 
method was utilized to probe the potential conformational change of domain C upon 
denaturation to gain insight into its native structure in solution. The results are more 
supportive of domain C existing in monomeric form in solution. Moreover, a chemical 
crosslinking experiment was also carried out to examine the protein–protein interactions 
involving domain C and other portions of PARP-1. No “PARP complex” with a defined 
molecular weight around 113 kDa was observed. But the existence of noncovalent 
interactions was implicated as distinct protein bands became smear after crosslinking. 
These results suggest that domain C is not the sole dimerization interface and 
interdomain contacts are more relevant during catalysis. 
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5.2 MATERIALS AND METHODS 
5.2.1 Cloning, expression, and purification of human PARP-1 fragments and 
mutants in E. coli 
DNAs encoding domains A-C (ABC, residues 1–373) and domains D-F (DEF, 
residues 374–1014) of human PARP-1 were cloned into MalE-pET vector by Dr. Peng 
Gao as described in Section 4.2.1. DNAs encoding domain C (residues 233–373) and 
domains ABDEF (residues 1–232 and 374–1014 as a single polypeptide chain, with two 
additional residues Asp and Ile in between due to primer design) of human PARP-1 were 
prepared and cloned into MalE-pET vector by Dr. Zhihua Tao. DNA encoding domain 
DEF was also cloned into the original pET-28b(+) vector (Novagen) for the expression of 
N-terminal His6-tagged protein. 
Site-directed mutagenesis was carried out using DEF/MalE-pET as the template 
and the primer pairs listed in Table 5-1 according to the protocol recommended by the 
manufacturer (Stratagene). Briefly, 5–50 ng of template DNA was PCR-amplified using 
125 ng of specific primer pairs under gradient annealing temperature (55–65 °C). The 
reaction mixtures were incubated overnight with DpnI at 37 °C to degrade the original 
template DNA. The resulting newly synthesized DNAs with desired mutations were 
individually introduced into E. coli XL 10-Gold (Stratagene) or DH5α (Invitrogen) strain 
for amplification based on their specific annealing temperature. Plasmids were then 
purified and sequence-verified by the ICMB DNA core facility at UT Austin. Double, 
triple, and quadrupole mutants were generated by cumulative mutagenesis. 
Procedures for MBP-tagged protein expression and purification were essentially 
the same as described previously. All buffers used except for the final elution buffer 
contained 1 M NaCl to disrupt nonspecific protein–DNA interactions. The proteins 
collected from the first Ni-NTA column purification were digested with TEV protease 
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(5% w/w) to cleave the MBP tag during the third-time dialysis. The mixture was then 
passed through the Ni-NTA column again to remove all His-tagged proteins, allowing 
non-tagged target protein to be eluted. His-tagged DEF was purified following similar 
procedures without TEV protease digestion and second Ni-NTA column purification. 
 
Mutation Direction Primer sequence 
M890V 
Forward 5′-CCCGTGACAGGCTACGTGTTTGGTAAAGGGATCTATTTCGC-3′ 
Reverse 5′-GCGAAATAGATCCCTTTACCAAACACGTAGCCTGTCACGGG-3′ 
K893I 
Forward 5′-GCCCGTGACAGGCTACATGTTTGGTATTGGGATCTATTTCGC-3′ 
Reverse 5′-GCGAAATAGATCCCAATACCAAACATGTAGCCTGTCACGGGC-3′ 
D899N 
Forward 5′-TAAAGGGATCTATTTCGCTAACATGGTCTCCAAGAGTGC-3′ 
Reverse 5′-GCACTCTTGGAGACCATGTTAGCGAAATAGATCCCTTTA -3′ 
E988A 
Forward 5′-CCTCTCTACTATATAACCAGTACATTGTCTATGATATTGCTC-3′ 
Reverse 5′-GAGCAATATCATAGACAATGTACTGGTTATATAGTAGAGAGG-3′ 
Table 5-1. Primer sequences for PARP-1 site-directed mutagenesis. Mutated 
nucleotides were underlined and in boldface. 
 
5.2.2 Cloning, expression, and purification of human full-length PARP-1 and 
mutants using baculovirus expression vector system in insect cells 
The gene encoding full-length human PARP-1 was cloned into the pFastBac HT 
B/MBP-Tev vector as described in Section 3.2.4. To construct the full-length PARP-1 
mutants, mutations were first generated in the DEF/MalE-pET vector. Taking advantage 
of the PstI restriction enzyme site located within domain E, the DEF mutant plasmids 
were ligated with the N-terminal fragment of wild type PARP-1/MalE-pET following 
PstI and XhoI digestion. The resulting full-length PARP-1 mutant genes were further 
cloned into the pFastBac HT B/MBP-Tev vector for protein expression in insect cells 
(see Section 3.2.4).  
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5.2.3 Poly(ADP-ribosyl)ation assay of PARP-1 and mutants using nonradioactive 
NAD+ 
Poly(ADP-ribosyl)ation of full-length PARP-1 and/or PARP-1 fragments/mutants 
was performed according to the procedures described in Section 3.2.5. Briefly, full-length 
PARP-1, truncated domains, or combination of the two (1–10 μM) were added to a 
reaction mixture containing NAD+ (50–1000 μM), 25–50 μg/mL calf thymus DNA, 250 
μM DTT, 10 mM MgCl2, 100 mM Tris-HCl at pH 8.0 to initiate the reaction. After 
incubation at room temperature for 30 min, the reaction was quenched by adding equal 
volume of 2× SDS-PAGE loading buffer and analyzed by SDS-PAGE. Protein signals 
were visualized by Coomassie stain, whereas poly(ADP-ribosyl)ation was detected by 
Amersham ECL Prime Western Blotting chemiluminescence substrate (GE Healthcare) 
using anti-PAR monoclonal primary antibody (Trevigen), and horseradish peroxidase-
conjugated anti-mouse IgG secondary antibody (Sigma-Aldrich). 
 
5.2.4 Poly(ADP-ribosyl)ation assay of PARP-1 and mutants using 32P-NAD+ 
A 6-μL reaction were conducted under the same condition described in Section 
3.2.5. The ratio of NAD+ to 32P-NAD+ was 0.1 mM–0.1 μCi μL−1. To obtain mono-ADP-
ribosylated species, samples were treated with PARG 30 min after initiation of the 
reaction, and were allowed to incubate for an additional 30 min at room temperature. 
After quenching by 6 μL 2× SDS-PAGE loading buffer, the reaction mixture was 
resolved by a 16 × 16 cm SDS-PAGE gel. Gels were dried (optional), exposed on a 
storage phosphor screen (GE Healthcare), and detected by Typhoon FLA 9500 (GE 
Healthcare). Gel images were processed by ImageJ (National Institutes of Health). 
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5.2.5 Probing the unfolding of PARP-1 domain C with mass spectrometry 
To provide structural information of domain C of PARP-1 in solution, domain C 
was dialyzed into phosphate-buffered saline (PBS, pH 7.4) containing 0%, 25%, and 50% 
of acetonitrile (ACN) for differential protein denaturation for 15 min on ice. The primary 
amine groups of the denatured protein were then selectively labeled with S-
ethylacetimidate (SETA) in a SETA-to-protein molar ratio of 475 on ice for 1 h. The 
labeling reaction was quench by adding 100-fold ammonium acetate relative to the 
concentration of SETA. Labeled proteins were collected by passing through a 10-kDa 
cut-off filtration unit and stored at −80 °C before MS analysis. 
Each protein sample was diluted to 10 μM in a ACN/water/formic acid solution 
(60:39.5:0.5, v/v/v) prior to direct infusion into an Orbitrap Elite mass spectrometer 
(Thermo Scientific) equipped with a 193-nm ArF excimer laser (Coherent) as described 
previously (300). Each sample was infused at a rate of 1.2 μL/min with a spray voltage of 
+3.5 kV. ESI-MS spectra were collected at 120,000 resolution at m/z 400, averaged for 
100 scans. MS/MS data was acquired by ultraviolet photodissociation (UVPD) for the 
+19 charge state envelopes of domain C including both the unmodified and SETA-
modified forms. MS/MS spectra were averaged over 2,000 scans at 120,000 resolution at 
m/z 400. The UVPD spectra were acquired at varying laser energies, from 1.5 mJ to 2.2 
mJ, using a single pulse per scan. All UVPD experiments were carried out at 5 mTorr N2 
in the higher-energy collisional dissociation (HCD) cell. MS experiments and subsequent 
analysis were conducted by Michael Cammarata, a graduate student in Dr. Jennifer 
Brodbelt’s lab in the Department of Chemistry, UT Austin. 
Data analysis has been described in details in a published manuscript (301). The 
structural environment of each primary amine residue (i.e., lysine and the N-terminal 
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amine) was assessed based on the SETA incorporation value (S.I.) per residue. The 
calculation of S.I. value was based on the following equations: 
S.I.N = S.I.total at (N) lysine − S.I.k at (N−1) lysine    (1) 
S.I.total = 
wav - masstheo.
massSETA
        (2) 
wav = 
!(product of m/z of each modified ion and its ion abundance)!(all ion abundances in modified series)   (3) 
where wav represents the weighted average of specific ion fragment bearing SETA 
modifications, S.I.total represents the total S.I. value of specific ion fragment, and S.I.N 
represents the calculated S.I. value of specific (N) lysine residue. 
 
5.2.6 Crosslinking assay of PARP-1 domain C and ABDEF 
Chemical crosslinking experiment using bis(sulfosuccinimidyl)suberate (BS3, 
Thermo Scientific) as the crosslinker was performed to explore the potential protein–
protein interaction within PARP-1 domains. A 100 mM sodium phosphate buffer (pH 
7.5) containing 10 μM of either domain C, ABDEF, or both in the presence of 50 μg/mL 
calf thymus DNA or 20 μM GGAATTCC 8-mer double-strand DNA was prepared. 
Bovine serum albumin (BSA) and the full-length PARP-1 were used as controls. No 
NAD+ was included in the reaction. BS3 (25 mM stock concentration in water, prepared 
immediately before use) was added to the protein solutions to reach 20-, 50-, and 100-
fold molar excess, respectively. The reaction mixtures were incubated on ice for 100 min 
and then quenched by adding Tris-HCl buffer (pH 7.5) to a final concentration of 50 mM. 
Quenched reactions were mixed with 2× SDS-PAGE loading buffer and analyzed by 
12% SDS-PAGE. Protein signals were either visualized by Coomassie stain or detected 
by immunoblotting using anti-PARP-1 monoclonal antibody C2-10 (Trevigen) which 
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recognizes the 85-kDa fragment containing the automodification domain and the catalytic 
domain of human PARP-1. 
 
5.3 RESULTS 
5.3.1 Preparation of full-length PARP-1, domain fragments, and the mutants 
PARP-1 is a modular protein comprised of six functional domains (Figure 1-11). 
Combination of PARP-1 domains to reconstitute its enzymatic activity has been 
demonstrated by our group (188) and Pascal’s laboratory (189). To study the mechanism 
of PARP-1 automodification reaction, two pairs of complementary domain fragments 
were utilized in this study: ABC/DEF and ABDEF/C. 
In addition to the truncated domains, mutations were also introduced into the DEF 
fragment as well as full-length PARP-1 in order to construct a protein which is 
catalytically inactive but still capable of serving as an acceptor for PAR polymers. Four 
amino acid point mutations, M890V, K893I, D899N, and E988A, were chosen based on 
the fact that PARP-1 harboring either one of these mutations had less than 0.5% activity 
compared to the wild type enzyme (246, 252, 302). As shown in Figure 5-1, these four 
residues are located within or near the active site of PARP-1. Met-890 is stacking with 
the adenine ring of the acceptor NAD+ molecule and may also help position the catalytic 
base Glu-988. The M890V mutant may disrupt the binding with the acceptor substrate 
and have adverse effect on the proper alignment of the catalytic base. Lys-893 forms 
extensive hydrogen bonding with three backbone carbonyl groups from Pro-881, Pro-
882, and Ala-884. Mutation of this residue to Ile could prevent these interactions and 
destabilize the loop structure around the NAD+-binding pocket. Asp-899 forms a 
hydrogen bond with Asn-987. The catalytic base Glu-988 of the D899N mutant may have 
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increased mobility caused due to the adjacent mutation. It is also possible that the 
acceptor substrate binding may be slightly hindered in the D899N mutant. Mutations 
were introduced sequentially according to the observed biochemical properties (which 
will be presented in the following sections) and the ease of purification. The 
nomenclature of these mutants is shown in Table 5-2. 
 
 
Figure 5-1. Locations of amino acid residues for targeted mutations in the PARP-1 
catalytic domain (PDB: 1A26). Targeted residues are shown in green; 
residues forming hydrogen-bond interactions with the targeted residues are 
shown in yellow; the AMP moiety of carba-NAD+ is shown in white. 
 
Construct name Description 
PARP-1 Wild-type non-tagged PARP-1 
DEF Wild-type N-His6-tagged DEF 
ke-DEF Non-tagged DEF with K893I and E988A 
de-DEF / de-PARP Non-tagged DEF or PARP-1 with D899N and E988A 
mde-DEF / mde-PARP Non-tagged DEF or PARP-1 with M890V, D899N, and E988A 
mkde-DEF / mkde-PARP Non-tagged DEF or PARP-1 with M890V, K893I, D899N, and E899A 
Table 5-2. Nomenclature of PARP-1 mutants used in this study. 
D899
E988
D899
Acceptor,NAD⁺
K893
M890
N987
P881 P882
A884Donor,NAD⁺
binding,pocket
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Shown in Figure 5-2 are the SDS-PAGE gel images containing protein constructs 
used in the experiments presented in this chapter. Wild-type full-length PARP-1 
displayed a major band around the 116-kDa marker, matching well with the expected 
molecular weight of 113 kDa (lanes 6, 9, and 12). A faint band of molecular weight 
higher than 116 kDa was observed for batch 1 (lane 6). This band is most likely the 
uncleaved MBP-PARP-1 fusion protein due to insufficient activity of TEV protease. 
Some minor degradation was also observed. Wild-type truncated domains including DEF, 
ABC, and domain C were all obtained in high purity (lanes 5, 11, and 14, respectively). 
ABDEF (~97 kDa) was purified in fair condition, with a significant degradation band 
around 45 kDa (lane 13). The protein was further purified through size exclusion 
chromatography to get rid of the degraded protein, but the resulting ABDEF still showed 
signs of degradation upon storage (data not shown). 
 
 
Figure 5-2. SDS-PAGE gel of purified full-length PARP-1, domain fragments, and the 
mutants. M, molecular weight marker; lane 1, mde-DEF; lane 2, de-DEF; 
lane 3, mkde-DEF; lane 4, ke-DEF; lane 5, wild-type His6-DEF; lane 6, 
wild-type PARP-1 (batch 1); lane 7, de-PARP; lane 8, mde-PARP; lane 9, 
wild-type PARP-1 (batch 2); lane 10, mkde-PARP; lane 11, ABC; lane 12, 
wild-type PARP-1 (batch 3); lane 13, ABDEF; lane 14, domain C. 
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Handling of DEF and full-length PARP-1 mutant proteins was more problematic. 
All DEF mutants expressed in E. coli contained several degraded products in addition to 
the desired 71-kDa protein (lanes 1–4). Switch of the expression system to insect cells 
did not improve the situation (data not shown). Among the four mutants, mkde-DEF had 
the lowest yield upon purification (lane 3). Hence, the number of mutations of DEF was 
limited to two or three residues and the resulting mutants were catalytically inactive. The 
mde-DEF and de-DEF mutant had a faint band around 116 kDa, representing their 
corresponding uncleaved MBP-fusion proteins. 
The expression and purification of full-length PARP-1 bearing any of the four 
mutations was difficult. Efforts to alter the growth conditions of the insect cells or to 
accelerate the purification process did not significantly improve the stability of these 
protein constructs. Of three mutants tested, only de-PARP showed a 113-kDa band 
corresponding to the molecular weight (lane 7), whereas mde-PARP and mkde-PARP 
were severely degraded (lanes 8 and 10, respectively). Nevertheless, the proteins were 
still pooled and used in the following experiments, with caveats added for data 
interpretation. 
Overall, the wild-type proteins were obtained in high purity, while the mutant 
proteins of DEF and full-length PARP-1 showed noticeable degradation problems. The 
degradation pattern and the difference in the expected molecular weight of DEF and full-
length PARP-1 proteins (71 kDa vs. 113 kDa) are two important criteria to be considered 
in the interpretation of the experimental results in the following sections. 
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5.3.2 Reconstitution of DNA-dependent poly(ADP-ribosyl)ation activity by PARP-
1 domain fragments 
To show that ABC/DEF and ABDEF/C, two pairs of PARP-1 truncated domains, 
are able to reconstitute DNA-dependent poly(ADP-ribosyl)ation activity in vitro, purified 
proteins pairs were added in 1:1 molar ratio to the PARP-1 reaction buffer containing 25–
50 μg/mL calf thymus DNA in the presence or absence of NAD+. Reactions were 
analyzed by SDS-PAGE followed by either Coomassie staining or anti-PAR immunoblot. 
Results of the ABC/DEF pair are shown in Figure 5-3A and B. Wide-type DEF 
showed basal activity in the absence of ABC, as detected by anti-PAR immunoblot (lane 
1), whereas DEF mutants ke-DEF and mkde-DEF did not show any poly(ADP-
ribosyl)ation activity (lanes 2 and 3, respectively). Reactions containing PARP-1 showed 
strong poly(ADP-ribosyl)ation activity, and the smear of PARP-1 protein can be seen 
from the Coomassie stain (lanes 4–6). The combination of DEF and ABC successfully 
reconstituted the DNA-dependent poly(ADP-ribosyl)ation activity, and a slight smear of 
the DEF protein band was observed (lane 7). No activity was detected for the DEF 
mutants even in the presence of ABC (lanes 8 and 9). This observation suggests that ke-
DEF and mkde-DEF are devoid of poly(ADP-ribosyl)ation activity. Whether these 
mutants still possess mono-ADP-ribosylation activity is unknown, since the anti-PAR 
antibody can only recognize PAR polymers, not mono-ADP-ribose. It is worth 
mentioning that as-purified wild-type DEF had already been automodified even in the 
absence of NAD+ (lane 10). 
Similar results were obtained from the ABDEF/C pair. The addition of C into 
ABDEF reaction can trigger the poly(ADP-ribosyl)ation activity. But the activity is 
weaker than that of the wild-type enzyme as judged by the extent of protein smear from 
the Coomassie stain (Figure 5-3C, lanes 4 and 6). 
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In short, the strategy to combine PARP-1 domain fragments in trans successfully 
reconstituted the DNA-dependent poly(ADP-ribosyl)ation activity, and the mutant 
enzymes prepared are catalytically inactive. These results pave the way for the design of 
the following experiments to determine the molecularity of PARP-1 automodification 
reaction. 
 
 
Figure 5-3. Complementation assay of DNA-dependent poly(ADP-ribosyl)ation of 
PARP-1. (A) SDS-PAGE gel of reactions containing ABC/DEF pair. Lane 
1, DEF; lane 2, ke-DEF; lane 3, mkde-DEF; lane 4, DEF+PARP-1; lane 5, 
ke-DEF+PARP-1; lane 6, mkde-DEF+PARP-1; lane 7, DEF+ABC; lane 8, 
ke-DEF+ABC; lane 9, mkde-DEF+ABC; lane 10, DEF only; lane 11, ke-
DEF only; lane 12, mkde-DEF only; lane 13, PARP-1 only; lane 14, ABC 
only. M, molecular weight marker. Reactions in lanes 1–9 include 50 μM 
NAD+ whereas those in lanes 10–14 do not. (B) Western blotting of the 
same reactions performed in (A) using anti-PAR monoclonal antibody. (C) 
SDS-PAGE gel of reactions containing ABDEF/C pair. Lane 1, PARP-1 
only; lane 2, ABDEF only; lane 3, C only; lane 4, PARP-1; lane 5, ABDEF; 
lane 6, ABDEF+C. Lanes 1–3 are purified proteins only whereas lanes 4–6 
are poly(ADP-ribosyl)ation reactions using 1 mM NAD+. 
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5.3.3 Overview of the poly(ADP-ribosyl)ation assay using PARP-1 constructs 
A mix-and-match strategy was utilized here to provide experimental evidence for 
the macromolecular mechanism of PARP-1 automodification reaction. Namely, a wild-
type enzyme is incubated with a catalytically inactive enzyme, which can still serve as 
the acceptor for PAR polymers. If poly(ADP-ribosyl)ation is observed for the inactive 
enzyme, this would suggest that an intermolecular mechanism is operating. A 
radioactivity-based assay was employed to achieve high sensitivity for any ADP-
ribosylation events, and to offer additional mechanistic information by monitoring the 
hydrolysis of NAD+ side reaction. 
To distinguish between the wild-type and the inactive enzyme, minimally active 
PARP-1 domain DEF was selected and mutated to serve as the inactive one. DEF has 
been demonstrated to possess basal poly(ADP-ribosyl)ation activity in the absence of its 
DNA-binding domain counterpart ABC (5). By using two size-distinguishable PARP-1 
domain constructs and taking advantage of PARP-1’s domain complementarity, the 
protein mixture after modification can be resolved by SDS-PAGE, and radiolabeled 
species can be visualized by autoradiography. Solid evidence for any attachment of the 
ADP-ribose unit can be obtained by PARG treatment, which eliminates the smear effect 
associated with poly(ADP-ribosyl)ated proteins, leaving the protein-proximal ADP-
ribose. 
Once the property of the DEF mutant was confirmed, the same mutations were 
introduced into the full-length PARP-1 and poly(ADP-ribosyl)ation assay was performed 
in the presence of wild-type DEF. The modification of the mutant PARP-1 would further 
support the intermolecular mechanism. 
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5.3.4 Poly(ADP-ribosyl)ation of ke-DEF mutant in the presence of PARP-1 or 
ABC 
DEF domain containing double mutations K893I and E988A was first prepared in 
an attempt to generate a catalytically inactive DEF mutant (ke-DEF). Poly(ADP-
ribosyl)ation assay of this mutant in the presence of PARP-1 was performed along with 
control reactions using wild-type DEF. As shown in Figure 5-4A, PARP-1 showed robust 
automodification activity, with major signal seen at the gel interface (lane 2). Wild-type 
DEF exhibited weak activity, as the NAD+ level was comparable to the control (lane 1 
and 3). Interestingly, very long and branched polymers were attached on the DEF protein, 
preventing it from entering the gel (lane 3). No radioactive signal was observed for the 
ke-DEF reaction and NAD+ remained in the solution (lane 4), suggesting it may not be 
active in the absence of other PARP-1 domains. 
To examine the feasibility of detecting poly(ADP-ribosyl)ated species from 
different protein constructs under current experimental settings, an increasing 
concentrations of wild-type DEF were titrated against PARP-1. From lanes 5–8, a distinct 
band below PARP-1 can be observed as the concentration of DEF increased, which 
appears in the region corresponds to the molecular weight of unmodified DEF. PARP-1 
automodification is still the dominant reaction. These results suggest that at least 
initiation of poly(ADP-ribosyl)ation of some DEF occurred as its concentration increased 
in the reactions. Whether this modification is catalyzed by DEF or PARP-1 cannot be 
distinguished at this point. 
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Figure 5-4. Autoradiography of poly(ADP-ribosyl)ation assays using DEF or ke-DEF 
incubated with (A) PARP-1 or (B) ABC in the presence of DNA and NAD+. 
All reactions contain 25 μg/mL calf thymus DNA and 100 μM NAD+ doped 
with 32P-NAD+. Protein concentration was 1 μM unless specified. ADPR, 
ADP-ribose. (A) Lane 1, NAD+ only; lane 2, PARP-1; lane 3 DEF; lane 4, 
ke-DEF; lanes 5–8, PARP-1 with 1, 2, 5, and 10 μM DEF, respectively; 
lanes 9–12, PARP-1 with 1, 2, 5, and 10 μM ke-DEF, respectively. (B) Lane 
1, NAD+ only; lane 2, DEF; lanes 3–7, ABC with 1, 2, 5, 10, and 20 μM 
DEF, respectively; lane 8, ke-DEF; lanes 9–13, ABC with 1, 2, 5, 10, and 20 
μM ke-DEF, respectively. Arrows indicate the expected positioning of the 
corresponding protein in its original molecular weight. Asterisk denotes the 
degraded proteins of ke-DEF. 
 
The results of titrating ke-DEF into PARP-1 reactions were similar to those of 
DEF (lanes 9–12). An even weaker band was observed at the DEF region. This can be 
explained by the over-estimation of the concentration of ke-DEF as a result of the 
presence of degraded ke-DEF in the protein solution (Figure 5-2, lane 4). NAD+ 
hydrolysis also decreased as ke-DEF concentration increased, suggesting that the mutant 
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may compete with PARP-1 for NAD+ binding which seems to “protect” NAD+ from 
hydrolysis. 
The modification of ke-DEF only in the presence of PARP-1 raises the question 
whether this modification is catalyzed by PARP-1, or ke-DEF with the assistance from 
the ABC domain of PARP-1. To investigate this issue, ke-DEF was incubated with 
purified ABC domain and poly(ADP-ribosyl)ation assay was carried out (Figure 5-4B). 
In the control reactions of wild-type DEF, the strongest PAR signal was observed for 
DEF and ABC in a 1:1 molar ratio (lane 3). As the concentration of DEF increased, the 
smearing of poly(ADP-ribosyl)ated proteins weakened and shifted toward the molecular 
weight of unmodified DEF (lanes 3–7). This observation is consistent with the notion that 
ABC is required for the initiation step of poly(ADP-ribosyl)ation (Dr. Meilan Wu, 
unpublished results). Excess amount of DEF are competing with each other for searching 
available ABC, therefore less modification can occur on the protein. Meanwhile, NAD+ 
was depleted in these reactions, either in the form of PAR polymers or being hydrolyzed 
to free ADP-ribose.  
The results of ke-DEF incubated with ABC were unexpected. A total of four 
protein bands can be clearly seen from the gel for all reactions (lanes 9–13). The pattern 
of these protein bands matches with that of the purified ke-DEF (Figure 5-2, lane 4). 
NAD+ was not consumed much as compared to the reaction of DEF alone (lane 2), and 
the addition of ABC did not increase the rate of hydrolysis. These results are mostly 
consistent with the explanation that ke-DEF is a mono-ADP-ribosyltransferase. The 
residual catalytic activity of ke-DEF even after double mutations prevent its use in the 
experiments for investigating intermolecular mechanism of PARP-1 automodification, as 
one cannot rule out the possibility that ke-DEF can be self-modified in the presence of 
other supporting domains such as ABC. Nonetheless, this set of experiments 
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demonstrated the feasibility to detect poly(ADP-ribosyl)ation of structurally 
distinguishable PARP-1 constructs using autoradiography. 
 
5.3.5 Poly(ADP-ribosyl)ation of catalytically inactive mkde-DEF or mkde-PARP 
To obtain a truly inactive PARP-1 mutant, four mutations were introduced into 
the DEF domain by site-directed mutagenesis (mkde-DEF) to ensure complete disruption 
of its catalytic activity. The purity of mkde-DEF was poor (Figure 5-2, lane 3), and 
efforts to improve its purity had limited success. The protein was still pooled and used in 
the poly(ADP-ribosyl)ation assay to gain some insight into the mechanistic proposal. 
The mkde-DEF was first incubated with ABC to examine if any residual activity 
can be detected. No signal was observed for either mkde-DEF alone or in the presence of 
ABC (Figure 5-5A, lanes 2–6). NAD+ remained in the samples. When increasing 
concentrations of mkde-DEF were titrated against PARP-1, a decreased trend of 
poly(ADP-ribosyl)ation around the gel interface region was observed, accompanied by 
the increasing amount of NAD+ left in each reaction (lanes 7–10). No explicit band below 
the dark smear from PARP-1 can be seen. Several explanations are possible to account 
for the observation: the modified mkde-DEF protein band may be too weak to be seen on 
top of the overall radioactivity background; insufficient amount of mkde-DEF protein 
was present in the sample due to severe degradation; no modification occurred on mkde-
DEF. With the current materials and method, it is difficult to distinguish between these 
possibilities, but at least the increasing NAD+ remained in the samples suggest the 
occurrence of some inhibitory effect upon the addition of mkde-DEF. 
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Figure 5-5. Autoradiography of poly(ADP-ribosyl)ation assays using PARP-1 bearing 
quadrupole mutations in the presence of DNA and NAD+. All reactions 
contain 25 μg/mL calf thymus DNA and 100 μM NAD+ doped with 32P-
NAD+. Protein concentration was 1 μM unless specified. (A) mkde-DEF 
incubated with ABC or PARP-1. Lane 1, NAD+ only; lane 2, mkde-PARP; 
lanes 3–6, ABC with 1, 2, 5, and 10 μM mkde-DEF, respectively; lanes 7–
10, PARP-1 with 1, 2, 5, and 10 μM mkde-DEF, respectively; lane 11, 
PARP-1; lane 12, DEF+ABC; lane 13, DEF+PARP-1; lane 14, ke-
DEF+ABC; lane 15, ke-DEF+PARP-1. Asterisk denotes the protein bands 
derived from ke-DEF. (B) mkde-PARP incubated with PARP-1 or ABC. 
Lane 1, NAD+ only; lane 2, PARP-1; lane 3, PARP-1+PARG; lanes 4–7, 0, 
1, 2, and 5 μM mkde-PARP, respectively; lanes 8–11, DEF with 0, 1, 2, and 
5 μM mkde-PARP, respectively; lanes 12–15, DEF with 0, 1, 2, and 5 μM 
mkde-PARP, respectively, and then treated with PARG. Arrows indicate 
radiolabeled protein in its original molecular weight. 
 
The corresponding full-length PARP-1 bearing the same mutations (mkde-PARP) 
was also constructed. Upon purification, the protein was again severely degraded, with no 
major band at 113 kDa (Figure 5-2, lane 10). The partially purified protein alone had no 
radiolabeled signal in the presence of NAD+ (Figure 5-5B, lanes 4–7), and the hydrolysis 
of NAD+ only slightly increased when using high concentration of mkde-PARP (lane 7). 
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In the absence of ABC, wild-type DEF showed signals at the well and gel interface 
region, as observed previously (lane 8 and Figure 5-4B lane 2). When adding 1:1 ratio of 
mkde-PARP to the reaction, the signal at the well region disappeared and a strong smear 
showed up at the DEF region (lane 9). NAD+ was consumed more than DEF alone. This 
result is consistent with the notion that the ABC domain of mkde-PARP together with 
wild-type DEF forms an active “PARP complex” where new polymers are both initiated 
and extended. Increasing concentrations of mkde-PARP seemed to lower the 
modification level of DEF and the signal at the well region appeared again (lanes 10 and 
11). To confirm if the proteins are indeed attached with PAR polymers, reactions having 
the same components as in lanes 8 to 11 were treated with PARG to hydrolyze the 
polymers, leaving mono-ADP-ribosylated proteins. As shown in lanes 12 to 15, the only 
protein signal can be seen corresponds to DEF. No modified mkde-PARP was observed, 
largely because there is no distinct major band for this protein being used (Figure 5-2, 
lane 10). Altogether, these results indicate that introducing mutations is possible to 
disrupt PARP-1’s activity without interfering its ability to serve as an acceptor for PAR 
polymers. PARG treatment can facilitate the visualization of modified proteins to a single 
band, mono-ADP-ribosylated form. How many point mutations are required to inactivate 
a protein and how to improve the purification of the mutants are subjects need to be 
further defined and optimized. 
 
5.3.6 Poly(ADP-ribosyl)ation of mde-DEF in the presence of PARP-1 
In order to obtain a completely inactive mutant while retaining the protein 
stability for in vitro purification, K893I mutation was converted back to lysine to restore 
three peptide backbone hydrogen bond interactions (Figure 5-1). The resulting mde-DEF 
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was expressed and purified (Figure 5-2, lane 1). Despite having degradations around 66 
kDa and 45 kDa, a major band corresponding to the correct DEF molecular weight can be 
seen by SDS-PAGE. 
 
 
Figure 5-6. Autoradiography of poly(ADP-ribosyl)ation assays using mde-DEF 
incubated with (A) ABC or (B) PARP-1 in the presence of DNA and NAD+. 
All reactions contain 25 μg/mL calf thymus DNA and 100 μM NAD+ doped 
with 32P-NAD+. Protein concentration was 1 μM unless specified. (A) Lane 
1, NAD+ only; lanes 2–4, ABC with 1, 5, and 10 μM mde-DEF, 
respectively. (B) Lane 1, NAD+ only, lanes 2–6, PARP-1 with 0, 1, 5, 10, 
and 25 μM mde-DEF, respectively; lanes 7–11, PARP-1 with 0, 1, 5, 10, 
and 25 μM mde-DEF, respectively, and then treated with PARG; lane 12, 4 
μM PARP-1+PARG; lane 13, 6 μM DEF+6 μM ABC+PARG. (C) 
Enhanced image contrast of lanes 7–13 of (B) to show mono-ADP-
ribosylated species after PARG treatment. Arrow indicates radiolabeled 
mde-DEF in its original molecular weight. 
 
Incubation of the purified protein with ABC did not show any radiolabeled signal 
in the presence of 32P-NAD+ (Figure 5-6A, lanes 2–4), suggesting that mde-DEF is 
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inactive. Adding increasing amount of mde-DEF into samples containing 1 μM PARP-1 
(batch 1 in Figure 5-2, lane 6) slightly reduced the overall poly(ADP-ribosyl)ation signal, 
and the remaining NAD+ became more evident (Figure 5-6B, lanes 3–6), suggesting the 
mutant’s inability to hydrolyze NAD+. To confirm the identity of proteins which had been 
modified by PAR polymers, same reactions of lane 2 to 6 were treated with PARG to 
simplify the modified proteins to mono-ADP-ribosylated species. Clearly, a band 
corresponding to the molecular weight of DEF (lane 13) showed up as the mde-DEF 
concentration increases (Figure 5-6B and C, lanes 7–11, arrow). The signal, however, is 
not as strong as the one from PARP-1, even in 25-fold molar excess (lane 11). These 
results suggest that mde-DEF is capable of being modified by PARP-1 intermolecularly, 
but PARP-1 itself is still a preferred substrate. 
 
5.3.7 Poly(ADP-ribosyl)ation of mde-PARP in the presence of DEF 
To confirm the above experimental observation that mde-DEF can be modified by 
PARP-1 intermolecularly, full-length PARP-1 with the same point mutations were 
constructed (mde-PARP), and a complementary poly(ADP-ribosyl)ation assay was 
carried out in the presence of wild-type DEF. 
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Figure 5-7. Autoradiography of poly(ADP-ribosyl)ation assays using mde-PARP 
incubated with DEF in the presence of DNA and NAD+. All reactions 
contain 25 μg/mL calf thymus DNA and 100 μM NAD+ doped with 32P-
NAD+. Protein concentration was 1 μM unless specified. (A) Lane 1, NAD+ 
only; lanes 2–4, 1, 5, and 8 μM mde-PARP, respectively; lane 5, DEF; lanes 
6–8, DEF with 1, 5, and 8 μM mde-PARP, respectively; lane 9, 
DEF+PARG; lanes 10–12, DEF with 1, 5, and 8 μM mde-PARP, 
respectively, and then treated with PARG; lane 13, 5 μM PARP-1+PARG; 
lane 14, 5 μM DEF+PARG; lane 15, 5 μM DEF+5 μM ABC+PARG. (B) 
Enhanced image contrast of lanes 9–15 of (A) to show mono-ADP-
ribosylated species after PARG treatment. Arrow indicates expected mde-
PARP in its original molecular weight. 
The purity of mde-PARP was not good, and no major band at 113 kDa can be 
observed (Figure 5-2, lane 8). This precludes the interpretation of mde-PARP being 
modified or not because there is no distinct band representing mde-PARP. Nonetheless, 
the mix-and-match poly(ADP-ribosyl)ation assay was still performed with caution. mde-
PARP was completely inactive (Figure 5-7A, lanes 2–4). In the presence of DEF, a smear 
in the separating gel can be clearly observed, with the strongest one being mde-PARP 
and DEF in a 1:1 ratio (lane 6). As the concentration of mde-PARP increased, less DEF 
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was modified, probably due to the poisonous effect of inactive mde-PARP (lanes 7 and 
8). Same reactions after PARG treatment gave distinct bands for DEF (lanes 9–12). There 
are some additional faint bands below the 71-kDa DEF major band in lane 10, and they 
are absent in lane 9. One possibility is that these protein bands are derived from degraded 
mde-PARP, and radiolabeled signals indicate that they were modified. NAD+ was nearly 
depleted in lane 10, probably due to the combination of an active PARP complex and 
PARG to form a “PAR turnover system.” The modification of DEF decreased when 
excess amount of mde-PARP was present, suggesting the possibility of a “dead complex” 
formed by mde-PARP itself which prevents the contribution of ABC domain to DEF for 
efficient catalysis. These results support the model that automodification of PARP-1 
appears to operate in an intermolecular fashion. But an in vitro experiment with better 
defined protein materials is needed to unambiguously valid this hypothesis. 
 
5.3.8 Poly(ADP-ribosyl)ation of de-DEF in the presence of PARP-1 
From the previous section, it has been shown that both mde-DEF and mde-PARP 
are inactive PARP-1 mutants. To further optimize the protein stability while maintaining 
inactive status of the enzyme, a double mutant de-DEF was constructed for this purpose. 
The purified protein has a major band at 71 kDa with some degradation (Figure 5-2, lane 
2). de-DEF was tested to be inactive in the presence of ABC (Figure 5-8A, lanes 2–4). 
When incubating with 1 μM PARP-1 (batch 1 in Figure 5-2, lane 6), no obvious 
difference was observed as poly(ADP-ribosyl)ation signal occupied the whole lane, and 
NAD+ was depleted to similar extent (Figure 5-8B, lanes 2–6). The corresponding 
reactions treated with PARG showed a clearer picture. As the concentration of de-DEF 
increased, a band matching with the wild-type DEF molecular weight (lane 13) became 
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more apparent (lanes 7–11, arrow). However, PARP-1 is still the dominant 
automodification species. NAD+ hydrolysis remained the same. The results, along with 
those obtained from mde-DEF, are in agreement with the model that de-DEF is modified 
intermolecularly by PARP-1 with PARP-1 being the preferred substrate. 
 
 
Figure 5-8. Autoradiography of poly(ADP-ribosyl)ation assays using de-DEF incubated 
with (A) ABC or (B) PARP-1 in the presence of DNA and NAD+. All 
reactions contain 25 μg/mL calf thymus DNA and 100 μM NAD+ doped 
with 32P-NAD+. Protein concentration was 1 μM unless specified. (A) Lane 
1, NAD+ only; lanes 2–4, ABC with 1, 5, and 10 μM de-DEF, respectively. 
(B) Lane 1, NAD+ only, lanes 2–6, PARP-1 with 0, 1, 5, 10, and 25 μM de-
DEF, respectively; lanes 7–11, PARP-1 with 0, 1, 5, 10, and 25 μM de-DEF, 
respectively, and then treated with PARG; lane 12, 4 μM PARP-1+PARG; 
lane 13, 6 μM DEF+6 μM ABC+PARG. (C) Enhanced image contrast of 
lanes 7–13 of (B) to show mono-ADP-ribosylated species after PARG 
treatment. Arrow indicates radiolabeled de-DEF in its original molecular 
weight. 
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5.3.9 Poly(ADP-ribosyl)ation of de-PARP in the presence of DEF 
With the success that D899N/E988A double mutations could inactivate the 
enzyme while preserving certain protein stability for purification, a full-length PARP-1 
containing these two mutations (de-PARP) was constructed for the complementary 
experiments using mutant PARP-1 and wild-type DEF. Even with some degradation 
bands present in the mixture, purified de-PARP has a major band around 113 kDa (Figure 
5-2, lane 7). The protein has no activity in the presence of 32P-NAD+ (Figure 5-9A, lanes 
2–4). When incubating with wild-type DEF in a 1:1 molar ratio, the active “PARP 
complex” lead to modified DEF which showed a smear in the gel (lane 6). Increasing de-
PARP concentration attenuated the modification (lanes 7 and 8), which can be explained 
by the inhibitory effect from de-PARP. PARG treatment of the reactions from lanes 5 to 
8 unequivocally showed that both wild-type DEF and de-PARP (arrow) were 32P-labeled 
when the two were in equimolar amount (lane 10). When de-PARP was in excess, DEF 
was almost not modified at all after PARG treatment. This is identical to the situation 
where ABC is absent in the solution, suggesting little or no initiation took place. NAD+ 
was not completely consumed in these reactions, perhaps because the PARP complex 
formed between DEF and de-PARP is much less reactive than that formed with mde-
PARP. Overall, these data clearly demonstrate that DNA-dependent PARP-1 
automodification reaction could proceed via an intermolecular mechanism, with the 
assembled full-length PARP-1 complex or a single PARP-1 polypeptide being the 
preferred substrate. However, one still cannot rule out the possibility that an 
intramolecular process is also involved based on the current experimental settings. 
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Figure 5-9. Autoradiography of poly(ADP-ribosyl)ation assays using de-PARP 
incubated with DEF in the presence of DNA and NAD+. All reactions 
contain 25 μg/mL calf thymus DNA and 100 μM NAD+ doped with 32P-
NAD+. Protein concentration was 1 μM unless specified. (A) Lane 1, NAD+ 
only; lanes 2–4, 1, 5, and 8 μM de-PARP, respectively; lane 5, DEF; lanes 
6–8, DEF with 1, 5, and 8 μM de-PARP, respectively; lane 9, DEF+PARG; 
lanes 10–12, DEF with 1, 5, and 8 μM de-PARP, respectively, and then 
treated with PARG; lane 13, 5 μM PARP-1+PARG; lane 14, 5 μM DEF+5 
μM ABC+PARG. (B) Enhanced image contrast of lanes 9–14 of (A) to 
show mono-ADP-ribosylated species after PARG treatment. Arrow 
indicates radiolabeled de-PARP in its original molecular weight. 
 
5.3.10 Domain C of PARP-1 exists as a monomer in solution revealed by UVPD-MS 
The mix-and-match poly(ADP-ribosyl)ation assay using distinguishable PARP-1 
active enzyme and inactive substrate strongly suggests an intermolecular mechanism for 
the DNA-dependent PARP-1 automodification reaction. This implies that PARP-1 may 
be self-associated during catalysis (238), or more explicitly, dimerization of PARP-1 may 
occur during DNA-dependent poly(ADP-ribosyl)ation of PARP-1 (239). Domain C of 
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PARP-1 has been proposed to be the dimerization site for PARP-1 based on a recent 
crystal structure (187), which is in contrast to the monomeric NMR solution structure 
reported by our group (188). Herein, we employed a MS-based methodology to 
characterize the chemically labeled domain C, in order to evaluate the conformational 
change as a function of acetonitrile-induced protein denaturation. The result may provide 
insight into the structure of domain C under physiological conditions. 
Domain C was first denatured by 25% or 50% acetonitrile for 15 min before 
reacting with the small molecule probe SETA which specifically labels free amino 
groups. Since protein conformation and local environment determine the reactivity of 
these amino groups, differential labeling can be achieved and then analyzed by top-down 
MS. UVPD is a novel MS technique which can efficiently generate a complete set of 
fragmented peptide ions for detection (293). The more fragment ions, the more sequence 
as well as modification information on the amino acid residues can be gathered by MS. 
By analyzing the spectra of the whole proteins species, the SETA incorporation value 
(S.I., 0–0.5) can be calculated, and the local environment of certain lysine residue can be 
inferred from the trend of S.I. value as a function of protein denaturation (301). 
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Figure 5-10. Domain C of PARP-1 (PDB:2JVN) showing the change of S.I. value of 
specific lysine residues as a function of protein denaturing buffer with 
increasing acetonitrile concentration. Blue represents decreasing SETA 
incorporation; pink represents increasing SETA incorporation; light brown 
represents no change in SETA incorporation; orange represents variable 
SETA incorporation. Adapted from (301). 
 
 
Figure 5-11. Superimposition of the domain C NMR structure (PDB: 2JVN, state 4, light 
brown) and the crystal structure (PDB: 2RIQ, pink and lemon). Residues 
331–359 from one crystal monomer are shown in raspberry to highlight the 
dimerization interface. Key amino acid residues are also highlighted. 
K349
K347
K346
K337
K331
E332
E332
K346
 163 
The overall trend of SETA incorporation of specific lysine residues is shown in 
Figure 5-10. Lysine residues with more solvent exposure have either decreasing or 
similar SETA incorporation, whereas more buried Lys-249, Lys-331, and Lys-346 have 
increasing SETA incorporation upon denaturation in 25% and 50% acetonitrile. 
The loop containing residues 331–359 occupies different conformations in the 
NMR and in the crystal structure (Figure 5-11). The change of S.I. values of the lysine 
residues within this loop is of particular interest. Lys-331 showed no reactivity toward 
SETA in 100% aqueous buffer (301). It forms hydrogen bonds with Arg-330 and Glu-
332 in the NMR structure, whereas being highly exposed in the crystal structure. 
Therefore, the result is more consistent with the monomeric form. Lys-337 has an S.I. 
value of 0.51 in 100% aqueous buffer, which would not be possible in the dimeric form 
with 27% solvent accessibility (301). Lys-346 had increased SETA incorporation upon 
denaturation, and this can be explained by the disruption of hydrogen bond interaction 
between Lys-346 and Glu-332 (Figure 5-11, italic highlight). Lys-347 and Lys-349 
showed variable SETA incorporation. But considering the high solvent accessibility of 
these two residues in the dimeric crystal structure as compared to their more buried 
locations in the monomeric structure, the SETA trend is more consistent with the latter 
structure. 
Despite having certain variability, the analysis suggests domain C exists in 
monomeric form in solution, and the primary protein dimerization interface is not located 
within this region. 
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5.3.11 Protein–protein interactions of PARP-1 domains 
Domain C of PARP-1 has been shown to be important for DNA-dependent 
PARP-1 activation (187-189). Since domain C is likely not the dimerization platform for 
PARP-1 activation (Section 5.3.10), it is hypothesized that protein–protein interaction 
exists between domain C and other domains to facilitate catalysis. To probe this potential 
noncovalent interaction, a chemical crosslinking assay using BS3 as the crosslinker was 
performed. The expected outcome was to see if there is any distinct band after 
crosslinking that correspond to full-length PARP-1 or other multimeric structures (dimer, 
trimer…etc.). Either calf thymus DNA or an 8-mer double-strand blunt end DNA was 
included in the reactions. BSA was used as a positive control that shows a higher 
molecular weight band matching with a dimeric structure (~132 kDa). Excess amount of 
BS3 was used to detect the trend of chemical crosslinking. 
The SDS-PAGE gels of these crosslinking reactions are shown in Figure 5-12. In 
the presence of 20-fold molar excess of BS3, reactions containing ABDEF showed 
significant smear above its original molecular weight (lanes 9–12). PARP-1 displayed 
similar phenomenon (lane 13). For the positive control, BSA had a major band around 
120 kDa, corresponding to the dimeric structure (lane 14) (303). Domain C alone did not 
have a smear distribution, perhaps due to the low concentration of the protein. Reactions 
containing both domain C and ABDEF did not have a distinct band corresponding to the 
molecular weight of full-length PARP-1, or any multimeric structures (lanes 10–12). 
Addition of DNA did not have observable effect on the smear (lanes 11 and 12). Similar 
results were observed for reaction treated with 50-fold and 100-fold molar excess of BS3 
reagent (Figure 5-2B), with more protein smear and reduced intensities for protein bands 
of their original molecular weights. Interestingly, a distinct band with molecular weight 
higher than 116 kDa (Figure 5-12B, lane 13, arrow) can be seen for PARP-1 under 1 mM 
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BS3 treatment. This band could be a dimeric form of PARP-1, although a clearer protein 
resolution and other analytical methods are needed to confirm the identity of this band. 
Proteins after crosslinking were also detected by immunoblotting using anti-PARP-1 
antibody which recognizes both the automodification and the catalytic domain of PARP-
1. However, the signals were too strong and had a large smear all over the gel lanes 
which prevent further interpretation of the results (data not shown). In short, the chemical 
crosslinking assay did not provide enough evidence to verify that domain C and ABDEF 
form a specific protein complex which is catalytically competent. However, protein–
protein interactions do exist among PARP-1 domains, and a possible dimeric structure of 
full-length PARP-1 could support the mechanism of its macromolecular association 
during catalysis. 
  
 
Figure 5-12. Crosslinking assay of PARP-1 domain C and ABDEF. Each protein (10 
μM) was incubated in the phosphate buffer containing specific amount of 
crosslinking reagent BS3 with or without 20 μM DNA. Lanes 1 and 8, 
domain C; lanes 2 and 9, ABDEF; lanes 3 and 10, C+ABDEF; lanes 4 and 
11, C+ABDEF+calf thymus DNA; lanes 5 and 12, C+ABDEF+8-mer DNA; 
lanes 6 and 13, PARP-1; lanes 7 and 14, BSA. M, molecular weight marker. 
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5.4 DISCUSSION 
5.4.1 Poly(ADP-ribosyl)ation activity can be reconstituted by PARP-1 ABC and 
DEF domains in trans 
PARP-1 catalyzes auto-poly(ADP-ribosyl)ation in the presence of DNA. Unlike 
typical transferase-catalyzed reactions where enzymes and substrates are of different 
sizes, one major obstacle to study this auto-catalytic process is to distinguish between the 
enzyme and the substrate, both are the same species and thus have the same molecular 
weight. Fortunately, PARP-1 is a modular protein composed of six subdomains. It has 
been demonstrated that these domains do not necessarily have to be in a single 
polypeptide chain as for the wild-type enzyme to exert activity. For example, deletion of 
domain C from the full-length PARP-1 drastically reduces the DNA-dependent 
poly(ADP-ribosyl)ation activity. However, the catalytic activity can be restored by the 
addition of domain C into reactions containing ABDEF (in the same polypeptide chain), 
NAD+, and DNA (187, 188). Taking advantage of this complementary feature, another 
pair of PARP-1 truncated domains, ABC/DEF, was constructed and characterized in 
detail. The results clearly demonstrate their ability to reconstitute poly(ADP-ribosyl)ation 
activity in trans. The successful combination of truncated PARP-1 domains to 
reconstitute enzyme activity has allowed the investigation of automodification reaction 
since the modified proteins can be readily differentiated by size. 
Domain ABC (residues 1–373) and DEF (residues 374–1014) represent the DNA-
binding domain and the automodification plus catalytic domain, respectively (Figure 1-
11). It is known that in the absence of DNA-binding domain, DEF possesses only basal 
level activity (201). Our results showed that the as-purified wild-type DEF from the E. 
coli expression host was already modified with some PAR polymers which could only be 
detected by anti-PAR immunoblotting (Figure 5-3B, lane 10), but not by Coomassie 
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staining (Figure 5-3A, lane 10). Similar observation was also made by Dr. Meilan Wu in 
our laboratory via treating the protein preparation with PARG. In the presence of NAD+, 
DEF alone catalyzes elongation of existing PAR polymers rather than initiating new PAR 
polymers, as evident by the PAR signals concentrated at well and gel interface region 
(Figure 5-3B, lane 1 and Figure 5-4A, lane 3). Addition of ABC domain stimulates the 
wild-type enzymatic activity. Consequently, NAD+ was efficiently consumed and the 
proteins were poly(ADP-ribosyl)ated (Figure 5-3B, lane 7 and Figure 5-4B, lane 6). 
Poly(ADP-ribosyl)ation activity of similar magnitude can also be achieved by the 
addition of full-length PARP-1 which contributes its ABC domain to the existing DEF 
domain (Figure 5-3B, lane 4 and Figure 5-4A, lanes 5–8), although the effect is not 
obvious due to the overlapping of poly(ADP-ribosyl)ated PARP-1 and DEF species. 
Treating the ABC/DEF reaction mixture with PARG reduces the poly(ADP-ribosyl)ated 
species down to mono-ADP-ribosylated ones, which have recognizable bands on SDS-
PAGE gels with defined molecular weight (Figure 5-6B, lane 13). These results 
demonstrate that ABC and DEF are capable of reconstituting poly(ADP-ribosyl)ation 
activity and set the stage for the development of a mix-and-match strategy to characterize 
PARP-1 automodification reaction products generated from size-distinguishable yet 
activity-complementary protein constructs. 
 
5.4.2 The enzymatic and the substrate aspects of PARP-1 are separable 
The challenge to study PARP-1 automodification reaction is to separate the 
enzymatic activity from its ability to serve as a substrate. Deletion and site-directed 
mutagenesis are two common ways to alter biochemical properties of the enzyme. The 
goal is to construct a mutant which can only serve as either an enzyme or a substrate, but 
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not both. These mutants, together with the wild-type enzymes, would facilitate the 
interpretation of experimental results because the role of enzyme and the role of substrate 
are clearly separated.  
For typical enzymes catalyzing posttranslational modification reactions such as 
phosphorylation or acetylation, it is common that the location of the amino acid residues 
being modified are known, and the number is few and fixed. In contrast, Glu, Asp, or Lys 
residues found on the loop structures of PARP-1 are all possible acceptors for PAR 
polymers (73). The reported number of automodification sites of PARP-1 already 
exceeds ninety, and not all the residues are modified on the same protein (295). The wide 
distribution of automodification sites on PARP-1 prevents the generation of a “polymer-
free” mutant by mutating every possible residue. Therefore, the only possible method to 
overcome this limitation is to construct a dominant-negative PARP-1 mutant devoid of 
enzymatic activity, while still capable of serving as a substrate. 
Random mutagenesis studies of PARP-1 have revealed the importance of several 
amino acid residues in catalysis (246, 252, 302). Four mutations, M890V, K893I, 
D899N, and E988A, which are close to the enzyme active site, were selected based on the 
impaired activity of PARP-1 carrying either one of these mutations. From a structural 
point of view, Met-890, Lys-893, and Asp-899 may be important for the correct folding 
of the NAD+-binding pocket, whereas Glu-988 is the catalytic base to facilitate the 
cleavage of the nicotinamide–ribose glycosidic bond (Figure 5-1). These mutations could 
impede the processing of NAD+ during catalysis without pertubing other part of the 
enzyme. 
The mutations were first introduced into the 71-kDa DEF construct. The ke-DEF 
mutant protein was always co-purified with several smaller protein contaminants (Figure 
5-2, lane 4), suggesting the mutations may cause instability of the protein. When 
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incubating with NAD+, ke-DEF did not show any poly(ADP-ribosyl)ation signals as 
judged from anti-PAR Western blot (Figure 5-3, lane 2). However, in the presence of 
ABC, DNA, and 32P-NAD+, radioactive signals were detected by autoradiography, 
displaying a pattern which corresponds to the protein bands of ke-DEF used in the 
reaction (Figure 5-4B, lanes 9–13). This finding suggests that ke-DEF, despite having no 
poly(ADP-ribosyl)ation activity, is still capable of catalyzing mono-ADP-ribosylation 
reaction. It also underscores the usefulness of radioactivity-based assay over anti-PAR 
immunoblotting to accurately describe reactions involving the cleavage of the 
nicotinamide–ribose glycosidic bond, whether it is PAR polymer initiation, elongation, or 
NAD+ hydrolysis.  
The observed residual activity of ke-DEF prompted the search for a completely 
inactive mutant. Consequently, mkde-DEF, which has all four mutations, was 
constructed. When ABC was added to the reaction, mkde-DEF did not show any 
radioactive signal on the gel (Figure 5-5A, lanes 3–6), suggesting the mutant should be 
completely inactive. But the protein itself was severely degraded since no band with the 
correct 71-kDa was discernible on SDSP-PAGE gel (Figure 5-2, lane 3). This result 
poses a caveat that disrupting the catalytic activity of PARP-1 domains may 
concomitantly result in protein degradation which complicates the interpretation of the 
experimental data. 
To reach a compromise between inactivating the enzyme and maintaining protein 
stability, two more mutants, mde-DEF and de-DEF were constructed. It was hoped that 
these mutants may be more stable by restoring three hydrogen bonding interactions 
associated with Lys-893. The purity of mde-DEF and de-DEF were fair with the 
recognizable 71-kDa band (Figure 5-2, lanes 1 and 2). Both proteins were inactive in the 
presence of ABC, DNA and 32P-NAD+, and the amount of NAD+ remained comparable to 
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the control (Figure 5-6A and Figure 5-8A, lanes 2–4). These data demonstrate that mde-
DEF and de-DEF may be useful for the mix-and-match poly(ADP-ribosyl)ation assay as 
DEF is distinguishable from the full-length PARP-1 protein. 
To confirm these mutations when introduced into full-length PARP-1 can also 
inactivate enzyme activity, equivalent mutants mkde-PARP, mde-PARP, and de-PARP 
were created. Only de-PARP had a correct band around 116 kDa (Figure 5-2, lane 7), 
whereas mde-PARP (Figure 5-2, lane 8) and mkde-PARP (Figure 5-2, lane 10) were 
severely degraded. Nevertheless, all proteins were still pooled and used in the 
experiments to see their effects on NAD+ hydrolysis to gain additional information of the 
catalysis. 
In short, efforts were devoted to dissecting the enzymatic activity and the 
substrate capacity within the same PARP-1 molecule. Dominant-negative mutants devoid 
of catalytic activity were successfully prepared for DEF domain and full-length PARP-1. 
These materials enable the subsequent study of macromolecular mechanism of DNA-
dependent PARP-1 automodification reaction. 
 
5.4.3 Intermolecular mechanism of DNA-dependent PARP-1 automodification 
reaction 
PARP-1 automodification reaction has been considered to be an intermolecular 
process largely based on the kinetic study done by Alvarez-Gonzalez et al. in 1993 (239). 
However, their argument that PARP-1 forms a catalytic dimer based on the quadratic 
fitting of the initial rate data as a function of enzyme concentration does not provide 
molecular details of how the catalysis proceeds. If dimerization or multimerization of 
PARP-1 is required for its activation, a mechanism of intramolecular automodification 
would follow the same nonlinear concentration dependence. Likewise, if PARP-1 prefers 
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to form an active dimer in the presence of DNA, a linear relationship between the activity 
and enzyme concentration will be observed regardless of automodification being an intra- 
or intermolecular process. Since the activation step cannot be separated from the 
automodification step, the kinetic analysis of poly(ADP-ribosyl)ation as a function of 
PARP-1 concentration cannot be used to distinguish between an intermolecular or 
intramolecular mechanism. 
Presented here are the results of a mix-and-match poly(ADP-ribosyl)ation assay 
aimed at providing biochemical evidence to unravel the mechanistic details of this 
reaction. mde-DEF was unable to catalyze ADP-ribosylation reaction when incubating 
with ABC (Figure 5-6A, lanes 2–4). But when titrating mde-DEF into reactions 
containing PARP-1, a decrease of overall poly(ADP-ribosyl)ated species was observed, 
and the consumption of NAD+ was also reduced (Figure 5-6B, lanes 2–6). Treating the 
reaction mixtures with PARG revealed a protein band corresponding to mde-DEF with 
greater intensity than the untreated samples (Figure 5-6B, lane 8–11). Interestingly, the 
highest band intensity of mde-DEF was still much weaker than 1 μM PARP-1, even 
though the concentration of mde-DEF was 25 μM. This result clearly shows that mde-
DEF can be poly(ADP-ribosyl)ated by wild-type PARP-1, which must be an 
intermolecular process. It also is suggests that mde-DEF competes with the activated 
PARP-1 molecules for poly(ADP-ribosyl)ation. The inability of mde-DEF to turnover 
NAD+ may lead to reduced level of poly(ADP-ribosyl)ated species.  
Similar trend was also observed for reactions containing de-DEF and PARP-1. de-
DEF was clearly modified by PARP-1, and the extent of its modification was much 
weaker than PARP-1. The only difference is that NAD+ was depleted in every reaction, 
and there was no inhibitory effect on overall poly(ADP-ribosyl)ation as the concentration 
of de-DEF increases. The explanation to this observation could be that de-DEF does not 
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bind to NAD+ as efficiently as mde-DEF, thereby having minimal effect on the turnover 
of NAD+. Another possibility is that the protein preparation of de-DEF contains much 
degradation products, resulting in over-estimation of de-DEF concentration to show 
inhibitory effect. Altogether, catalytically inactive mutants mde-DEF and de-DEF can be 
poly(ADP-ribosyl)ated in the presence of wild-type PARP-1. The reaction is not 
catalyzed by the assistance of ABC domain from PARP-1 to form a pseudo-ABC/DEF 
mutants complex (Figure 5-6A and 5-8A). Instead, it proceeds in an intermolecular 
process which PARP-1 poly(ADP-ribosyl)ates DEF mutants. 
To test whether the intermolecular process also holds true for full-length PARP-1, 
mde-PARP and de-PARP were purified and incubated with wild-type DEF. Indeed, when 
present in a 1:1 ratio, de-PARP can be seen to be modified by DEF as shown in smear or 
as a clear band after PARG treatment (Figure 5-9, lanes 6 and 10). The lack of the 113-
kDa major band of mde-PARP made it difficult to draw conclusion that the modification 
of mde-PARP is catalyzed by DEF. But a strong smear did appear when mixing with 
DEF in equimolar ratio (Figure 5-7, lanes 6 and 10). When both mutants were added in 
excess amount, the overall poly(ADP-ribosyl)ation signals decreased, and the pattern 
shift toward more like DEF alone in the absence of ABC where signals are concentrated 
at the well and gel interface region (Figure 5-7 and 5-9, lanes 7 and 8). This observation 
is consistent with the notion that full-length PARP-1 mutant forming a “dead complex,” 
leaving wild-type DEF alone in the solution. 
Taken together, the observation that a PARP-1 inactive mutant is able to be 
poly(ADP-ribosyl)ated by another active PARP-1 molecule is in agreement with the 
model that PARP-1 automodification proceeds via an intermolecular process. Although 
the experimental data presented here cannot rule out the possibility of an intramolecular 
mechanism utilized by PARP-1 during catalysis, it is difficult to rationalize the fact that 
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multiple automodification sites exist beyond domain D (73, 112, 194, 195, 295), which is 
in close proximity to the enzyme active site based on the monomeric, near full-length 
PARP-1 crystal structure (200). PARP-1 domains have also been shown to be able to 
bind PAR polymers noncovalently (188). Thus, it is possible that noncovalent PAR–
protein interaction would be a common feature to recruit substrates more favorable to be 
poly(ADP-ribosyl)ated, and is important for the oligomerization of PARP-1. 
The inhibitory effect on poly(ADP-ribosyl)ation due to the presence of excess 
amount of mutant proteins also implies that full-length PARP-1 prefers interacting with 
full-length PARP-1 rather than DEF, and the intermolecular modification process could 
be disrupted when other protein constructs alike (e.g., DEF) can compete with full-length 
PARP-1. In the case of mutant DEF and wild-type PARP-1, excess amount of mutant 
DEF outcompetes PARP-1 and the overall poly(ADP-ribosyl)ation decreases. Similarly, 
when excess amount of mutant PARP-1 is added into wild-type DEF, the mutant PARP-1 
prefers to associate with itself and form a dead complex which is catalytically inactive, 
and prevent its intact ABC domain from interacting with DEF, thereby reducing the level 
of active “PARP complex.” Characterization of such protein–protein interactions could 
be challenging, but may provide significant insight into this complicated catalytic 
process. 
In conclusion, the data presented here support the model of intermolecular 
mechanism during DNA-dependent PARP-1 automodification reaction (Figure 1-13). 
Oligomerization of PARP-1, either mediated by the protein itself or in the presence of 
DNA, or PAR polymers, is consistent with the observation of the change in poly(ADP-
ribosyl)ation, but definitive evidence awaits further investigation. 
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5.4.4 The role of domain C during PARP-1 catalysis 
The function of domain C of PARP-1 has remained elusive for a long time. It 
resides within C-terminus of the DNA-binding domain identified by proteolytic digestion 
in the early 80s (178), and has no sequence homology to any other known domain. It was 
until recent structural studies that began to shed light on the role of this domain during 
catalysis (187, 188). The addition of domain C into the ABDEF deletion mutant restores 
its DNA-dependent poly(ADP-ribosyl)ation activity. This special property is presumably 
mediated by protein–protein interactions involving domain C and other parts of PARP-1 
molecule. Given the fact that discrepancy exists between two structural studies 
(monomeric vs. dimeric), and the prevailed model of functional PARP-1 being an 
homodimer, it is of great interest to further examine the structural feature of domain C in 
solution and to probe the potential protein–protein interactions.  
In collaboration with Dr. Brodbelt’s lab in the Department of Chemistry, an 
UVPD-MS-based methodology was developed to evaluate the conformational change of 
domain C in solution upon denaturation. The feature of this MS technique is to use 
ultraviolet light for the generation of fragmented peptide ions from the whole protein 
without protease digestion. One major challenge for protein mass specetrometry is to 
produce large amount of fragmented peptide ions that cover as much protein sequence as 
possible. The more fragments are produced and detected by the instrument, the more 
information of the protein sequence can be mapped, including posttranslational 
modifications or any kinds of mass difference. The size of domain C is about 16 kDa, 
which is suitable for this top-down protein MS analysis.  
To obtain structural information of domain C, the protein was first denatured 
using buffers containing different percentage of acetonitrile. After differential 
denaturation, the protein was then labeled with a small molecule probe “SETA” which 
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specifically reacts with primary amino groups. Only free, exposed to solvent, and 
deprotonated amino groups are able to react with SETA. After the reaction, the protein 
was subject to UVPD-MS analysis directly without protease digestion. Since the 
modification of specific lysine group by SETA creates a mass difference of 41 Da, 
MS/MS analysis can locate the modification site accurately. By examination of the total 
ion spectra, the SETA incorporation value S.I. for each lysine residue can be calculated. 
Each S.I. value reflects the local environment of specific lysine residue, and the change in 
S.I. value can be correlated to potential conformational change. The trend of the S.I. 
values of the lysine residues within a.a. 331–359 pointed toward a more exposed, solvent-
accessible environment upon denaturation (Figure 5-10). This result suggests that the 
native conformation of domain C is more compact, in agreement with the monomeric 
structure observed in solution NMR experiment (Figure 5-11). Furthermore, site-directed 
mutagenesis of the amino acid residues involving dimerization interactions based on the 
crystal structure did not alter the mutant PARP-1’s catalytic activity (189). In the near 
full-length PARP-1 crystal structure in complex with a blunt-end DNA, domain C (or 
FIII) exists in a position where dimerization is impossible to take place (200). These 
results are more consistent with domain C in a monomeric form in solution, and the 
potential dimerization interface does not lie within domain C. 
Instead of self-dimerization, domain C may also interact with other segments of 
PARP-1 molecule. To investigate this protein–protein interaction, a chemical 
crosslinking assay of domain C and ABDEF was performed using BS3 as the chemical 
crosslinker. BS3 contains two N-hydroxylsulfosuccinimide (NHS) ester moieties which 
are reactive toward free amino groups. In the presence of 20-fold excess of BS3 (200 
μM), domain C did not crosslink to ABDEF to form a well-defined molecule with a 
molecular weight about 116 kDa. Rather, ABDEF showed a smear above its original 
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molecular weight on the SDS-PAGE gel, similar to the effect of protein poly(ADP-
ribosyl)ation (Figure 5-12). The inclusion of DNA in the reactions did not have 
significant difference. Similar results were obtained for reactions using 50-fold or 100-
fold BS3. The aggregate formation of ABDEF was confirmed by anti-PARP immunoblot 
which recognizes the C-terminal portion of the protein. Noticeably, a relatively distinct 
band appeared in the PARP-1 control reactions using 100-fold BS3 (Figure 5-12B, lane 
13, arrow). The band is consistent with the species being a PARP-1 dimer, but the 
identity needs further verification. Except for this, chemical crosslinking assay of PARP-
1 domains failed to provide clean evidence for the existence of C/ABDEF protein 
complex, but interdomain interactions are likely, despite being weak and transient. In 
addition, domain C may also interact with PAR polymers noncovalently (188), which 
may facilitate the correct orientation of PARP-1 domains poised for polymer elongation 
or branching. 
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Appendix 
1H NMR spectrum for 2NF-NAD+ 
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19F NMR spectrum for 2NF-NAD+ 
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31P NMR spectrum for 2NF-NAD+ 
 
 
 
 
 
 
 
 
 
 
 180 
ESI-MS spectrum for 2NF-NAD+ 
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